
<html lang="en"     class="pb-page"  data-request-id="e5393622-5752-4b3a-915e-940a2c758ec2"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/acs.jmedchem.0c00891;requestedJournal:journal:jmcmar;journal:journal:jmcmar;issue:issue:10.1021/jmcmar.2020.63.issue-15;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Structural Basis of AZD9291 Selectivity for EGFR T790M" /></meta><meta name="dc.Creator" content="Xiao-E  Yan" /></meta><meta name="dc.Creator" content="Pelin  Ayaz" /></meta><meta name="dc.Creator" content="Su-Jie  Zhu" /></meta><meta name="dc.Creator" content="Peng  Zhao" /></meta><meta name="dc.Creator" content="Ling  Liang" /></meta><meta name="dc.Creator" content="Casey H.  Zhang" /></meta><meta name="dc.Creator" content="Ya-Chuang  Wu" /></meta><meta name="dc.Creator" content="Je-Luen  Li" /></meta><meta name="dc.Creator" content="Hwan Geun  Choi" /></meta><meta name="dc.Creator" content="Xin  Huang" /></meta><meta name="dc.Creator" content="Yibing  Shan" /></meta><meta name="dc.Creator" content="David E.  Shaw" /></meta><meta name="dc.Creator" content="Cai-Hong  Yun" /></meta><meta name="dc.Description" content="AZD9291 (Osimertinib) is highly effective in treating EGFR-mutated non-small-cell lung cancers (NSCLCs) with T790M-mediated drug resistance. Despite the remarkable success of AZD9291, its binding p..." /></meta><meta name="Description" content="AZD9291 (Osimertinib) is highly effective in treating EGFR-mutated non-small-cell lung cancers (NSCLCs) with T790M-mediated drug resistance. Despite the remarkable success of AZD9291, its binding p..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="July 16, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c00891" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright Â© 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00891" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c00891" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00891" /></link>
        
    
    

<title>Structural Basis of AZD9291 Selectivity for EGFR T790M | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c00891" /></meta><meta property="og:title" content="Structural Basis of AZD9291 Selectivity for EGFR T790M" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00891/20200806/images/large/jm0c00891_0007.jpeg" /></meta><meta property="og:description" content="AZD9291 (Osimertinib) is highly effective in treating EGFR-mutated non-small-cell lung cancers (NSCLCs) with T790M-mediated drug resistance. Despite the remarkable success of AZD9291, its binding pose with EGFR T790M remains unclear. Here, we report unbiased, atomic-level molecular dynamics (MD) simulations in which spontaneous association of AZD9291 with EGFR kinases having WT and T790M mutant gatekeepers was observed. Simulation-generated structural models suggest that the binding pose of AZD9291 with T790M differs from its binding pose with the WT, and that AZD9291 interacts extensively with the gatekeeper residue (Met 790) in T790M but not with Thr 790 in the WT, which explains why AZD9291 binds T790M with higher affinity. The MD simulation-generated models were confirmed by experimentally determined EGFR/T790M complex crystal structures. This work may facilitate the rational design of drugs that can overcome resistance mutations to AZD9291, and more generally it suggests the potential of using unbiased MD simulation to elucidate small-molecule binding poses." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c00891"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00891">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c00891&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c00891&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c00891&amp;href=/doi/10.1021/acs.jmedchem.0c00891" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 15</span><span class="cit-fg-pageRange">, 8502-8511</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/15" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c00855" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c00893" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Structural Basis of AZD9291 Selectivity for EGFR T790M</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Xiao-E Yan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiao-E Yan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biochemistry and Biophysics,Â  Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiao-E++Yan">Xiao-E Yan</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Pelin Ayaz</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Pelin Ayaz</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">D. E. Shaw Research, New York, New York 10036, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Pelin++Ayaz">Pelin Ayaz</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Su-Jie Zhu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Su-Jie Zhu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Translational Medicine, The Affiliated Hospital of Qingdao University, College of Medicine, Qingdao University, Qingdao 266021, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Su-Jie++Zhu">Su-Jie Zhu</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Peng Zhao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Peng Zhao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biochemistry and Biophysics,Â  Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Peng++Zhao">Peng Zhao</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Ling Liang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ling Liang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biochemistry and Biophysics,Â  Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ling++Liang">Ling Liang</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Casey H. Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Casey H. Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">D. E. Shaw Research, New York, New York 10036, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Casey+H.++Zhang">Casey H. Zhang</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Ya-Chuang Wu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ya-Chuang Wu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biochemistry and Biophysics,Â  Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ya-Chuang++Wu">Ya-Chuang Wu</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Je-Luen Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Je-Luen Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">D. E. Shaw Research, New York, New York 10036, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Je-Luen++Li">Je-Luen Li</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Hwan Geun Choi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hwan Geun Choi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115, United States</div><div class="loa-info-affiliations-info">Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hwan+Geun++Choi">Hwan Geun Choi</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Xin Huang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xin Huang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Hongyun Biotech Co., Ltd., Nanjing, Jiangsu 211112, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xin++Huang">Xin Huang</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Yibing Shan</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yibing Shan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">D. E. Shaw Research, New York, New York 10036, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#421b2b202b2c256c112a232c020607112a2335102731272330212a6c212d2f"><span class="__cf_email__" data-cfemail="520b3b303b3c357c013a333c121617013a3325003721373320313a7c313d3f">[emailÂ protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yibing++Shan">Yibing Shan</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">David E. Shaw</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David E. Shaw</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">D. E. Shaw Research, New York, New York 10036, United States</div><div class="loa-info-affiliations-info">Department of Biochemistry and Molecular Biophysics, Columbia University, New York, New York 10032, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#d591b4a3bcb1fb86bdb4a295919086bdb4a287b0a6b0b4a7b6bdfbb6bab8"><span class="__cf_email__" data-cfemail="ade9ccdbc4c983fec5ccdaede9e8fec5ccdaffc8dec8ccdfcec583cec2c0">[emailÂ protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David+E.++Shaw">David E. Shaw</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8265-5761" title="Orcid link">http://orcid.org/0000-0001-8265-5761</a></div></div></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor">Cai-Hong Yun</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Cai-Hong Yun</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biochemistry and Biophysics,Â  Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#7c0509121f143c0c170952191809521f12"><span class="__cf_email__" data-cfemail="ed9498838e85ad9d8698c3888998c38e83">[emailÂ protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Cai-Hong++Yun">Cai-Hong Yun</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5880-8307" title="Orcid link">http://orcid.org/0000-0002-5880-8307</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00891&amp;href=/doi/10.1021%2Facs.jmedchem.0c00891" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 15</span><span class="cit-pageRange">, 8502â8511</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">July 16, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>26 May 2020</li><li><span class="item_label"><b>Published</b> online</span>16 July 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 13 August 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c00891" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00891</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8502%26pageCount%3D10%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DXiao-E%2BYan%252C%2BPelin%2BAyaz%252C%2BSu-Jie%2BZhu%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D15%26contentID%3Dacs.jmedchem.0c00891%26title%3DStructural%2BBasis%2Bof%2BAZD9291%2BSelectivity%2Bfor%2BEGFR%2BT790M%26numPages%3D10%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D8511%26publicationDate%3DAugust%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c00891"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2274</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">13</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c00891" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Structural Basis of AZD9291 Selectivity for EGFR T790M&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Xiao-E&quot;,&quot;last_name&quot;:&quot;Yan&quot;},{&quot;first_name&quot;:&quot;Pelin&quot;,&quot;last_name&quot;:&quot;Ayaz&quot;},{&quot;first_name&quot;:&quot;Su-Jie&quot;,&quot;last_name&quot;:&quot;Zhu&quot;},{&quot;first_name&quot;:&quot;Peng&quot;,&quot;last_name&quot;:&quot;Zhao&quot;},{&quot;first_name&quot;:&quot;Ling&quot;,&quot;last_name&quot;:&quot;Liang&quot;},{&quot;first_name&quot;:&quot;Casey&quot;,&quot;last_name&quot;:&quot;H. Zhang&quot;},{&quot;first_name&quot;:&quot;Ya-Chuang&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Je-Luen&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Hwan&quot;,&quot;last_name&quot;:&quot;Geun Choi&quot;},{&quot;first_name&quot;:&quot;Xin&quot;,&quot;last_name&quot;:&quot;Huang&quot;},{&quot;first_name&quot;:&quot;Yibing&quot;,&quot;last_name&quot;:&quot;Shan&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;E. Shaw&quot;},{&quot;first_name&quot;:&quot;Cai-Hong&quot;,&quot;last_name&quot;:&quot;Yun&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;07&quot;,&quot;day&quot;:&quot;16&quot;,&quot;issue&quot;:&quot;15&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;8502-8511&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c00891&quot;},&quot;abstract&quot;:&quot;AZD9291 (Osimertinib) is highly effective in treating EGFR-mutated non-small-cell lung cancers (NSCLCs) with T790M-mediated drug resistance. Despite the remarkable success of AZD9291, its binding pose with EGFR T790M remains unclear. Here, we report unbiased, atomic-level molecular dynamics (MD) simulations in which spontaneous association of AZD9291 with EGFR kinases having WT and T790M mutant gatekeepers was observed. Simulation-generated structural models suggest that the binding pose of AZD9291 with T790M differs from its binding pose with the WT, and that AZD9291 interacts extensively with the gatekeeper residue (Met 790) in T790M but not with Thr 790 in the WT, which explains why AZD9291 binds T790M with higher affinity. The MD simulation-generated models were confirmed by experimentally determined EGFR/T790M complex crystal structures. This work may facilitate the rational design of drugs that can overcome resistance mutations to AZD9291, and more generally it suggests the potential of using unbiased M&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00891&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00891" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00891&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00891" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00891&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00891" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00891&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00891&amp;href=/doi/10.1021/acs.jmedchem.0c00891" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c00891" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c00891" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00891&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c00891%26sid%3Dliteratum%253Aachs%26pmid%3D32672461%26genre%3Darticle%26aulast%3DYan%26date%3D2020%26atitle%3DStructural%2BBasis%2Bof%2BAZD9291%2BSelectivity%2Bfor%2BEGFR%2BT790M%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D15%26spage%3D8502%26epage%3D8511%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">Â»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292290" title="Crystallization">Crystallization</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a>,</li><li><a href="/action/doSearch?ConceptID=291880" title="Crystal structure">Crystal structure</a>,</li><li><a href="/action/doSearch?ConceptID=291026" title="Conformation">Conformation</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/15" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/jmcmar.2020.63.issue-15/20200813/jmcmar.2020.63.issue-15.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00891/20200806/images/medium/jm0c00891_0007.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00891/20200806/images/large/jm0c00891_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00891&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">AZD9291 (Osimertinib) is highly effective in treating EGFR-mutated non-small-cell lung cancers (NSCLCs) with T790M-mediated drug resistance. Despite the remarkable success of AZD9291, its binding pose with EGFR T790M remains unclear. Here, we report unbiased, atomic-level molecular dynamics (MD) simulations in which spontaneous association of AZD9291 with EGFR kinases having WT and T790M mutant gatekeepers was observed. Simulation-generated structural models suggest that the binding pose of AZD9291 with T790M differs from its binding pose with the WT, and that AZD9291 interacts extensively with the gatekeeper residue (Met 790) in T790M but not with Thr 790 in the WT, which explains why AZD9291 binds T790M with higher affinity. The MD simulation-generated models were confirmed by experimentally determined EGFR/T790M complex crystal structures. This work may facilitate the rational design of drugs that can overcome resistance mutations to AZD9291, and more generally it suggests the potential of using unbiased MD simulation to elucidate small-molecule binding poses.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61225" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61225" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Activating mutations in the kinase domain of EGFR, such as the exon-19 deletions (among which the most prominent is del E746_A750, also known as Del19) and the L858R single-site mutation, are among the major causes of non-small-cell lung cancers (NSCLCs). The 4-anilinoquinazoline-based reversible EGFR tyrosine kinase inhibitors (TKIs) Gefitinib and Erlotinib (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) have been demonstrated to be effective in treating NSCLCs harboring these EGFR mutations.<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1â3)</a> Unfortunately, tumors eventually develop resistance to these drugs, and in at least half of such cases the resistance is caused by the secondary EGFR mutation T790M.<a onclick="showRef(event, 'ref4 ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref6">(4â6)</a> Previous structural and mechanistic studies have suggested that new agents to inhibit the T790M drug-resistance mutation must overcome the enhanced adenosine triphosphate (ATP)-binding affinity conferred by T790M.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Second-generation irreversible inhibitors such as Neratinib (HKI-272, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), however, were not effective in clinical trials, due to the lack of selectivity against the L858R/T790M mutation over wild-type (WT) EGFR.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Pyrimidine-based irreversible EGFR inhibitors, such as WZ4002, Rociletinib (CO-1686), and Osimertinib (AZD9291) (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), selectively inhibit EGFR mutants including T790M and hence are expected to be better tolerated in humans than Neratinib.<a onclick="showRef(event, 'ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref8 ref9 ref10">(8â10)</a> In clinical trials, treatment with either CO-1686 or AZD9291 has resulted in a more than 50% response rate in NSCLC patients harboring T790M, and patients experience substantially less skin toxicity than typically observed for first-generation EGFR TKIs.<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11,12)</a> AZD9291 was approved by the FDA for the treatment of patients with metastatic EGFR T790M mutation-positive NSCLCs that have progressed during or after EGFR TKI therapy,<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> while CO-1686 was discontinued due to an insufficient objective response rate (ORR) in human NSCLC trials.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> The superior efficacy of AZD9291 stems at least partly from its preference for binding to EGFR kinase with the T790M mutation. In EGFR recombinant enzyme assays, AZD9291 showed an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M; while in the cell line assays, this agent was found to inhibit EGFR phosphorylation with IC50 values of about 15 nM versus 55 nM for H1975 (L858R/T790M) versus H3255 (L858R), and about 6nM versus 17nM for PC-9 VanR (ex19del/T790M) versus PC-9 (ex19del), respectively.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> These data clearly showed that AZD9291 preferentially binds to EGFR with the T790M mutation.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00891/20200806/images/medium/jm0c00891_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00891/20200806/images/large/jm0c00891_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Compounds discussed in this report.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00891/20200806/images/large/jm0c00891_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00891&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">EGFR T790M mutation stimulated significant efforts to discover other third-generation EGFR TKIs (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). Olmutinib (HM61713), with a thieno[3,2-<i>d</i>]pyrimidine-based scaffold developed by Hanmi, was approved by the Korean Ministry of Food and Drug Safety in 2016 as the second third-generation drug for the treatment of NSCLC patients with EGFR T790M mutation.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Almonertinib (HS-10296), a derivative of AZD9291, was approved by the National Medical Products Administration of China in 2020 for the treatment of metastatic NSCLC patients with EGFR T790M (<a href="http://www.nmpa.gov.cn/WS04/CL2056/376189.html" class="extLink">http://www.nmpa.gov.cn/WS04/CL2056/376189.html</a>). Lazertinib also bears a pyrimidine scaffold. This agent inhibits EGFR L858R/T790M and wild-type with IC50 values of 2 and 76 nM, respectively. Lazertinib achieved similar antitumor efficacy in a phase 2 study compared with AZD9291 and showed an apparently more favorable toxicity profile than osimertinib, which may be an advantage for this agent in further clinical study.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> In addition, several other third-generation EGFR TKIs, including Naquotinib (ASP8273), Nazartinib (EGF816), and Mavelertinib (PF-06747775), have halted their clinical development because of safety concerns, low levels of activity, or other reasons.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a></div><div class="NLM_p">Despite the success of AZD9291, the mechanism by which it well tolerates and preferentially binds to the T790M gatekeeper mutation remains elusive. This is because the binding mode of AZD9291 to EGFR T790M mutant kinase has not been properly determined. Cross et al. proposed a theoretical model of the EGFR T790M/AZD9291 complex based on the previously reported EGFR T790M/WZ4002 complex crystal structure.<a onclick="showRef(event, 'ref8 ref10'); return false;" href="javascript:void(0);" class="ref ref8 ref10">(8,10)</a> According to this model, the AZD9291 indole group is located underneath Val726, with the phenyl moiety of the indole group pointing to the opening/solvent side of the ATP-binding pocket (we will refer to this conformation as the âunflippedâ binding pose to distinguish it from a âflippedâ binding pose revealed by this study). Yosaatmadja et al. reported the first experimentally determined EGFR/AZD9291 complex crystal structure.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> The indole group of AZD9291 in this structure adopted a conformation essentially the same as that proposed by Cross et al.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> However, in this complex structure, the EGFR kinase was the WT instead of the T790M mutant, and AZD9291 did not covalently link to the EGFR. Therefore, it remains a question if this structure captured the true binding mode of AZD9291 to EGFR T790M.</div><div class="NLM_p last">All-atom, unbiased molecular dynamics (MD) simulations of the biophysical processes of proteinâprotein and proteinâsmall-molecule binding, and thus the use of such simulations to predict binding poses, have become increasingly feasible (see, for example, refs <a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18,19)</a>). Such simulations of spontaneous biomolecular binding, which do not utilize any structural information about the binding a priori, start from systems in which a protein and (one or multiple copies of) its binding partners are arbitrarily positioned without being in contact. This MD simulation approach may thus hold great potential in many drug discovery projects in which X-ray crystallographic characterization of small-molecule binding poses is not readily available. We illustrate that potential here, in our investigation of the binding poses of AZD9291 for the T790M EGFR cancer mutant. More specifically, the unbiased MD simulation studies found different binding poses of AZD9291 with T790M and with the WT gatekeeper EGFR kinases and indicated the preference of this agent for a Met 790 gatekeeper, which was supported by the complex crystal structures prepared by co-crystallization. These results may aid the development of a new generation of EGFR inhibitors and more generally show the potential for using unbiased MD simulation to elucidate small-molecule binding poses.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70530" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70530" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> MD Simulations Suggest a Flipped AZD9291 Binding Pose With T790M but not With the WT Gatekeeper</h3><div class="NLM_p">To study the interaction between AZD9291 and EGFR kinase, we performed unbiased MD simulations of the spontaneous binding of AZD9291 to L858R/T790M and to L858R (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>a,b). These simulations started from the unbound state, with three AZD9291 molecules arbitrarily placed in the simulation system. The simulations were conducted without using any structural information (experimental or otherwise) about the small-molecule binding poses or the location of the binding site. Such binding simulations have previously produced kinase-ligand binding poses highly consistent with the corresponding crystal structure poses.<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18,19)</a> The formation or breaking of covalent bonds cannot be simulated with standard biomolecular MD force fields, including the one used here, so the simulations show binding, but not bond formation, between AZD9291 and EGFR.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00891/20200806/images/medium/jm0c00891_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00891/20200806/images/large/jm0c00891_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. MD simulations of AZD9291 binding to EGFR L858R and L858R/T790M. (Note that because the cancer mutation L858R is included in all simulations, L858R/T790M simulations are labeled âT790Mâ and L858R simulations are labeled âT790â in all panels.) (a) Spontaneous binding of AZD9291 to EGFR L858R in a simulation. Equally spaced snapshots from a 10 Î¼s simulation are superimposed on EGFR. AZD9291 is colored from red to green, representing the time progression. The opening of the binding site (as measured by the CÎ± distance between Ala 722, at the tip of the P-loop, and Ala 839, at the C-terminal of the catalytic loop) is shown by a dashed line. The root-mean-square deviation (RMSD) of AZD9291 with respect to the crystal structure of AZD9291-bound EGFR kinase (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZAU">4ZAU</a>) is plotted. (b) Spontaneous binding of AZD9291 with EGFR L858R/T790M in a simulation. The ligand RMSD of AZD9291 with respect to our crystal structure of AZD9291-bound T790M is plotted (bottom). The opening of the binding site is shown (middle), as is the AZD9291 dihedral angle that distinguishes the flipped and unflipped ligand conformations (top). As shown, the ligand was in the unflipped conformation when it first entered the binding site. (c) Left, the unflipped EGFR binding pose of AZD9291 in the binding simulations of L858R, in which Thr 790 is not mutated, compared with the crystal structure of the AZD9291-bound WT (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZAU">4ZAU</a>); right, the flipped EGFR binding pose from the binding simulations of L858R/T790M compared with our crystal structure of the AZD9291-bound T790M EGFR mutant (T790M/ccAZD9291). (d) Plots of the NHâO distances of the hinge hydrogen bonds (i.e., hydrogen bonds between AZD9291 and residues of the hinge of EGFR), where the stability of the hinge hydrogen bonds indicates a stable binding pose. The simulations that reached stable binding poses are shown in color and the others in gray. The top panel includes seventeen 10 Î¼s binding simulations of AZD9291 to EGFR L858R/T790M (8 of which reached the bound state), and the bottom panel includes 17 similar binding simulations to EGFR L858R (8 of which reached the bound state). The black arrows indicate binding events in which AZD9291 adopted an unflipped pose, and the red arrows indicate binding events in which it adopted a flipped pose. (e) Distribution of the dihedral angle associated with the flipping of AZD9291. The blue histogram was calculated based on 5 Î¼s of simulations of AZD9291 in solution, whereas the red histogram is based on aggregation of the portion of AZD9291 binding simulations to T790M/L858R in which a stable binding pose had been reached; the green histogram is based on the binding simulations of AZD9291 to L858R. Although the latter two histograms indicate that the T790M mutation favors the flipped binding pose, the histograms are likely unconverged and are meaningful only qualitatively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00891/20200806/images/large/jm0c00891_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00891&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We first simulated the binding of AZD9291 to L858R/T790M and, in 17 independent 10 Î¼s simulations we observed eight binding events (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>d, top). In four of the eight binding events, an AZD9291 molecule assumed a stable, flipped binding pose (the phenyl moiety of the indole group points toward the gatekeeper residue. See <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>c, right) and in the other four binding events, an AZD9291 molecule was bound in an unflipped pose similar to that seen in the previously reported complex crystal structure of AZD9291 with the WT EGFR (the phenyl moiety of the indole group points toward the opening/solvent side of the ATP-binding pocket).<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> The flipped pose is similar to the unflipped pose in maintaining the âhingeâ hydrogen bonds between AZD9291 and the backbone amide/carbonyl groups of Met 793, but the two poses differ in that, in the flipped pose, the indole moiety is rotated by â¼180Â° and the phenyl moiety of the indole points toward the side chain of Met 790.</div><div class="NLM_p">We then simulated the binding of AZD9291 to EGFR L858R, and in 8 of the 17 independent 10 Î¼s simulations, an AZD9291 molecule reached a stable binding pose (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>d, bottom). The simulations resulted in the unflipped pose in 7 of these 8 binding events (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>c, left). In the other binding event, AZD9291 settled in the flipped binding pose observed in our unbiased MD simulations of AZD9291 binding to L858R/T790M. Based on the increased frequency of the flipped binding pose with T790M, we infer that it is likely energetically more favorable in T790M than in the WT due to the attractive van der Waals interactions between the small molecule and the Met 790 residue in T790M. This extra favorable interaction between AZD9291 and EGFR T790M indicates that this agent may prefer binding to EGFR with a Met 790 gatekeeper. In contrast to the flipped binding pose of AZD9291 with EGFR T790M, in the unflipped pose with WT EGFR, the indole moiety of AZD9291 was located relatively distal from the Thr 790 side chain, which is incompatible with the strong packing between AZD9291 and the gatekeeper residue (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>c).</div><div class="NLM_p">Analysis of the binding process showed that AZD9291 first entered the binding site in the unflipped conformation. After entering the binding site, both the binding pose of AZD9291 and the conformation of the binding site fluctuated significantly. The fluctuation subsided after AZD9291 adopted the flipped conformation (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>b). The fact that it was after entering the binding site and approaching Met 790 that AZD9291 adopted the flipped pose suggests that the T790M mutation helps induce the flipped pose by interacting with the small molecule during binding.</div><div class="NLM_p">To examine the inherent equilibrium between the flipped and unflipped conformations of AZD9291, we simulated AZD9291 in solution and observed that it adopted two flipped and two unflipped conformations, each with similar frequency (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>e). Dihedral angle analysis of AZD9291 in the EGFR binding simulation revealed that, when bound in the flipped pose, AZD9291 accessed both of the two flipped conformations observed in the solution simulations; in the unflipped bound pose, it accessed only one of the two unflipped conformations observed in the solution simulations. The flipped conformation thus has a favorable entropic contribution to its free energy (â¼0.4 kcal/mol) that is not associated with the unflipped conformation, whether or not the T790M mutation is present.</div><div class="NLM_p">The different binding modes not only affected the stability of the AZD9291-EGFR complex but also affected bond formation. We measured the distance between the thiol group of Cys797 and the AZD9291 warhead in the simulations (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>) as a proxy for gauging the efficiency of bond formation. We found that overall this distance was significantly smaller in the flipped binding pose than in the unflipped pose (<4 Ã and 7 Ã, respectively). These findings suggest that the unflipped pose may not be compatible with bond formation due to the large distance between the warhead and the thiol group and that instead the flipped pose may be the one conducive to bond formation. Furthermore, for the same flipped pose, we found that the smaller distance was more prevalent in simulations with L858R/T790M than in those with L858R (Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.0c00891/suppl_file/jm0c00891_si_001.pdf" class="ext-link">Figure S1</a>). Since the flipped binding pose was also observed more often in simulations of the former (4 out of 8 and 1 out of 8, respectively), we suggest that part of the AZD9291 selectivity may arise from the effect of the T790M mutation in promoting the productive Michaelis EGFR-AZD9291 complex.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00891/20200806/images/medium/jm0c00891_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00891/20200806/images/large/jm0c00891_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Plots of the Cys797(SG)-AZD9291 warhead distances in binding simulations of AZD9291 to EGFR L858R/T790M (labeled T790M) and EGFR L858R (labeled T790); smaller distances may indicate more productive binding modes (i.e., those conducive to covalent bond formation). The black arrows indicate binding events in which AZD9291 adopted an unflipped pose, and the red arrows indicate binding events in which it adopted a flipped pose. (See Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.0c00891/suppl_file/jm0c00891_si_001.pdf" class="ext-link">Figure S1</a> for the plots for the rest of the 16 ligand-binding simulations.).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00891/20200806/images/large/jm0c00891_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00891&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> AZD9291 Binding Pose in the EGFR/AZD9291 Complex Crystals Prepared by Soaking</h3><div class="NLM_p">We then sought to validate the MD simulation-generated structural models through experimental determination of the EGFR/AZD9291 complex crystal structures. We first determined the crystal structure of EGFR T790M in complex with AZD9291 prepared by soaking at 2.53 Ã resolution, which we refer to as the T790M/skAZD9291 structure (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>a, Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.0c00891/suppl_file/jm0c00891_si_001.pdf" class="ext-link">Table S1 and Figure S2a</a>). In this structure, AZD9291 did not adopt the flipped pose, but instead adopted the unflipped pose that was previously predicted by Cross et al.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> and reported by Yosaatmadja et al.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZAU">4ZAU</a>, <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>f). Through soaking with AZD9291, we also obtained the complex crystal structure of AZD9291 with the L858R mutant, which we refer to as L858R/skAZD9291 (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>d, Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.0c00891/suppl_file/jm0c00891_si_001.pdf" class="ext-link">Table S2 and Figure S2c</a>), wherein AZD9291 also adopted the unflipped pose. Unlike the EGFR WT/AZD9291 structure reported by Yosaatmadja et al., these two crystal structures captured the covalent linkage between AZD9291 and Cys797, which is clearly evidenced by the electron density (Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.0c00891/suppl_file/jm0c00891_si_001.pdf" class="ext-link">Figure S2a,c</a>). We note that AZD9291 bound to EGFR T790M only in the unflipped conformation in the complex crystals prepared by soaking, thus not reproducing the two-mode binding of this compound to T790M predicted in our MD simulations. However, since in the soaked complex crystals AZD9291 was introduced into already established EGFR crystals in which conformation of the EGFR protein molecules is confined by crystal packing, the binding mode of the compound may be restricted in terms of representing its native binding mode to the target in solution, where the protein can freely change its conformation.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00891/20200806/images/medium/jm0c00891_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00891/20200806/images/large/jm0c00891_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Crystal structures of EGFR mutants in complex with AZD9291. The overall structures (upper subpanel) and the close views of the ATP-binding sites (lower subpanel) are shown for T790M/skAZD9291 (a), T790M/ccAZD9291 (b and c), L858R/skAZD9291 (d), WT/ccAZD9291 (e), and WT/skAZD9291 by Yosaatmadja et al. (f). Panel (c) shows the 2Fo-Fc electron density maps (blue meshes, contoured at 1.2Ï) and Fo-Fc electron density maps (green meshes, contoured at 3.0Ï) for the extra AZD9291 molecules (top) and the AZD9291 molecule in the ATP-binding site (bottom) in the T790M/ccAZD9291 crystal structure. These maps are omit maps, i.e., they were calculated after simulated annealing refinement (starting from 300 K) of the coordinates omitting the three AZD9291 molecules. The black dashes indicate hydrogen bonds between the compound and EGFR.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00891/20200806/images/large/jm0c00891_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00891&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> AZD9291 Adopted the Flipped Binding Pose in a T790M/AZD9291 Complex Crystal Prepared by Co-crystallization</h3><div class="NLM_p">Since the binding mode of the compound may be affected by the confined target protein conformation in crystals when prepared by soaking, we tried to determine the complex crystal structure of EGFR T790M with AZD9291 by co-crystallization. Using this technique, AZD9291 was first preincubated with EGFR in solution to enable free conformational changes both in the compound and in the protein during binding, and then the EGFR/AZD9291 complex sample was subjected to crystallization.</div><div class="NLM_p">After a number of attempts, we obtained EGFR T790M/AZD9291 and EGFR WT/AZD9291 complex crystals by co-crystallization and determined the structures of these two complexes to 2.53 Ã and 2.30 Ã resolution, respectively (referred as T790M/ccAZD9291 and WT/ccAZD9291, <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>b,e, Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.0c00891/suppl_file/jm0c00891_si_001.pdf" class="ext-link">Tables S1 and S2</a>). In the T790M/ccAZD9291 structure, as opposed to the one obtained from soaking (T790M/skAZD9291), AZD9291 adopted the flipped binding pose (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>b,c; Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.0c00891/suppl_file/jm0c00891_si_001.pdf" class="ext-link">Figures S2b and S3</a>). An explanation for this difference is the significant conformational changes during AZD9291 binding in solution, as observed in our simulations, especially in terms of P-loop movement and variation at the opening of the ATP-binding site, as well as the position of the C-helix. During soaking, the crystal lattice may preclude conformational changes of this magnitude and as a result prevent AZD9291 from arriving at the flipped binding pose. For example, the C-helix of EGFR in the crystal structures from soaking adopted the Î±C-in conformation. This conformation narrowed the binding space for AZD9291, potentially precluding the flipping of the indole group (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>a). In the co-crystallization procedure, the EGFR kinase was preincubated with AZD9291 for 2 h in solution before setting up the crystallization tray, which would thus enable substantial conformational movements during AZD9291 binding, making the capture of the true binding mode of the compound in solution more likely.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00891/20200806/images/medium/jm0c00891_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00891/20200806/images/large/jm0c00891_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Comparison of AZD9291 binding poses observed in the co-crystallization and soaked complex crystal structures. (a) Superimposition of T790M/ccAZD9291 (slate) with T790M/skAZD9291 (lime). (b) Superimposition of T790M/ccAZD9291 (slate) with WT/ccAZD9291 (cyan). Note that the C-helix in the T790M/skAZD9291 structure is in the Î±C-in position (a), while in the WT/ccAZD9291 structure it takes the Î±C-out conformation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00891/20200806/images/large/jm0c00891_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00891&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The flipped pose adopted by AZD9291 in this co-crystallization structure and the one it adopted in our MD simulations are the same. In this pose, the attractive van der Waals interactions between the indole and the Met 790 side chain are likely stronger than those in the unflipped pose, as is evidenced by the shorter distance (â¼3.8 Ã versus â¼4.9 Ã) and larger interaction surface (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>a). Consistent with the notion that AZD9291 preferentially adopts the flipped pose with T790M but not with the WT EGFR kinase, our complex crystal structure of AZD9291 with the WT (WT/ccAZD9291) from co-crystallization showed that AZD9291 adopts the unflipped binding pose (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>e). Like the two soaked structures (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>a,d), these two co-crystallization structures also captured the covalent bond between the AZD9291 and Cys797 of EGFR kinase (Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.0c00891/suppl_file/jm0c00891_si_001.pdf" class="ext-link">Figure S2b,d</a>). Notably, in the WT/ccAZD9291 structure, although the Î±C-out inactive conformation produced an enlarged pocket at the ATP-binding site (compared to the Î±C-in active conformation of EGFR) that would easily accommodate a flipped indole, AZD9291 still maintained the unflipped binding pose (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>b). This observation again suggests that the flipped pose of AZD9291 is induced by interaction between the indole group of AZD9291 and the Met 790 side chain in T790M, and that the flipped pose is unlikely to be an artifact resulting from the larger binding pocket observed in the T790M/ccAZD9291 crystal structure.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Unique Conformation of EGFR in the T790M/AZD9291 Co-crystallization Structure</h3><div class="NLM_p">The EGFR kinase in T790M/ccAZD9291 adopted a conformation previously unobserved in crystal structures. In this structure, the C-helix is kinked, with the N-terminal half of the helix (residues 753â759) displaced by 4â7 Ã from the Î±C-in position of the helix, while the rest of the C-helix (residues 760â768) maintained the Î±C-in position that was observed in the previously reported apo-EGFR T790M kinase structure in an active conformation (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>a,b). Apparently related to the displacement of the N-terminal half of the C-helix, a part of the A-loop (residues 867â872) formed a short helix closely associating with the N-lobe (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>c). Although to our knowledge this activation loop conformation has not been captured in crystal structures of EGFR kinase, in a previous simulation study the activation loop of EGFR was very flexible, and similar conformations were observed.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00891/20200806/images/medium/jm0c00891_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00891/20200806/images/large/jm0c00891_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Extra binding site of AZD9291 to EGFR T790M in T790M/ccAZD9291 and the unusual conformation of EGFR in this structure. (a) Superimposition of T790M/ccAZD9291 (slate) on apo-T790M (active conformation of T790M, shown in yellow-orange, drawn from PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIT">2JIT</a>). (b) Superimposition of T790M/ccAZD9291 (slate) on V948R (inactive conformation of EGFR, shown in cyan, drawn from PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2GS7">2GS7</a>). (c) Conformation of the C-terminal end of A-loop in T790M/ccAZD9291 and its interaction with the N-lobe residues. (d) Classic asymmetric dimer described by Zhang et al.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> The donor and receiver EGFRs are shown in pink and cyan, respectively. (e) Altered asymmetric dimer observed in T790M/ccAZD9291. An enlarged close view of AZD9291 binding at the extra site is shown on the right. The black dashes indicate the polar interactions between Asp974 and AZD9291(2). AZD9291(3) is not shown for a better view of AZD9291(2). The P-loop, A-loop, and C-helix in panels (d) and (e) are shown in blue, orange, and red, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00891/20200806/images/large/jm0c00891_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00891&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Despite the unique C-helix conformation, the overall conformation of the T790M/ccAZD9291 structure was more similar to the active conformation of EGFR (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>a, yellow) than to the inactive conformation (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>b, cyan). In the T790M/ccAZD9291 structure, an âasymmetric dimerâ of EGFR was also observed (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>e), but it differs from the classic asymmetric dimer of EGFR kinase described by Zhang et al. (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>d)<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> in that the âdonorâ EGFR in the T790M/ccAZD9291 structure is rotated by about 90Â° compared to the donor EGFR in the classic dimer.</div><div class="NLM_p last">Two parallel layers of extra electron density were observed near the EGFR dimer interface and the N-terminus of the C-helix in close proximity to Pro753 (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>c, top). After analyzing the shape of the density and testing different models in refinement, we concluded that the extra density represents two free AZD9291 molecules (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>b,c, top). These two AZD9291 molecules stacked together in parallel through the interaction between their aromatic scaffolds, reminiscent of the nucleotide base stacking in DNA. One of the AZD9291 molecules (AZD9291(2)) interacts with the donor EGFR through polar interactions with Asp974 and the receiver EGFR through hydrophobic interaction with Pro753 (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>e), which may help induce the kink in the C-helix of the receiver kinase and alter the position of the donor kinase in the nonclassic asymmetric dimer. Since AZD9291(2) seems to connect two EGFR molecules to facilitate the formation of this nonclassic dimer, we set out to clarify whether this is a true event in solution or just an artifact due to the high concentration of the compound and EGFR in crystallization. To do so, we designed an experiment to cross-link EGFR kinases to capture their dimerization, which showed that the dimerization of EGFR is barely affected by the increased AZD9291 concentration (Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.0c00891/suppl_file/jm0c00891_si_001.pdf" class="ext-link">Figure S4</a>). We thus concluded that AZD9291 binding between the two EGFR kinases in the crystal was likely a crystallization artifact and does not indicate an allosteric AZD9291 binding site.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14831" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14831" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The first-generation EGFR inhibitors gefitinib and erlotinib are effective in inhibiting tumor cells harboring primary EGFR L858R and exon-19 deletions. The selectivity of these ATP-competitive agents for these EGFR mutants is not solely determined by the higher binding potency (smaller <i>K</i><sub>d</sub> or <i>K</i><sub>i</sub>) to the mutants; a substantial contribution comes from the compromised ATP-binding potency (larger <i>K</i><sub>m</sub>) of the mutants.<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22,23)</a> However, the efficacy of these drugs is much diminished by the emergence of the T790M drug-resistance mutation. Since the T790M mutation increases the mutant kinaseâs affinity for ATP to a level similar to that of the WT EGFR,<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> the new drugs must bind to the mutant kinase much tighter than the first-generation drugs to overcome the resistance. Covalent inhibition through Cys797 has been shown to be a successful strategy to gain such high inhibition potency,<a onclick="showRef(event, 'ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref8 ref9 ref10">(8â10)</a> but since wild-type EGFR kinase also has a Cys797 that can react with the covalent inhibitors, preference of the compounds for binding to the mutants in the reversible binding stage is critical for the selectivity of these compounds to spare wild-type EGFR. For WZ4002/4003, this is shown in <a href="/doi/suppl/10.1021/acs.jmedchem.0c00891/suppl_file/jm0c00891_si_001.pdf" class="ext-link">Table S10</a> of the Zhou et al. paper.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a></div><div class="NLM_p">AZD9291 has been shown to bind to EGFR T790M mutation with higher affinity than binding to EGFR with the wild-type gatekeeper and it selectively inhibits NSCLC cell lines harboring T790M<sup>+</sup> (L858R/T790M or Del19/T790M) while sparing WT EGFR cell lines.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> However, the structural basis of such binding specificity has been unclear. A covalent inhibitorâs in vitro potency is <i>k</i><sub>inact</sub>/<i>K</i><sub>i</sub>, where <i>K</i><sub>i</sub> is the dissociation constant of the reversible binding and <i>k</i><sub>inact</sub> is the on-rate constant of the bond formation. Detailed biochemical analysis on a series of EGFR covalent inhibitors (excluding AZD9291) showed that strong reversible EGFR binding is important to the overall potency of a covalent inhibitor.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Our unbiased MD simulations of AZD9291 binding and X-ray crystallography have together revealed a previously unknown binding pose of AZD9291 with the T790M mutant of EGFR kinase, in which the indole group of AZD9291 is flipped compared to the binding pose with the WT EGFR. This flipped binding pose led to attractive <i>van der Waals</i> interaction between the compound and the Met 790 side chain, potentially conferring a lower <i>K</i><sub>i</sub>. Further, our study suggested that the flipped pose features a short distance between the AZD9291 warhead and Cys797 and likely represents the productive binding mode needed for bond formation. The T790M mutation may thus also promote bond formation and confer a higher <i>k</i><sub>inact</sub> for AZD9291. These observations suggest that the <i>k</i><sub>inact</sub>/<i>K</i><sub>i</sub> values of AZD9291 should be higher for the T790M mutation. This may play an important role in the efficacy of this drug toward T790M<sup>+</sup>, because the T790M mutation had been shown to enhance the binding of ATP and therefore a higher binding affinity of the inhibitor is required to compete off ATP in the reversible binding stage to inhibit T790M<sup>+.</sup><a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> For EGFRm<sup>+</sup> (L858R or Del19), though AZD9291 binds to these mutants with lower affinity in the reversible binding stage, this does not abrogate the overall efficacy of the drug at all, because ATP also binds significantly weaker to L858R and Del19.<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22,23)</a></div><div class="NLM_p last">Application of AZD9291 has been shown to be limited by the emergence of the second-generation drug-resistance mutation C797S (such as Del19/T790M/C797S).<a onclick="showRef(event, 'ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref25 ref26">(25,26)</a> Therefore, developing new agents to overcome the new generation of AZD9291-resistant mutants harboring C797S is urgently demanded. Since seemingly minor differences in binding poses may substantially affect chemical design in drug discovery, understanding the structural basis of AZD9291 selectivity may significantly help the development of such new agents.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24377" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24377" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In this work, the theoretical (unbiased atomic-level MD simulations) and experimental (X-ray crystallography) approaches were combined to elucidate the interaction details and dynamics of AZD9291 binding to EGFR mutants, which showed that:<table class="listgroup" border="0" width="95%" list-type="label"><tr class="li1"><td valign="top">(i)</td><td colspan="5" valign="top" class="paragraph"><p class="last">when binding to EGFR T790M, AZD9291 tends to adopt an alternative binding pose in which the indole rotates for â¼180Â° compared to its binding pose to EGFR with wild-type gatekeeper (Thr 790).</p></td></tr><tr class="li1"><td valign="top">(ii)</td><td colspan="5" valign="top" class="paragraph"><p class="last">the flipped binding pose of AZD9291 with T790M leads to attractive van der Waals interaction between the compound and Met 790, likely conferring higher binding affinity of this agent to T790M at the reversible binding stage.</p></td></tr><tr class="li1"><td valign="top">(iii)</td><td colspan="5" valign="top" class="paragraph"><p class="last">the flipped binding pose of AZD9291 with T790M also brings the warhead of the compound (acrylamide) closer to the EGFR Cys797 side chain, likely promoting the formation of the covalent bond between the compound and EGFR.</p></td></tr></table></div><div class="NLM_p last">Interestingly, in this study, it was observed that different methods to prepare the target/drug complex crystals may result in slightly different binding modes, and that a complex crystal structure prepared by co-crystallization might be more trustable than that prepared by soaking.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24521" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24521" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> MD Simulations</h3><div class="NLM_p last">Simulation systems were prepared by placing the structure of the L858R mutant or the L858R/T790M mutant (based on PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZAU">4ZAU</a>â¯<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a>) in a cubic simulation box with periodic boundary conditions. (In the simulations of AZD9291-bound EGFR kinase, the box was â¼72.5 Ã wide and contained â¼50â¯000 atoms; in the spontaneous simulations of AZD9291 binding to EGFR, the box was â¼76 Ã wide and contained â¼58â¯000 atoms). Water molecules were represented explicitly, and Na<sup>+</sup> and Cl<sup>â</sup> ions were added to neutralize the system and achieve the physiological concentration (150 mM). The systems were parameterized with the Amber99SB*-ILDN<a onclick="showRef(event, 'ref27 ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref27 ref28 ref29">(27â29)</a> force field with TIP3P water;<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> AZD9291 was protonated at dimethylaminoethyl moiety and had a net charge of +1; the small molecule was parameterized using the general Amber force field (GAFF).<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> The systems were each equilibrated on GPU Desmond using a mixed NVT/NPT schedule.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> MD simulations were performed on the special-purpose machine Anton<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> in the NPT ensemble with <i>T</i> = 310 K and <i>P</i> = 1 bar using a variant<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> of the NosÃ©âHoover<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> and the MartynaâTobiasâKlein algorithms.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> The simulation time step was 2 fs; the r-RESPA integration method was used, with long-range electrostatics evaluated every three time steps. A 9 Ã cut off was applied for the van der Waals calculations. The pairwise summation of electrostatic forces was cutoff at 13.7 Ã, and long-range electrostatics were computed in k-space using a grid-based method (using Gaussian spreading to the grid<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a>).</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Validation of the GAFF Parameters Used for AZD9291</h3><div class="NLM_p last">We adopt the GAFF<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> parameters for AZD9291 in our MD simulations for two main reasons. First, they are widely available, which means that other researchers can easily reproduce and investigate the work further. Second, given that the compound consists of common functional groups, we expect the nonbonding interactions (atomic partial charges and van der Waals interactions) to be well described in GAFF, which is a widely used ligand force field. We examined the energetics of the flipped and the unflipped conformations by carrying out quantum mechanics (QM) and GAFF calculations in vacuum to obtain the energy profiles of AZD9291 as functions of the indole-pyrimidine torsion angle (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>e). For the QM calculation, we used the PBEh-3c method.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> When reporting the final QM energy of the relaxed structure, we use the dispersion-corrected density-functional theory (DFT) method wB97M-V.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> As shown in <a href="/doi/suppl/10.1021/acs.jmedchem.0c00891/suppl_file/jm0c00891_si_001.pdf" class="ext-link">Figure S5</a>, the GAFF energy profile agrees well with the observed relative population in solution (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>e); the QM energy profile indicates that both flipped and unflipped conformations can constitute viable stable binding poses. In solvent, both conformations are likely equally populated (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>e).</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Protein Expression, Crystallization, and Structure Determination</h3><div class="NLM_p">Constructs spanning residues 696â1022 of the wild type or mutant human EGFR were expressed and purified using the baculovirus/insect cell system as previously described.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> To improve the resolution of WT/ccAZD9291, we introduced three A-loop mutations E865A/E866A/K867A to the wild-type EGFR according to a previous report.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a></div><div class="NLM_p">Crystals used in this study were prepared by hanging drop vapor diffusion. For soaking, the reservoir solutions used to grow the inhibitor-free L858R and T790M crystals were 0.1 M HEPES pH7.8, 40% PEG400, 0.15 M NaCl, 5 mM tris(2-carboxyethyl)-phosphine (TCEP) and 38% PEG300, 150 mM KCl, 0.1 M HEPES (pH 8.0), 50 mM glycyl-glycyl-glycine, 5 mM Co-enzyme A (pH 8.0), and 2 mM TCEP. AZD9291 was then introduced by soaking the crystals for 3 h at room temperature in the crystallization buffer supplemented with 1 mM compound. For co-crystallization, the compound was added to 8.8 mg/mL T790M or 7.0 mg/mL WT proteins to a final concentration of 1 mM and incubated at 4 Â°C for 2 h before setting up the crystallization tray. The reservoir solutions to grow T790M/ccAZD9291 and WT/ccAZD9291 crystals were 0.1 M BIS-Tris propane pH 7.0, 1.3 M ammonium tartrate dibasic, and 0.2 M potassium sodium tartrate tetrahydrate, 20% w/v polyethylene glycol 3350, respectively.</div><div class="NLM_p last">The diffraction data were collected on beamline APS ID-19 at 100 K at the Argonne National Laboratory or beamline BL19U1 at Shanghai Synchrotron Radiation Facility (SSRF). The diffraction data were processed using HKL3000.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> The structures were all solved by molecular replacement with Phaser<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> using the previously determined EGFR L858R+ANP structure (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2itv">2itv</a>)<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> as the search model for the L858R/skAZD9291 and T790M/skAZD9291, and EGFR T790M structure (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2jit">2jit</a>)<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> as the search model for T790M/ccAZD9291. CNS<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> was then used to obtain a less biased model (by simulated annealing) and calculate the sigmaA-weighted 2Fo-Fc and Fo-Fc maps for manual inspection and adjustment. Repeated rounds of manual refitting and crystallographic refinement were then performed using COOT<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> and Phenix.<a onclick="showRef(event, 'ref45 ref46'); return false;" href="javascript:void(0);" class="ref ref45 ref46">(45,46)</a> The inhibitor was modeled into the closely fitting positive Fo-Fc electron density and included in following refinement cycles. Topology and parameter files for the inhibitor were generated using PRODRG. The diffraction data collection and refinement statistics are summarized in Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.0c00891/suppl_file/jm0c00891_si_001.pdf" class="ext-link">Tables S1 and S2</a>.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Cross-Linking Assay of EGFR Dimerization/Oligomerization</h3><div class="NLM_p last">Twenty micromolar EGFR mutant protein in 20 mM sodium phosphate, 0.15 M NaCl, pH 8.0 was incubated at room temperature for 30 min in the absence or presence of AZD9291 or CO-1686 at different concentrations. The cross-linker BS3 (Thermo scientific) was added to the mixture to the final concentration of 0.4 mM and then the mixture was incubated at room temperature for 30 min. Finally, 50 mM Tris (pH 8.0) was added to stop the reaction before analysis by SDS-polyacrylamide gel electrophoresis (SDS-PAGE).</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15"><a href="/doi/suppl/10.1021/acs.jmedchem.0c00891" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32613" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32613" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c00891?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00891</a>.<ul class="NLM_list-list_type-label"><li><p class="inline">Data collection and refinement statistics; plots of the Cys797 SGâAZD9291 warhead distances; Stereo views of 2Fo-Fc and Fo-Fc maps; Stereo views of omit maps; In vitro cross-linking assay; comparison of the quantum mechanics (QM) energy profile of AZD9291) (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00891/suppl_file/jm0c00891_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00891/suppl_file/jm0c00891_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00891/suppl_file/jm0c00891_si_001.pdf">jm0c00891_si_001.pdf (2.19 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00891/suppl_file/jm0c00891_si_002.csv">jm0c00891_si_002.csv (1.53 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Coordinates and structural factors of T790M/skAZD9291, T790M/ccAZD9291, L858R/skAZD9291, and WT/ccAZD9291 have been deposited in the Protein Data Bank under the accession code 6JX4, 6JX0, 6JWL, and 6JXT, respectively.</p><div class="testing" data-doi="10.1021/acs.jmedchem.0c00891" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18521" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18521" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yibing Shan</span> - <span class="hlFld-Affiliation affiliation">D.
E. Shaw Research, New York, New York 10036, United States</span>;Â 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#530a3a313a3d347d003b323d131716003b3224013620363221303b7d303c3e"><span class="__cf_email__" data-cfemail="aaf3c3c8c3c4cd84f9c2cbc4eaeeeff9c2cbddf8cfd9cfcbd8c9c284c9c5c7">[emailÂ protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David E. Shaw</span> - <span class="hlFld-Affiliation affiliation">D.
E. Shaw Research, New York, New York 10036, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Department
of Biochemistry and Molecular Biophysics, Columbia University, New York, New York 10032, United States</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8265-5761" title="Orcid link">http://orcid.org/0000-0001-8265-5761</a>;Â 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#3f7b5e49565b116c575e487f7b7a6c575e486d5a4c5a5e4d5c57115c5052"><span class="__cf_email__" data-cfemail="89cde8ffe0eda7dae1e8fec9cdccdae1e8fedbecfaece8fbeae1a7eae6e4">[emailÂ protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Cai-Hong Yun</span> - <span class="hlFld-Affiliation affiliation">Department
of Biochemistry and Biophysics,Â 
    Department of Integration of Chinese
and Western Medicine, School of Basic Medical Sciences,Â 
     and , Peking University Health Science Center, Beijing 100191, China</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5880-8307" title="Orcid link">http://orcid.org/0000-0002-5880-8307</a>;Â 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#1f666a717c775f6f746a317a7b6a317c71"><span class="__cf_email__" data-cfemail="cbb2bea5a8a38bbba0bee5aeafbee5a8a5">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiao-E Yan</span> - <span class="hlFld-Affiliation affiliation">Department
of Biochemistry and Biophysics,Â 
    Department of Integration of Chinese
and Western Medicine, School of Basic Medical Sciences,Â 
     and , Peking University Health Science Center, Beijing 100191, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pelin Ayaz</span> - <span class="hlFld-Affiliation affiliation">D.
E. Shaw Research, New York, New York 10036, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Su-Jie Zhu</span> - <span class="hlFld-Affiliation affiliation">Institute
of Translational Medicine, The Affiliated
Hospital of Qingdao University, College of Medicine, Qingdao University, Qingdao 266021, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peng Zhao</span> - <span class="hlFld-Affiliation affiliation">Department
of Biochemistry and Biophysics,Â 
    Department of Integration of Chinese
and Western Medicine, School of Basic Medical Sciences,Â 
     and , Peking University Health Science Center, Beijing 100191, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ling Liang</span> - <span class="hlFld-Affiliation affiliation">Department
of Biochemistry and Biophysics,Â 
    Department of Integration of Chinese
and Western Medicine, School of Basic Medical Sciences,Â 
     and , Peking University Health Science Center, Beijing 100191, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Casey H. Zhang</span> - <span class="hlFld-Affiliation affiliation">D.
E. Shaw Research, New York, New York 10036, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ya-Chuang Wu</span> - <span class="hlFld-Affiliation affiliation">Department
of Biochemistry and Biophysics,Â 
    Department of Integration of Chinese
and Western Medicine, School of Basic Medical Sciences,Â 
     and , Peking University Health Science Center, Beijing 100191, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Je-Luen Li</span> - <span class="hlFld-Affiliation affiliation">D.
E. Shaw Research, New York, New York 10036, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hwan Geun Choi</span> - <span class="hlFld-Affiliation affiliation">Department
of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Department
of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xin Huang</span> - <span class="hlFld-Affiliation affiliation">Hongyun
Biotech Co., Ltd., Nanjing, Jiangsu 211112, China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>X.-E.Y., P.A., S.-J.Z., and P.Z. contributed equally to this work.</p><span class="author-information-subsection-header">Author Contributions</span><p>C.-H.Y. and Y.S. conceived this study. C.-H.Y. oversaw the experimental aspect of the study. Y.S. and D.E.S. oversaw the simulation aspect of the study. S.-J.Z., X.-E.Y., and P.Z. conducted the wet-lab experiments. P.A. and Y.S. conducted the molecular dynamics studies. H.G.C. synthesized the compounds. All authors except H.G.C. analyzed the data. C.-H.Y., Y.S., P.A., and S.-J.Z. wrote the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): X.H. is a shareholder of Hongyun Biotech Co., Ltd.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e1003-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77438" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77438" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank the staff of APS beamline ID-19 and SSRF beamlines BL18U/BL19U1 for assistance in data collection. We thank Nathanael Gray, Michael Eck, and Michael Eastwood for helpful discussions. This study was funded by the National Natural Science Foundation of China (No. 31270769), the National Basic Research Program of China (973 Program, No. 2012CB917202), and the Ministry of Education of China (NCET-12-0013).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">Epidermal Growth Factor Receptor</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84850" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84850" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 46 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paez, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tracy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greulich, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabriel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaye, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindeman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggon, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naoki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujii, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span> <span> </span><span class="NLM_article-title">EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>304</i></span>,  <span class="NLM_fpage">1497</span>â <span class="NLM_lpage">1500</span>, <span class="refDoi">Â DOI: 10.1126/science.1099314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1126%2Fscience.1099314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=15118125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVGmsbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=304&publication_year=2004&pages=1497-1500&author=J.+G.+Paezauthor=P.+A.+Janneauthor=J.+C.+Leeauthor=S.+Tracyauthor=H.+Greulichauthor=S.+Gabrielauthor=P.+Hermanauthor=F.+J.+Kayeauthor=N.+Lindemanauthor=T.+J.+Boggonauthor=K.+Naokiauthor=H.+Sasakiauthor=Y.+Fujiiauthor=M.+J.+Eckauthor=W.+R.+Sellersauthor=B.+E.+Johnsonauthor=M.+Meyerson&title=EGFR+mutations+in+lung+cancer%3A+correlation+with+clinical+response+to+gefitinib+therapy&doi=10.1126%2Fscience.1099314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy</span></div><div class="casAuthors">Paez, J. Guillermo; Jaenne, Pasi A.; Lee, Jeffrey C.; Tracy, Sean; Greulich, Heidi; Gabriel, Stacey; Herman, Paula; Kaye, Frederic J.; Lindeman, Neal; Boggon, Titus J.; Naoki, Katsuhiko; Sasaki, Hidefumi; Fujii, Yoshitaka; Eck, Michael J.; Sellers, William R.; Johnson, Bruce E.; Meyerson, Matthew</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">304</span>
        (<span class="NLM_cas:issue">5676</span>),
    <span class="NLM_cas:pages">1497-1500</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Receptor tyrosine kinase genes were sequenced in non-small cell lung cancer (NSCLC) and matched normal tissue.  Somatic mutations of the epidermal growth factor receptor gene EGFR were found in 15 of 58 unselected tumors from Japan and 1 of 61 from the United States.  Treatment with the EGFR kinase inhibitor gefitinib (Iressa) causes tumor regression in some patients with NSCLC, more frequently in Japan.  EGFR mutations were found in addnl. lung cancer samples from U.S. patients who responded to gefitinib therapy and in a lung adenocarcinoma cell line that was hypersensitive to growth inhibition by gefitinib, but not in gefitinib-insensitive tumors or cell lines.  These results suggest that EGFR mutations may predict sensitivity to gefitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGxLJH5f3Kb7Vg90H21EOLACvtfcHk0li4PQhBTAmO_w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVGmsbs%253D&md5=6df1b11bf9b3c284fbe000e34c61ebac</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1126%2Fscience.1099314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1099314%26sid%3Dliteratum%253Aachs%26aulast%3DPaez%26aufirst%3DJ.%2BG.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DTracy%26aufirst%3DS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DGabriel%26aufirst%3DS.%26aulast%3DHerman%26aufirst%3DP.%26aulast%3DKaye%26aufirst%3DF.%2BJ.%26aulast%3DLindeman%26aufirst%3DN.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DNaoki%26aufirst%3DK.%26aulast%3DSasaki%26aufirst%3DH.%26aulast%3DFujii%26aufirst%3DY.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DMeyerson%26aufirst%3DM.%26atitle%3DEGFR%2520mutations%2520in%2520lung%2520cancer%253A%2520correlation%2520with%2520clinical%2520response%2520to%2520gefitinib%2520therapy%26jtitle%3DScience%26date%3D2004%26volume%3D304%26spage%3D1497%26epage%3D1500%26doi%3D10.1126%2Fscience.1099314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sordella, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurubhagavatula, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okimoto, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brannigan, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haserlat, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Supko, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haluska, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louis, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christiani, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Settleman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haber, D. A.</span></span> <span> </span><span class="NLM_article-title">Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>350</i></span>,  <span class="NLM_fpage">2129</span>â <span class="NLM_lpage">2139</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa040938</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1056%2FNEJMoa040938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=15118073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BD2cXktF2js7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=2004&pages=2129-2139&author=T.+J.+Lynchauthor=D.+W.+Bellauthor=R.+Sordellaauthor=S.+Gurubhagavatulaauthor=R.+A.+Okimotoauthor=B.+W.+Branniganauthor=P.+L.+Harrisauthor=S.+M.+Haserlatauthor=J.+G.+Supkoauthor=F.+G.+Haluskaauthor=D.+N.+Louisauthor=D.+C.+Christianiauthor=J.+Settlemanauthor=D.+A.+Haber&title=Activating+mutations+in+the+epidermal+growth+factor+receptor+underlying+responsiveness+of+non-small-cell+lung+cancer+to+gefitinib&doi=10.1056%2FNEJMoa040938"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Lynch, Thomas J.; Bell, Daphne W.; Sordella, Raffaella; Gurubhagavatula, Sarada; Okimoto, Ross A.; Brannigan, Brian W.; Harris, Patricia L.; Haserlat, Sara M.; Supko, Jeffrey G.; Haluska, Frank G.; Louis, David N.; Christiani, David C.; Settleman, Jeff; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">350</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2129-2139</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Most patients with non-small-cell lung cancer have no response to the tyrosine kinase inhibitor gefitinib, which targets the epidermal growth factor receptor (EGFR).  However, about 10% of patients have a rapid and often dramatic clin. response.  The mol. mechanisms underlying sensitivity to gefitinib are unknown.  We searched for mutations in the EGFR gene in primary tumors from patients with non-small-cell lung cancer who had a response to gefitinib, those who did not have a response, and those who had not been exposed to gefitinib.  The functional consequences of identified mutations were evaluated after the mutant proteins were expressed in cultured cells.  Somatic mutations were identified in the tyrosine kinase domain of the EGFR gene in eight of nine patients with gefitinib-responsive lung cancer, as compared with none of the seven patients with no response (P < 0.001).  Mutations were either small, in-frame deletions or amino acid substitutions clustered around the ATP-binding pocket of the tyrosine kinase domain.  Similar mutations were detected in tumors from 2 of 25 patients with primary non-small-cell lung cancer who had not been exposed to gefitinib (8%).  All mutations were heterozygous, and identical mutations were obsd. in multiple patients, suggesting an additive specific gain of function.  In vitro, EGFR mutants demonstrated enhanced tyrosine kinase activity in response to epidermal growth factor and increased sensitivity to inhibition by gefitinib.  A subgroup of patients with non-small-cell lung cancer have specific mutations in the EGFR gene, which correlate with clin. responsiveness to the tyrosine kinase inhibitor gefitinib.  These mutations lead to increased growth factor signaling and confer susceptibility to the inhibitor.  Screening for such mutations in lung cancers may identify patients who will have a response to gefitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXwWGeAQrNTLVg90H21EOLACvtfcHk0li4PQhBTAmO_w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXktF2js7c%253D&md5=fad70aa0f32ad4105ad6f3db98135bf9</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa040938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa040938%26sid%3Dliteratum%253Aachs%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DGurubhagavatula%26aufirst%3DS.%26aulast%3DOkimoto%26aufirst%3DR.%2BA.%26aulast%3DBrannigan%26aufirst%3DB.%2BW.%26aulast%3DHarris%26aufirst%3DP.%2BL.%26aulast%3DHaserlat%26aufirst%3DS.%2BM.%26aulast%3DSupko%26aufirst%3DJ.%2BG.%26aulast%3DHaluska%26aufirst%3DF.%2BG.%26aulast%3DLouis%26aufirst%3DD.%2BN.%26aulast%3DChristiani%26aufirst%3DD.%2BC.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DActivating%2520mutations%2520in%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520underlying%2520responsiveness%2520of%2520non-small-cell%2520lung%2520cancer%2520to%2520gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2004%26volume%3D350%26spage%3D2129%26epage%3D2139%26doi%3D10.1056%2FNEJMoa040938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zakowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doherty, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Politi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkaria, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heelan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulton, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mardis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kupfer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kris, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varmus, H.</span></span> <span> </span><span class="NLM_article-title">EGF receptor gene mutations are common in lung cancers from ânever smokersâ and are associated with sensitivity of tumors to gefitinib and erlotinib</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">13306</span>â <span class="NLM_lpage">13311</span>, <span class="refDoi">Â DOI: 10.1073/pnas.0405220101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1073%2Fpnas.0405220101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=15329413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnvFems70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=13306-13311&author=W.+Paoauthor=V.+Millerauthor=M.+Zakowskiauthor=J.+Dohertyauthor=K.+Politiauthor=I.+Sarkariaauthor=B.+Singhauthor=R.+Heelanauthor=V.+Ruschauthor=L.+Fultonauthor=E.+Mardisauthor=D.+Kupferauthor=R.+Wilsonauthor=M.+Krisauthor=H.+Varmus&title=EGF+receptor+gene+mutations+are+common+in+lung+cancers+from+%E2%80%9Cnever+smokers%E2%80%9D+and+are+associated+with+sensitivity+of+tumors+to+gefitinib+and+erlotinib&doi=10.1073%2Fpnas.0405220101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib</span></div><div class="casAuthors">Pao, William; Miller, Vincent; Zakowski, Maureen; Doherty, Jennifer; Politi, Katerina; Sarkaria, Inderpal; Singh, Bhuvanesh; Heelan, Robert; Rusch, Valerie; Fulton, Lucinda; Mardis, Elaine; Kupfer, Doris; Wilson, Richard; Kris, Mark; Varmus, Harold</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">13306-13311</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Somatic mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene are reportedly assocd. with sensitivity of lung cancers to gefitinib (Iressa), kinase inhibitor.  In-frame deletions occur in exon 19, whereas point mutations occur frequently in codon 858 (exon 21).  We found from sequencing the EGFR TK domain that 7 of 10 gefitinib-sensitive tumors had similar types of alterations; no mutations were found in eight gefitinib-refractory tumors (P = 0.004).  Five of seven tumors sensitive to erlotinib (Tarceva), a related kinase inhibitor for which the clin. relevant target is undocumented, had analogous somatic mutations, as opposed to none of 10 erlotinib-refractory tumors (P = 0.003).  Because most mutation-pos. tumors were adenocarcinomas from patients who smoked <100 cigarettes in a lifetime ("never smokers"), we screened EGFR exons 2-28 in 15 adenocarcinomas resected from untreated never smokers.  Seven tumors had TK domain mutations, in contrast to 4 of 81 non-small cell lung cancers resected from untreated former or current smokers (P = 0.0001).  Immunoblotting of lysates from cells transiently transfected with various EGFR constructs demonstrated that, compared to wild-type protein, an exon 19 deletion mutant induced diminished levels of phosphotyrosine, whereas the phosphorylation at tyrosine 1092 of an exon 21 point mutant was inhibited at 10-fold lower concns. of drug.  Collectively, these data show that adenocarcinomas from never smokers comprise a distinct subset of lung cancers, frequently contg. mutations within the TK domain of EGFR that are assocd. with gefitinib and erlotinib sensitivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovevWonTGqELVg90H21EOLACvtfcHk0liUYJcI8QBKQQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnvFems70%253D&md5=38f491968552501b7463a688fa0e62ff</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0405220101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0405220101%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%26aulast%3DZakowski%26aufirst%3DM.%26aulast%3DDoherty%26aufirst%3DJ.%26aulast%3DPoliti%26aufirst%3DK.%26aulast%3DSarkaria%26aufirst%3DI.%26aulast%3DSingh%26aufirst%3DB.%26aulast%3DHeelan%26aufirst%3DR.%26aulast%3DRusch%26aufirst%3DV.%26aulast%3DFulton%26aufirst%3DL.%26aulast%3DMardis%26aufirst%3DE.%26aulast%3DKupfer%26aufirst%3DD.%26aulast%3DWilson%26aufirst%3DR.%26aulast%3DKris%26aufirst%3DM.%26aulast%3DVarmus%26aufirst%3DH.%26atitle%3DEGF%2520receptor%2520gene%2520mutations%2520are%2520common%2520in%2520lung%2520cancers%2520from%2520%25E2%2580%259Cnever%2520smokers%25E2%2580%259D%2520and%2520are%2520associated%2520with%2520sensitivity%2520of%2520tumors%2520to%2520gefitinib%2520and%2520erlotinib%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2004%26volume%3D101%26spage%3D13306%26epage%3D13311%26doi%3D10.1073%2Fpnas.0405220101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggon, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dayaram, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocher, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tenen, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halmos, B.</span></span> <span> </span><span class="NLM_article-title">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>352</i></span>,  <span class="NLM_fpage">786</span>â <span class="NLM_lpage">792</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa044238</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1056%2FNEJMoa044238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=15728811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=786-792&author=S.+Kobayashiauthor=T.+J.+Boggonauthor=T.+Dayaramauthor=P.+A.+Janneauthor=O.+Kocherauthor=M.+Meyersonauthor=B.+E.+Johnsonauthor=M.+J.+Eckauthor=D.+G.+Tenenauthor=B.+Halmos&title=EGFR+mutation+and+resistance+of+non-small-cell+lung+cancer+to+gefitinib&doi=10.1056%2FNEJMoa044238"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Kobayashi, Susumu; Boggon, Titus J.; Dayaram, Tajhal; Jaenne, Pasi A.; Kocher, Olivier; Meyerson, Matthew; Johnson, Bruce E.; Eck, Michael J.; Tenen, Daniel G.; Halmos, Balizs</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">786-792</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Mutations of the epidermal growth factor receptor (EGFR) gene were identified in specimens from patients with non-small-cell lung cancer who have a response to anilinoquinazoline EGFR inhibitors.  Despite the dramatic responses to such inhibitors, most patients ultimately have a relapse.  The mechanism of the drug resistance is unknown.  Here the authors report the case of a patient with EGFR-mutant, gefitinib-responsive, advanced non-small-cell lung cancer who had a relapse after 2 years of complete remission during treatment with gefitinib.  The DNA sequence of the EGFR gene in his tumor biopsy specimen at relapse revealed the presence of a second point mutation, resulting in threonine-to-methionine amino acid change at position 790 of EGFR.  Structural modeling and biochem. studies showed that this second mutation led to gefitinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8XXhT1hrbe7Vg90H21EOLACvtfcHk0liUYJcI8QBKQQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D&md5=808223ad566e2a3748977727cc5a9846</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa044238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa044238%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DDayaram%26aufirst%3DT.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DKocher%26aufirst%3DO.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DTenen%26aufirst%3DD.%2BG.%26aulast%3DHalmos%26aufirst%3DB.%26atitle%3DEGFR%2520mutation%2520and%2520resistance%2520of%2520non-small-cell%2520lung%2520cancer%2520to%2520gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26spage%3D786%26epage%3D792%26doi%3D10.1056%2FNEJMoa044238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Politi, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somwar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zakowski, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kris, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varmus, H.</span></span> <span> </span><span class="NLM_article-title">Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain</span>. <i>PLoS Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>2</i></span>, <span class="NLM_elocation-id">e73</span> <span class="refDoi">Â DOI: 10.1371/journal.pmed.0020073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1371%2Fjournal.pmed.0020073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=15737014" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A280%3ADC%252BD2MzjtVehsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&author=W.+Paoauthor=V.+A.+Millerauthor=K.+A.+Politiauthor=G.+J.+Rielyauthor=R.+Somwarauthor=M.+F.+Zakowskiauthor=M.+G.+Krisauthor=H.+Varmus&title=Acquired+resistance+of+lung+adenocarcinomas+to+gefitinib+or+erlotinib+is+associated+with+a+second+mutation+in+the+EGFR+kinase+domain&doi=10.1371%2Fjournal.pmed.0020073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain</span></div><div class="casAuthors">Pao William; Miller Vincent A; Politi Katerina A; Riely Gregory J; Somwar Romel; Zakowski Maureen F; Kris Mark G; Varmus Harold</div><div class="citationInfo"><span class="NLM_cas:title">PLoS medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e73</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Lung adenocarcinomas from patients who respond to the tyrosine kinase inhibitors gefitinib (Iressa) or erlotinib (Tarceva) usually harbor somatic gain-of-function mutations in exons encoding the kinase domain of the epidermal growth factor receptor (EGFR).  Despite initial responses, patients eventually progress by unknown mechanisms of "acquired" resistance.  METHODS AND FINDINGS:  We show that in two of five patients with acquired resistance to gefitinib or erlotinib, progressing tumors contain, in addition to a primary drug-sensitive mutation in EGFR, a secondary mutation in exon 20, which leads to substitution of methionine for threonine at position 790 (T790M) in the kinase domain.  Tumor cells from a sixth patient with a drug-sensitive EGFR mutation whose tumor progressed on adjuvant gefitinib after complete resection also contained the T790M mutation.  This mutation was not detected in untreated tumor samples.  Moreover, no tumors with acquired resistance had KRAS mutations, which have been associated with primary resistance to these drugs.  Biochemical analyses of transfected cells and growth inhibition studies with lung cancer cell lines demonstrate that the T790M mutation confers resistance to EGFR mutants usually sensitive to either gefitinib or erlotinib.  Interestingly, a mutation analogous to T790M has been observed in other kinases with acquired resistance to another kinase inhibitor, imatinib (Gleevec).  CONCLUSION:  In patients with tumors bearing gefitinib- or erlotinib-sensitive EGFR mutations, resistant subclones containing an additional EGFR mutation emerge in the presence of drug.  This observation should help guide the search for more effective therapy against a specific subset of lung cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcREkXMV3u1nwwMthz5_Rx5rfW6udTcc2eYPujMznnik5bntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MzjtVehsw%253D%253D&md5=3e626105e0dea2a38997156ae513f56b</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pmed.0020073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pmed.0020073%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPoliti%26aufirst%3DK.%2BA.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DSomwar%26aufirst%3DR.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DVarmus%26aufirst%3DH.%26atitle%3DAcquired%2520resistance%2520of%2520lung%2520adenocarcinomas%2520to%2520gefitinib%2520or%2520erlotinib%2520is%2520associated%2520with%2520a%2520second%2520mutation%2520in%2520the%2520EGFR%2520kinase%2520domain%26jtitle%3DPLoS%2520Med.%26date%3D2005%26volume%3D2%26doi%3D10.1371%2Fjournal.pmed.0020073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Balak, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somwar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zakowski, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouerfelli, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kris, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladanyi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span> <span> </span><span class="NLM_article-title">Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">6494</span>â <span class="NLM_lpage">6501</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-06-1570</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1158%2F1078-0432.CCR-06-1570" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=17085664" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFKitbrI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=6494-6501&author=M.+N.+Balakauthor=Y.+Gongauthor=G.+J.+Rielyauthor=R.+Somwarauthor=A.+R.+Liauthor=M.+F.+Zakowskiauthor=A.+Chiangauthor=G.+Yangauthor=O.+Ouerfelliauthor=M.+G.+Krisauthor=M.+Ladanyiauthor=V.+A.+Millerauthor=W.+Pao&title=Novel+D761Y+and+common+secondary+T790M+mutations+in+epidermal+growth+factor+receptor-mutant+lung+adenocarcinomas+with+acquired+resistance+to+kinase+inhibitors&doi=10.1158%2F1078-0432.CCR-06-1570"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor-Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors</span></div><div class="casAuthors">Balak, Marissa N.; Gong, Yixuan; Riely, Gregory J.; Somwar, Romel; Li, Allan R.; Zakowski, Maureen F.; Chiang, Anne; Yang, Guangli; Ouerfelli, Ouathek; Kris, Mark G.; Ladanyi, Marc; Miller, Vincent A.; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6494-6501</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: In patients whose lung adenocarcinomas harbor epidermal growth factor receptor (EGFR) tyrosine kinase domain mutations, acquired resistance to the tyrosine kinase inhibitors (TKI) gefitinib (Iressa) and erlotinib (Tarceva) has been assocd. with a second-site EGFR mutation, which leads to substitution of methionine for threonine at position 790 (T790M).  We aimed to elucidate the frequency and nature of secondary EGFR mutations in patients with acquired resistance to TKI monotherapy.  Exptl. Design: Tumor cells from patients with acquired resistance were examd. for secondary EGFR kinase domain mutations by mol. analyses.  RESULTS: Eight of 16 patients (50% obsd. rate; 95% confidence interval, 25-75%) had tumor cells with second-site EGFR mutations.  Seven mutations were T790M and one was a novel D761Y mutation found in a brain metastasis.  When combined with a drug-sensitive L858R mutation, the D761Y mutation modestly reduced the sensitivity of mutant EGFR to TKIs in both surrogate kinase and cell viability assays.  In an autopsy case, the T790M mutation was found in multiple visceral metastases but not in a brain lesion.  CONCLUSIONS: The T790M mutation is common in patients with acquired resistance.  The limited spectrum of TKI-resistant mutations in EGFR, which binds to erlotinib in the active conformation, contrasts with a wider range of second-site mutations seen with acquired resistance to imatinib, which binds to ABL and KIT, resp., in closed conformations.  Collectively, our data suggest that the type and nature of kinase inhibitor resistance mutations may be influenced by both anat. site and mode of binding to the kinase target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmeHDQldYeDLVg90H21EOLACvtfcHk0lgz2jjycM8tgg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFKitbrI&md5=e817eb717673081d89ec3d58a04a7d4d</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-1570&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-1570%26sid%3Dliteratum%253Aachs%26aulast%3DBalak%26aufirst%3DM.%2BN.%26aulast%3DGong%26aufirst%3DY.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DSomwar%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DA.%2BR.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DChiang%26aufirst%3DA.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DOuerfelli%26aufirst%3DO.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DNovel%2520D761Y%2520and%2520common%2520secondary%2520T790M%2520mutations%2520in%2520epidermal%2520growth%2520factor%2520receptor-mutant%2520lung%2520adenocarcinomas%2520with%2520acquired%2520resistance%2520to%2520kinase%2520inhibitors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D6494%26epage%3D6501%26doi%3D10.1158%2F1078-0432.CCR-06-1570" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mengwasser, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toms, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greulich, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span> <span> </span><span class="NLM_article-title">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">2070</span>â <span class="NLM_lpage">2075</span>, <span class="refDoi">Â DOI: 10.1073/pnas.0709662105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1073%2Fpnas.0709662105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=18227510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2070-2075&author=C.+H.+Yunauthor=K.+E.+Mengwasserauthor=A.+V.+Tomsauthor=M.+S.+Wooauthor=H.+Greulichauthor=K.+K.+Wongauthor=M.+Meyersonauthor=M.+J.+Eck&title=The+T790M+mutation+in+EGFR+kinase+causes+drug+resistance+by+increasing+the+affinity+for+ATP&doi=10.1073%2Fpnas.0709662105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span></div><div class="casAuthors">Yun, Cai-Hong; Mengwasser, Kristen E.; Toms, Angela V.; Woo, Michele S.; Greulich, Heidi; Wong, Kwok-Kin; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2070-2075</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to small mol. tyrosine kinase inhibitors (TKIs), but the efficacy of these agents is often limited because of the emergence of drug resistance conferred by a second mutation, T790M.  Threonine 790 is the "gatekeeper" residue, an important determinant of inhibitor specificity in the ATP binding pocket.  The T790M mutation has been thought to cause resistance by sterically blocking binding of TKIs such as gefitinib and erlotinib, but this explanation is difficult to reconcile with the fact that it remains sensitive to structurally similar irreversible inhibitors.  Here, we show by using a direct binding assay that T790M mutants retain low-nanomolar affinity for gefitinib.  Furthermore, we show that the T790M mutation activates WT EGFR and that introduction of the T790M mutation increases the ATP affinity of the oncogenic L858R mutant by more than an order of magnitude.  The increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance.  Crystallog. anal. of the T790M mutant shows how it can adapt to accommodate tight binding of diverse inhibitors, including the irreversible inhibitor HKI-272, and also suggests a structural mechanism for catalytic activation.  We conclude that the T790M mutation is a "generic" resistance mutation that will reduce the potency of any ATP-competitive kinase inhibitor and that irreversible inhibitors overcome this resistance simply through covalent binding, not as a result of an alternative binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXXP7TBlyrdrVg90H21EOLACvtfcHk0lgPDEbSQ4t5Jw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D&md5=f5f5d791a65f73ca628d95e9922b8ea8</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0709662105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0709662105%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DMengwasser%26aufirst%3DK.%2BE.%26aulast%3DToms%26aufirst%3DA.%2BV.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520T790M%2520mutation%2520in%2520EGFR%2520kinase%2520causes%2520drug%2520resistance%2520by%2520increasing%2520the%2520affinity%2520for%2520ATP%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2008%26volume%3D105%26spage%3D2070%26epage%3D2075%26doi%3D10.1073%2Fpnas.0709662105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capelletti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortot, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chirieac, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacob, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padera, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engen, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span> <span> </span><span class="NLM_article-title">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>462</i></span>,  <span class="NLM_fpage">1070</span>â <span class="NLM_lpage">1074</span>, <span class="refDoi">Â DOI: 10.1038/nature08622</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1038%2Fnature08622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=20033049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2009&pages=1070-1074&author=W.+Zhouauthor=D.+Ercanauthor=L.+Chenauthor=C.+H.+Yunauthor=D.+Liauthor=M.+Capellettiauthor=A.+B.+Cortotauthor=L.+Chirieacauthor=R.+E.+Iacobauthor=R.+Paderaauthor=J.+R.+Engenauthor=K.+K.+Wongauthor=M.+J.+Eckauthor=N.+S.+Grayauthor=P.+A.+Janne&title=Novel+mutant-selective+EGFR+kinase+inhibitors+against+EGFR+T790M&doi=10.1038%2Fnature08622"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span></div><div class="casAuthors">Zhou, Wenjun; Ercan, Dalia; Chen, Liang; Yun, Cai-Hong; Li, Danan; Capelletti, Marzia; Cortot, Alexis B.; Chirieac, Lucian; Iacob, Roxana E.; Padera, Robert; Engen, John R.; Wong, Kwok-Kin; Eck, Michael J.; Gray, Nathanael S.; Janne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">462</span>
        (<span class="NLM_cas:issue">7276</span>),
    <span class="NLM_cas:pages">1070-1074</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR-mutant non-small-cell lung cancer (NSCLC) is limited by the development of drug-resistance mutations, including the gatekeeper T790M mutation.  Strategies targeting EGFR T790M with irreversible inhibitors have had limited success and are assocd. with toxicity due to concurrent inhibition of wild-type EGFR.  All current EGFR inhibitors possess a structurally related quinazoline-based core scaffold and were identified as ATP-competitive inhibitors of wild-type EGFR.  Here we identify a covalent pyrimidine EGFR inhibitor by screening an irreversible kinase inhibitor library specifically against EGFR T790M.  These agents are 30- to 100-fold more potent against EGFR T790M, and up to 100-fold less potent against wild-type EGFR, than quinazoline-based EGFR inhibitors in vitro.  They are also effective in murine models of lung cancer driven by EGFR T790M.  Co-crystn. studies reveal a structural basis for the increased potency and mutant selectivity of these agents.  These mutant-selective irreversible EGFR kinase inhibitors may be clin. more effective and better tolerated than quinazoline-based inhibitors.  Our findings demonstrate that functional pharmacol. screens against clin. important mutant kinases represent a powerful strategy to identify new classes of mutant-selective kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcksZlIe-1bbVg90H21EOLACvtfcHk0lin_VGD_VajcA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI&md5=9b5d41a2be401c67a4b9f04a41cf1725</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnature08622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08622%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DCortot%26aufirst%3DA.%2BB.%26aulast%3DChirieac%26aufirst%3DL.%26aulast%3DIacob%26aufirst%3DR.%2BE.%26aulast%3DPadera%26aufirst%3DR.%26aulast%3DEngen%26aufirst%3DJ.%2BR.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DNovel%2520mutant-selective%2520EGFR%2520kinase%2520inhibitors%2520against%2520EGFR%2520T790M%26jtitle%3DNature%26date%3D2009%26volume%3D462%26spage%3D1070%26epage%3D1074%26doi%3D10.1038%2Fnature08622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walter, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sjin, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haringsma, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubrovskiy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labenski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheets, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St Martin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karp, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Kalken, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaturvedi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nacht, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petter, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westlin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaw-Tsai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raponi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Dyke, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Etter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmons, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harding, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, A.</span></span> <span> </span><span class="NLM_article-title">Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1404</span>â <span class="NLM_lpage">1415</span>, <span class="refDoi">Â DOI: 10.1158/2159-8290.CD-13-0314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1158%2F2159-8290.CD-13-0314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=24065731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvV2rtLvN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=1404-1415&author=A.+O.+Walterauthor=R.+T.+Sjinauthor=H.+J.+Haringsmaauthor=K.+Ohashiauthor=J.+Sunauthor=K.+Leeauthor=A.+Dubrovskiyauthor=M.+Labenskiauthor=Z.+Zhuauthor=Z.+Wangauthor=M.+Sheetsauthor=T.+St+Martinauthor=R.+Karpauthor=D.+van+Kalkenauthor=P.+Chaturvediauthor=D.+Niuauthor=M.+Nachtauthor=R.+C.+Petterauthor=W.+Westlinauthor=K.+Linauthor=S.+Jaw-Tsaiauthor=M.+Raponiauthor=T.+Van+Dykeauthor=J.+Etterauthor=Z.+Weaverauthor=W.+Paoauthor=J.+Singhauthor=A.+D.+Simmonsauthor=T.+C.+Hardingauthor=A.+Allen&title=Discovery+of+a+mutant-selective+covalent+inhibitor+of+EGFR+that+overcomes+T790M-mediated+resistance+in+NSCLC&doi=10.1158%2F2159-8290.CD-13-0314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC</span></div><div class="casAuthors">Walter, Annette O.; Sjin, Robert Tjin Tham; Haringsma, Henry J.; Ohashi, Kadoaki; Sun, Jing; Lee, Kwangho; Dubrovskiy, Aleksandr; Labenski, Matthew; Zhu, Zhendong; Wang, Zhigang; Sheets, Michael; St. Martin, Thia; Karp, Russell; van Kalken, Dan; Chaturvedi, Prasoon; Niu, Deqiang; Nacht, Mariana; Petter, Russell C.; Westlin, William; Lin, Kevin; Jaw-Tsai, Sarah; Raponi, Mitch; Van Dyke, Terry; Etter, Jeff; Weaver, Zoe; Pao, William; Singh, Juswinder; Simmons, Andrew D.; Harding, Thomas C.; Allen, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1404-1415</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Patients with non-small cell lung cancer (NSCLC) with activating EGF receptor (EGFR) mutations initially respond to first-generation reversible EGFR tyrosine kinase inhibitors.  However, clin. efficacy is limited by acquired resistance, frequently driven by the EGFRT790M mutation.  CO-1686 is a novel, irreversible, and orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR, including T790M, while exhibiting minimal activity toward the wild-type (WT) receptor.  Oral administration of CO-1686 as single agent induces tumor regression in EGFR-mutated NSCLC tumor xenograft and transgenic models.  Minimal activity of CO-1686 against the WT EGFR receptor was obsd.  In NSCLC cells with acquired resistance to CO-1686 in vitro, there was no evidence of addnl. mutations or amplification of the EGFR gene, but resistant cells exhibited signs of epithelial-mesenchymal transition and demonstrated increased sensitivity to AKT inhibitors.  These results suggest that CO-1686 may offer a novel therapeutic option for patients with mutant EGFR NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR0CDWQZ5wn7Vg90H21EOLACvtfcHk0lin_VGD_VajcA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvV2rtLvN&md5=3d111f4bf958f2fda6890fbc0e1d99f5</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-13-0314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-13-0314%26sid%3Dliteratum%253Aachs%26aulast%3DWalter%26aufirst%3DA.%2BO.%26aulast%3DSjin%26aufirst%3DR.%2BT.%26aulast%3DHaringsma%26aufirst%3DH.%2BJ.%26aulast%3DOhashi%26aufirst%3DK.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DDubrovskiy%26aufirst%3DA.%26aulast%3DLabenski%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DSt%2BMartin%26aufirst%3DT.%26aulast%3DKarp%26aufirst%3DR.%26aulast%3Dvan%2BKalken%26aufirst%3DD.%26aulast%3DChaturvedi%26aufirst%3DP.%26aulast%3DNiu%26aufirst%3DD.%26aulast%3DNacht%26aufirst%3DM.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DWestlin%26aufirst%3DW.%26aulast%3DLin%26aufirst%3DK.%26aulast%3DJaw-Tsai%26aufirst%3DS.%26aulast%3DRaponi%26aufirst%3DM.%26aulast%3DVan%2BDyke%26aufirst%3DT.%26aulast%3DEtter%26aufirst%3DJ.%26aulast%3DWeaver%26aufirst%3DZ.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DSimmons%26aufirst%3DA.%2BD.%26aulast%3DHarding%26aufirst%3DT.%2BC.%26aulast%3DAllen%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520a%2520mutant-selective%2520covalent%2520inhibitor%2520of%2520EGFR%2520that%2520overcomes%2520T790M-mediated%2520resistance%2520in%2520NSCLC%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D1404%26epage%3D1415%26doi%3D10.1158%2F2159-8290.CD-13-0314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghiorghiu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberlein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nebhan, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitzler, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orme, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finlay, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Red Brewer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichihara, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Kadhimi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowlinson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinowska, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantarini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranson, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span> <span> </span><span class="NLM_article-title">AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1046</span>â <span class="NLM_lpage">1061</span>, <span class="refDoi">Â DOI: 10.1158/2159-8290.CD-14-0337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1158%2F2159-8290.CD-14-0337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=24893891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=1046-1061&author=D.+A.+Crossauthor=S.+E.+Ashtonauthor=S.+Ghiorghiuauthor=C.+Eberleinauthor=C.+A.+Nebhanauthor=P.+J.+Spitzlerauthor=J.+P.+Ormeauthor=M.+R.+Finlayauthor=R.+A.+Wardauthor=M.+J.+Mellorauthor=G.+Hughesauthor=A.+Rahiauthor=V.+N.+Jacobsauthor=M.+Red+Brewerauthor=E.+Ichiharaauthor=J.+Sunauthor=H.+Jinauthor=P.+Ballardauthor=K.+Al-Kadhimiauthor=R.+Rowlinsonauthor=T.+Klinowskaauthor=G.+H.+Richmondauthor=M.+Cantariniauthor=D.+W.+Kimauthor=M.+R.+Ransonauthor=W.+Pao&title=AZD9291%2C+an+irreversible+EGFR+TKI%2C+overcomes+T790M-mediated+resistance+to+EGFR+inhibitors+in+lung+cancer&doi=10.1158%2F2159-8290.CD-14-0337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer</span></div><div class="casAuthors">Cross, Darren A. E.; Ashton, Susan E.; Ghiorghiu, Serban; Eberlein, Cath; Nebhan, Caroline A.; Spitzler, Paula J.; Orme, Jonathon P.; Finlay, M. Raymond V.; Ward, Richard A.; Mellor, Martine J.; Hughes, Gareth; Rahi, Amar; Jacobs, Vivien N.; Brewer, Monica Red; Ichihara, Eiki; Sun, Jing; Jin, Hailing; Ballard, Peter; Al-Kadhimi, Katherine; Rowlinson, Rachel; Klinowska, Teresa; Richmond, Graham H. P.; Cantarini, Mireille; Kim, Dong-Wan; Ranson, Malcolm R.; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1046-1061</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A third-generation EGFR inhibitor selectively targets EGFR mutants, including T790M, but not wild-type EGFR, and induces durable antitumor responses in preclin. models and patients with NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDo3e2pAh8YbVg90H21EOLACvtfcHk0lj6BOCFJu2FSg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP&md5=f72e56f9463236ddc89eef32a4ab61b3</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0337%26sid%3Dliteratum%253Aachs%26aulast%3DCross%26aufirst%3DD.%2BA.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DNebhan%26aufirst%3DC.%2BA.%26aulast%3DSpitzler%26aufirst%3DP.%2BJ.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DHughes%26aufirst%3DG.%26aulast%3DRahi%26aufirst%3DA.%26aulast%3DJacobs%26aufirst%3DV.%2BN.%26aulast%3DRed%2BBrewer%26aufirst%3DM.%26aulast%3DIchihara%26aufirst%3DE.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DAl-Kadhimi%26aufirst%3DK.%26aulast%3DRowlinson%26aufirst%3DR.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DRichmond%26aufirst%3DG.%2BH.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DRanson%26aufirst%3DM.%2BR.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DAZD9291%252C%2520an%2520irreversible%2520EGFR%2520TKI%252C%2520overcomes%2520T790M-mediated%2520resistance%2520to%2520EGFR%2520inhibitors%2520in%2520lung%2520cancer%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26spage%3D1046%26epage%3D1061%26doi%3D10.1158%2F2159-8290.CD-14-0337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planchard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horn, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haggstrom, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frewer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantarini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickinson, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghiorghiu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranson, M.</span></span> <span> </span><span class="NLM_article-title">AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>372</i></span>,  <span class="NLM_fpage">1689</span>â <span class="NLM_lpage">1699</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa1411817</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1056%2FNEJMoa1411817" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=25923549" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A280%3ADC%252BC2Mjpt1yltA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2015&pages=1689-1699&author=P.+A.+Janneauthor=J.+C.+Yangauthor=D.+W.+Kimauthor=D.+Planchardauthor=Y.+Oheauthor=S.+S.+Ramalingamauthor=M.+J.+Ahnauthor=S.+W.+Kimauthor=W.+C.+Suauthor=L.+Hornauthor=D.+Haggstromauthor=E.+Felipauthor=J.+H.+Kimauthor=P.+Frewerauthor=M.+Cantariniauthor=K.+H.+Brownauthor=P.+A.+Dickinsonauthor=S.+Ghiorghiuauthor=M.+Ranson&title=AZD9291+in+EGFR+inhibitor-resistant+non-small-cell+lung+cancer&doi=10.1056%2FNEJMoa1411817"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer</span></div><div class="casAuthors">Janne Pasi A; Yang James Chih-Hsin; Kim Dong-Wan; Planchard David; Ohe Yuichiro; Ramalingam Suresh S; Ahn Myung-Ju; Kim Sang-We; Su Wu-Chou; Horn Leora; Haggstrom Daniel; Felip Enriqueta; Kim Joo-Hang; Frewer Paul; Cantarini Mireille; Brown Kathryn H; Dickinson Paul A; Ghiorghiu Serban; Ranson Malcolm</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1689-99</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The EGFR T790M mutation is the most common mechanism of drug resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in patients who have lung cancer with an EGFR mutation (EGFR-mutated lung cancer).  In preclinical models, the EGFR inhibitor AZD9291 has been shown to be effective against both EGFR tyrosine kinase inhibitor-sensitizing and T790M resistance mutations.  METHODS:  We administered AZD9291 at doses of 20 to 240 mg once daily in patients with advanced lung cancer who had radiologically documented disease progression after previous treatment with EGFR tyrosine kinase inhibitors.  The study included dose-escalation cohorts and dose-expansion cohorts.  In the expansion cohorts, prestudy tumor biopsies were required for central determination of EGFR T790M status.  Patients were assessed for safety, pharmacokinetics, and efficacy.  RESULTS:  A total of 253 patients were treated.  Among 31 patients enrolled in the dose-escalation cohorts, no dose-limiting toxic effects occurred at the doses evaluated.  An additional 222 patients were treated in five expansion cohorts.  The most common all-cause adverse events were diarrhea, rash, nausea, and decreased appetite.  The overall objective tumor response rate was 51% (95% confidence interval [CI], 45 to 58).  Among 127 patients with centrally confirmed EGFR T790M who could be evaluated for response, the response rate was 61% (95% CI, 52 to 70).  In contrast, among 61 patients without centrally detectable EGFR T790M who could be evaluated for response, the response rate was 21% (95% CI, 12 to 34).  The median progression-free survival was 9.6 months (95% CI, 8.3 to not reached) in EGFR T790M-positive patients and 2.8 months (95% CI, 2.1 to 4.3) in EGFR T790M-negative patients.  CONCLUSIONS:  AZD9291 was highly active in patients with lung cancer with the EGFR T790M mutation who had had disease progression during prior therapy with EGFR tyrosine kinase inhibitors. (Funded by AstraZeneca; ClinicalTrials.gov number, NCT01802632.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQME11ovAjH3SnGiHuhFGv8fW6udTcc2eavUEAM1xPuS7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mjpt1yltA%253D%253D&md5=7304f406bb2e568fb08b6d524d027389</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1411817&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1411817%26sid%3Dliteratum%253Aachs%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DPlanchard%26aufirst%3DD.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26aulast%3DAhn%26aufirst%3DM.%2BJ.%26aulast%3DKim%26aufirst%3DS.%2BW.%26aulast%3DSu%26aufirst%3DW.%2BC.%26aulast%3DHorn%26aufirst%3DL.%26aulast%3DHaggstrom%26aufirst%3DD.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DFrewer%26aufirst%3DP.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DK.%2BH.%26aulast%3DDickinson%26aufirst%3DP.%2BA.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DRanson%26aufirst%3DM.%26atitle%3DAZD9291%2520in%2520EGFR%2520inhibitor-resistant%2520non-small-cell%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D372%26spage%3D1689%26epage%3D1699%26doi%3D10.1056%2FNEJMoa1411817" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sequist, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakelee, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadgeel, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varga, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadimitrakopoulou, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oxnard, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dziadziuszko, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aisner, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doebele, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galasso, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garon, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heist, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Logan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neal, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendenhall, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piotrowska, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wozniak, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raponi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlovich, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaw-Tsai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isaacson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Despain, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matheny, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolfe, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D. R.</span></span> <span> </span><span class="NLM_article-title">Rociletinib in EGFR-mutated non-small-cell lung cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>372</i></span>,  <span class="NLM_fpage">1700</span>â <span class="NLM_lpage">1709</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa1413654</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1056%2FNEJMoa1413654" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=25923550" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A280%3ADC%252BC2Mjpt1yltQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2015&pages=1700-1709&author=L.+V.+Sequistauthor=J.+C.+Soriaauthor=J.+W.+Goldmanauthor=H.+A.+Wakeleeauthor=S.+M.+Gadgeelauthor=A.+Vargaauthor=V.+Papadimitrakopoulouauthor=B.+J.+Solomonauthor=G.+R.+Oxnardauthor=R.+Dziadziuszkoauthor=D.+L.+Aisnerauthor=R.+C.+Doebeleauthor=C.+Galassoauthor=E.+B.+Garonauthor=R.+S.+Heistauthor=J.+Loganauthor=J.+W.+Nealauthor=M.+A.+Mendenhallauthor=S.+Nicholsauthor=Z.+Piotrowskaauthor=A.+J.+Wozniakauthor=M.+Raponiauthor=C.+A.+Karlovichauthor=S.+Jaw-Tsaiauthor=J.+Isaacsonauthor=D.+Despainauthor=S.+L.+Mathenyauthor=L.+Rolfeauthor=A.+R.+Allenauthor=D.+R.+Camidge&title=Rociletinib+in+EGFR-mutated+non-small-cell+lung+cancer&doi=10.1056%2FNEJMoa1413654"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Rociletinib in EGFR-mutated non-small-cell lung cancer</span></div><div class="casAuthors">Sequist Lecia V; Soria Jean-Charles; Goldman Jonathan W; Wakelee Heather A; Gadgeel Shirish M; Varga Andrea; Papadimitrakopoulou Vassiliki; Solomon Benjamin J; Oxnard Geoffrey R; Dziadziuszko Rafal; Aisner Dara L; Doebele Robert C; Galasso Cathy; Garon Edward B; Heist Rebecca S; Logan Jennifer; Neal Joel W; Mendenhall Melody A; Nichols Suzanne; Piotrowska Zofia; Wozniak Antoinette J; Raponi Mitch; Karlovich Chris A; Jaw-Tsai Sarah; Isaacson Jeffrey; Despain Darrin; Matheny Shannon L; Rolfe Lindsey; Allen Andrew R; Camidge D Ross</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1700-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Non-small-cell lung cancer (NSCLC) with a mutation in the gene encoding epidermal growth factor receptor (EGFR) is sensitive to approved EGFR inhibitors, but resistance develops, mediated by the T790M EGFR mutation in most cases.  Rociletinib (CO-1686) is an EGFR inhibitor active in preclinical models of EGFR-mutated NSCLC with or without T790M.  METHODS:  In this phase 1-2 study, we administered rociletinib to patients with EGFR-mutated NSCLC who had disease progression during previous treatment with an existing EGFR inhibitor.  In the expansion (phase 2) part of the study, patients with T790M-positive disease received rociletinib at a dose of 500 mg twice daily, 625 mg twice daily, or 750 mg twice daily.  Key objectives were assessment of safety, side-effect profile, pharmacokinetics, and preliminary antitumor activity of rociletinib.  Tumor biopsies to identify T790M were performed during screening.  Treatment was administered in continuous 21-day cycles.  RESULTS:  A total of 130 patients were enrolled.  The first 57 patients to be enrolled received the free-base form of rociletinib (150 mg once daily to 900 mg twice daily).  The remaining patients received the hydrogen bromide salt (HBr) form (500 mg twice daily to 1000 mg twice daily).  A maximum tolerated dose (the highest dose associated with a rate of dose-limiting toxic effects of less than 33%) was not identified.  The only common dose-limiting adverse event was hyperglycemia.  In an efficacy analysis that included patients who received free-base rociletinib at a dose of 900 mg twice daily or the HBr form at any dose, the objective response rate among the 46 patients with T790M-positive disease who could be evaluated was 59% (95% confidence interval [CI], 45 to 73), and the rate among the 17 patients with T790M-negative disease who could be evaluated was 29% (95% CI, 8 to 51).  CONCLUSIONS:  Rociletinib was active in patients with EGFR-mutated NSCLC associated with the T790M resistance mutation. (Funded by Clovis Oncology; ClinicalTrials.gov number, NCT01526928.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQME11ovAjH3ZPq5LRczm8ffW6udTcc2eZPsoLDuSLrRrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mjpt1yltQ%253D%253D&md5=5a5d21d36c081a5ef0f9e650d5cc84b9</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1413654&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1413654%26sid%3Dliteratum%253Aachs%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26aulast%3DGoldman%26aufirst%3DJ.%2BW.%26aulast%3DWakelee%26aufirst%3DH.%2BA.%26aulast%3DGadgeel%26aufirst%3DS.%2BM.%26aulast%3DVarga%26aufirst%3DA.%26aulast%3DPapadimitrakopoulou%26aufirst%3DV.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DOxnard%26aufirst%3DG.%2BR.%26aulast%3DDziadziuszko%26aufirst%3DR.%26aulast%3DAisner%26aufirst%3DD.%2BL.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26aulast%3DGalasso%26aufirst%3DC.%26aulast%3DGaron%26aufirst%3DE.%2BB.%26aulast%3DHeist%26aufirst%3DR.%2BS.%26aulast%3DLogan%26aufirst%3DJ.%26aulast%3DNeal%26aufirst%3DJ.%2BW.%26aulast%3DMendenhall%26aufirst%3DM.%2BA.%26aulast%3DNichols%26aufirst%3DS.%26aulast%3DPiotrowska%26aufirst%3DZ.%26aulast%3DWozniak%26aufirst%3DA.%2BJ.%26aulast%3DRaponi%26aufirst%3DM.%26aulast%3DKarlovich%26aufirst%3DC.%2BA.%26aulast%3DJaw-Tsai%26aufirst%3DS.%26aulast%3DIsaacson%26aufirst%3DJ.%26aulast%3DDespain%26aufirst%3DD.%26aulast%3DMatheny%26aufirst%3DS.%2BL.%26aulast%3DRolfe%26aufirst%3DL.%26aulast%3DAllen%26aufirst%3DA.%2BR.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26atitle%3DRociletinib%2520in%2520EGFR-mutated%2520non-small-cell%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D372%26spage%3D1700%26epage%3D1709%26doi%3D10.1056%2FNEJMoa1413654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greig, S. L.</span></span> <span> </span><span class="NLM_article-title">Osimertinib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">263</span>â <span class="NLM_lpage">273</span>, <span class="refDoi">Â DOI: 10.1007/s40265-015-0533-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1007%2Fs40265-015-0533-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=26729184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BC28XlvFymtA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=263-273&author=S.+L.+Greig&title=Osimertinib%3A+First+Global+Approval&doi=10.1007%2Fs40265-015-0533-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Osimertinib: First Global Approval</span></div><div class="casAuthors">Greig, Sarah L.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">263-273</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Osimertinib (Tagrisso, AZD9291) is an oral, third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) that is being developed by AstraZeneca for the treatment of advanced non-small cell lung cancer (NSCLC).  Osimertinib has been designed to target the EGFR T790M mutation that is often present in NSCLC patients with acquired EGFR TKI resistance, while sparing wild-type EGFR.  In Nov. 2015, the tablet formulation of osimertinib was granted accelerated approval in the USA for the treatment of patients with metastatic EGFR T790M mutation-pos. NSCLC (as detected by an FDA-approved test) who have progressed on or after EGFR TKI therapy.  Osimertinib has also been granted accelerated assessment status for this indication in the EU, and is in phase III development for first- and second-line and adjuvant treatment of advanced EGFR mutation-pos. NSCLC in several countries.  Phase I trials in patients with advanced solid tumors are also being conducted.  This article summarizes the milestones in the development of osimertinib leading to this first approval for NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD-OV6l6JC5rVg90H21EOLACvtfcHk0lgy01UciQFJwg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlvFymtA%253D%253D&md5=fb46898918bdfe76320c26177710fb11</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0533-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0533-4%26sid%3Dliteratum%253Aachs%26aulast%3DGreig%26aufirst%3DS.%2BL.%26atitle%3DOsimertinib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2016%26volume%3D76%26spage%3D263%26epage%3D273%26doi%3D10.1007%2Fs40265-015-0533-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ayati, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moghimi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salarinejad, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safavi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pouramiri, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foroumadi, A.</span></span> <span> </span><span class="NLM_article-title">A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>99</i></span>, <span class="NLM_elocation-id">103811</span> <span class="refDoi">Â DOI: 10.1016/j.bioorg.2020.103811</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1016%2Fj.bioorg.2020.103811" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=32278207" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmvFWjt7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2020&author=A.+Ayatiauthor=S.+Moghimiauthor=S.+Salarinejadauthor=M.+Safaviauthor=B.+Pouramiriauthor=A.+Foroumadi&title=A+review+on+progression+of+epidermal+growth+factor+receptor+%28EGFR%29+inhibitors+as+an+efficient+approach+in+cancer+targeted+therapy&doi=10.1016%2Fj.bioorg.2020.103811"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy</span></div><div class="casAuthors">Ayati, Adileh; Moghimi, Setareh; Salarinejad, Somayeh; Safavi, Maliheh; Pouramiri, Behjat; Foroumadi, Alireza</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">103811</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The identification of mol. agents inhibiting specific functions in cancer cells progression is considered as one of the most successful plans in cancer treatment.  The epidermal growth factor receptor (EGFR) over-activation is obsd. in a vast no. of cancers, so, targeting EGFR and its downstream signaling cascades are regarded as a rational and valuable approach in cancer therapy.  Several synthetic EGFR tyrosine kinase inhibitors (TKIs) have been evaluated in recent years, mostly exhibited clin. efficacy in relevant models and categorized into first, second, third and fourth-generation.  However, studies are still ongoing to find more efficient EGFR inhibitors in light of the resistance to the current inhibitors.  In this review, the importance of targeting EGFR signaling pathway in cancer therapy and related epigenetic mutations are highlighted.  The recent advances on the discovery and development of different EGFR inhibitors and the use of various therapeutic strategies such as multi-targeting agents and combination therapies have also been reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVrJxSVWovxbVg90H21EOLACvtfcHk0lgy01UciQFJwg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmvFWjt7Y%253D&md5=3f0d8f98e46bc5b5bc5a6f29190f7881</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2020.103811&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2020.103811%26sid%3Dliteratum%253Aachs%26aulast%3DAyati%26aufirst%3DA.%26aulast%3DMoghimi%26aufirst%3DS.%26aulast%3DSalarinejad%26aufirst%3DS.%26aulast%3DSafavi%26aufirst%3DM.%26aulast%3DPouramiri%26aufirst%3DB.%26aulast%3DForoumadi%26aufirst%3DA.%26atitle%3DA%2520review%2520on%2520progression%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520inhibitors%2520as%2520an%2520efficient%2520approach%2520in%2520cancer%2520targeted%2520therapy%26jtitle%3DBioorg.%2520Chem.%26date%3D2020%26volume%3D99%26doi%3D10.1016%2Fj.bioorg.2020.103811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, E. S.</span></span> <span> </span><span class="NLM_article-title">Olmutinib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">1153</span>â <span class="NLM_lpage">1157</span>, <span class="refDoi">Â DOI: 10.1007/s40265-016-0606-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1007%2Fs40265-016-0606-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=27357069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFaitr%252FP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=1153-1157&author=E.+S.+Kim&title=Olmutinib%3A+First+Global+Approval&doi=10.1007%2Fs40265-016-0606-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Olmutinib: First Global Approval</span></div><div class="casAuthors">Kim, Esther S.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1153-1157</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Olmutinib (OlitaTM) is an oral, third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) that is being developed by Boehringer Ingelheim and Hanmi Pharmaceutical Co.  Ltd for the treatment of non-small cell lung cancer (NSCLC).  Third-generation EGFR TKIs with covalent binding to the receptors demonstrate irreversible enzymic inhibition of activating EGFR mutations and T790M mutation (a common reason for acquired EGFR TKI resistance), while sparing wild-type EGFR.  In Dec. 2015, olmutinib was granted breakthrough therapy designation in NSCLC by the US FDA.  In May 2016, olmutinib received its first global approval in South Korea for the treatment of patients with locally advanced or metastatic EGFR T790M mutation-pos. NSCLC.  This article summarizes the milestones in the development of olmutinib leading to this first approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriY-HbqvpWrrVg90H21EOLACvtfcHk0lgRaAfGk4h8lA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFaitr%252FP&md5=749828b58c3a4ce11f607c2dcfef6b9c</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1007%2Fs40265-016-0606-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-016-0606-z%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DE.%2BS.%26atitle%3DOlmutinib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2016%26volume%3D76%26spage%3D1153%26epage%3D1157%26doi%3D10.1007%2Fs40265-016-0606-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span> <span> </span><span class="NLM_article-title">Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1681</span>â <span class="NLM_lpage">1690</span>, <span class="refDoi">Â DOI: 10.1016/S1470-2045(19)30504-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1016%2FS1470-2045%2819%2930504-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=31587882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFCntb%252FJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=1681-1690&author=M.+J.+Ahnauthor=J.+Y.+Hanauthor=K.+H.+Leeauthor=S.+W.+Kimauthor=D.+W.+Kimauthor=Y.+G.+Leeauthor=E.+K.+Choauthor=J.+H.+Kimauthor=G.+W.+Leeauthor=J.+S.+Leeauthor=Y.+J.+Minauthor=J.+S.+Kimauthor=S.+S.+Leeauthor=H.+R.+Kimauthor=M.+H.+Hongauthor=J.+S.+Ahnauthor=J.+M.+Sunauthor=H.+T.+Kimauthor=D.+H.+Leeauthor=S.+Kimauthor=B.+C.+Cho&title=Lazertinib+in+patients+with+EGFR+mutation-positive+advanced+non-small-cell+lung+cancer%3A+results+from+the+dose+escalation+and+dose+expansion+parts+of+a+first-in-human%2C+open-label%2C+multicentre%2C+phase+1-2+study&doi=10.1016%2FS1470-2045%2819%2930504-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study</span></div><div class="casAuthors">Ahn, Myung-Ju; Han, Ji-Youn; Lee, Ki Hyeong; Kim, Sang-We; Kim, Dong-Wan; Lee, Yun-Gyoo; Cho, Eun Kyung; Kim, Joo-Hang; Lee, Gyeong-Won; Lee, Jong-Seok; Min, Young Joo; Kim, Jin-Soo; Lee, Sung Sook; Kim, Hye Ryun; Hong, Min Hee; Ahn, Jin Seok; Sun, Jong-Mu; Kim, Heung Tae; Lee, Dae Ho; Kim, Sohee; Cho, Byoung Chul</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1681-1690</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Patients with EGFR-mutated non-small-cell lung cancer (NSCLC) given EGFR tyrosine kinase inhibitors (TKIs) inevitably become resistant to first-generation or second-generation drugs.  We assessed the safety, tolerability, pharmacokinetics, and activity of lazertinib-an irreversible, third-generation, mutant-selective, EGFR TKI-in patients with advanced NSCLC progressing after EGFR TKI therapy.  This first-in-human, open-label, multicentre, phase 1-2 study had three parts: dose escalation, dose expansion, and dose extension; here, we report results on dose escalation and dose expansion.  The study was done in 14 hospitals in Korea.  Eligible patients were aged 20 years or older and had advanced NSCLC harbouring an activating EGFR mutation and progressing after first-generation or second-generation EGFR TKI treatment, a defined tumor T790M mutation status, an Eastern Cooperative Oncol. Group performance status of 0-1, at least one measurable extracranial lesion, defined according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, and adequate organ function.  Patients were enrolled to seven dose-escalation cohorts according to a rolling six design; five cohorts were expanded.  Patients were given oral lazertinib 20 mg, 40 mg, 80 mg, 120 mg, 160 mg, 240 mg, or 320 mg once daily continuously in 21-day cycles.  Primary endpoints were safety and tolerability and secondary endpoints included objective response in evaluable patients.  This study is registered with ClinicalTrials.gov, NCT03046992, and the phase 2 extension study is ongoing.  Between Feb 15, 2017, and May 28, 2018, 127 patients were enrolled into the dose escalation group (n=38) and dose expansion group (n=89).  No dose-limiting toxicities occurred.  There was no dose-dependent increase in adverse events.  The most commonly reported adverse events were grade 1-2 rash or acne (in 38 [30%] of 127 patients) and pruritus (in 34 [27%]).  Grade 3 or grade 4 adverse events occurred in 20 (16%) patients, with the most common being grade 3 pneumonia (four [3%]).  Treatment-related grade 3 or 4 adverse events occurred in four (3%) patients; treatment-related serious adverse events were reported in six patients (5%).  There were no adverse events with an outcome of death and no treatment-related deaths.  The proportion of patients achieving an objective response by independent central review assessment was 69 (54%; 95% CI 46-63) of 127.  Lazertinib had a tolerable safety profile and showed promosing clin. activity in patients with NSCLC progressing on or after EGFR TKI therapy.  Our findings provide a rationale for further clin. investigations.Yuhan Corporation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAxYXGWFPC0LVg90H21EOLACvtfcHk0lgRaAfGk4h8lA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFCntb%252FJ&md5=5d7c0d41b1c9273f4dd800b7a52ae08c</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2819%2930504-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252819%252930504-2%26sid%3Dliteratum%253Aachs%26aulast%3DAhn%26aufirst%3DM.%2BJ.%26aulast%3DHan%26aufirst%3DJ.%2BY.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3DKim%26aufirst%3DS.%2BW.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DLee%26aufirst%3DY.%2BG.%26aulast%3DCho%26aufirst%3DE.%2BK.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DLee%26aufirst%3DG.%2BW.%26aulast%3DLee%26aufirst%3DJ.%2BS.%26aulast%3DMin%26aufirst%3DY.%2BJ.%26aulast%3DKim%26aufirst%3DJ.%2BS.%26aulast%3DLee%26aufirst%3DS.%2BS.%26aulast%3DKim%26aufirst%3DH.%2BR.%26aulast%3DHong%26aufirst%3DM.%2BH.%26aulast%3DAhn%26aufirst%3DJ.%2BS.%26aulast%3DSun%26aufirst%3DJ.%2BM.%26aulast%3DKim%26aufirst%3DH.%2BT.%26aulast%3DLee%26aufirst%3DD.%2BH.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DCho%26aufirst%3DB.%2BC.%26atitle%3DLazertinib%2520in%2520patients%2520with%2520EGFR%2520mutation-positive%2520advanced%2520non-small-cell%2520lung%2520cancer%253A%2520results%2520from%2520the%2520dose%2520escalation%2520and%2520dose%2520expansion%2520parts%2520of%2520a%2520first-in-human%252C%2520open-label%252C%2520multicentre%252C%2520phase%25201-2%2520study%26jtitle%3DLancet%2520Oncol.%26date%3D2019%26volume%3D20%26spage%3D1681%26epage%3D1690%26doi%3D10.1016%2FS1470-2045%2819%2930504-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yosaatmadja, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silva, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickson, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smaill, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, J. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKeage, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Squire, C. J.</span></span> <span> </span><span class="NLM_article-title">Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed</span>. <i>J. Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>192</i></span>,  <span class="NLM_fpage">539</span>â <span class="NLM_lpage">544</span>, <span class="refDoi">Â DOI: 10.1016/j.jsb.2015.10.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1016%2Fj.jsb.2015.10.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=26522274" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslKksLbN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=192&publication_year=2015&pages=539-544&author=Y.+Yosaatmadjaauthor=S.+Silvaauthor=J.+M.+Dicksonauthor=A.+V.+Pattersonauthor=J.+B.+Smaillauthor=J.+U.+Flanaganauthor=M.+J.+McKeageauthor=C.+J.+Squire&title=Binding+mode+of+the+breakthrough+inhibitor+AZD9291+to+epidermal+growth+factor+receptor+revealed&doi=10.1016%2Fj.jsb.2015.10.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed</span></div><div class="casAuthors">Yosaatmadja, Yuliana; Silva, Shevan; Dickson, James M.; Patterson, Adam V.; Smaill, Jeff B.; Flanagan, Jack U.; McKeage, Mark J.; Squire, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Structural Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">192</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">539-544</span>CODEN:
                <span class="NLM_cas:coden">JSBIEM</span>;
        ISSN:<span class="NLM_cas:issn">1047-8477</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The discovery of genetic drivers of lung cancer in patient sub-groups has led to their use as predictive biomarkers and as targets for selective drug therapy.  Some of the most important lung cancer drivers are mutations in the EGFR gene, for example, the exon 19 deletions and the L858R variant that confer sensitivity to the front line drugs erlotinib and gefitinib; the acquired T790M variants confer drug resistance and a poor prognosis.  A challenge then in targeting EGFR is to produce drugs that inhibit both sensitizing variants and resistance variants, leaving wild type protein in healthy cells unaffected.  One such agent is AstraZeneca's "breakthrough" AZD9291 mol. that shows a 200-fold selectivity for T790M/L858R over wild type EGFR.  Our X-ray crystal structure reveals the binding mode of AZD9291 to the kinase domain of wild type EGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSZ-1Gcecv3LVg90H21EOLACvtfcHk0ljZ2AGTNtA_lg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslKksLbN&md5=330ba9239615813dbe0009e29d2e0983</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.jsb.2015.10.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jsb.2015.10.018%26sid%3Dliteratum%253Aachs%26aulast%3DYosaatmadja%26aufirst%3DY.%26aulast%3DSilva%26aufirst%3DS.%26aulast%3DDickson%26aufirst%3DJ.%2BM.%26aulast%3DPatterson%26aufirst%3DA.%2BV.%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DFlanagan%26aufirst%3DJ.%2BU.%26aulast%3DMcKeage%26aufirst%3DM.%2BJ.%26aulast%3DSquire%26aufirst%3DC.%2BJ.%26atitle%3DBinding%2520mode%2520of%2520the%2520breakthrough%2520inhibitor%2520AZD9291%2520to%2520epidermal%2520growth%2520factor%2520receptor%2520revealed%26jtitle%3DJ.%2520Struct.%2520Biol.%26date%3D2015%26volume%3D192%26spage%3D539%26epage%3D544%26doi%3D10.1016%2Fj.jsb.2015.10.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eastwood, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dror, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeliger, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, D. E.</span></span> <span> </span><span class="NLM_article-title">How does a drug molecule find its target binding site?</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>133</i></span>,  <span class="NLM_fpage">9181</span>â <span class="NLM_lpage">9183</span>, <span class="refDoi">Â DOI: 10.1021/ja202726y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja202726y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtVWgtb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2011&pages=9181-9183&author=Y.+Shanauthor=E.+T.+Kimauthor=M.+P.+Eastwoodauthor=R.+O.+Drorauthor=M.+A.+Seeligerauthor=D.+E.+Shaw&title=How+does+a+drug+molecule+find+its+target+binding+site%3F&doi=10.1021%2Fja202726y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">How Does a Drug Molecule Find Its Target Binding Site?</span></div><div class="casAuthors">Shan, Yibing; Kim, Eric T.; Eastwood, Michael P.; Dror, Ron O.; Seeliger, Markus A.; Shaw, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">9181-9183</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Although the thermodn. principles that control the binding of drug mols. to their protein targets are well understood, detailed exptl. characterization of the process by which such binding occurs has proven challenging.  We conducted relatively long, unguided mol. dynamics simulations in which a ligand (the cancer drug dasatinib or the kinase inhibitor PP1) was initially placed at a random location within a box that also contained a protein (Src kinase) to which that ligand was known to bind.  In several of these simulations, the ligand correctly identified its target binding site, forming a complex virtually identical to the crystallog. detd. bound structure.  The simulated trajectories provide a continuous, at.-level view of the entire binding process, revealing persistent and noteworthy intermediate conformations and shedding light on the role of water mols.  The technique we employed, which does not assume any prior knowledge of the binding site's location, may prove particularly useful in the development of allosteric inhibitors that target previously undiscovered binding sites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfc8mwES5csLVg90H21EOLACvtfcHk0lghClW8VZ0FmA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtVWgtb8%253D&md5=11847733dfeb27ed5ec1a565327b258c</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fja202726y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja202726y%26sid%3Dliteratum%253Aachs%26aulast%3DShan%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DE.%2BT.%26aulast%3DEastwood%26aufirst%3DM.%2BP.%26aulast%3DDror%26aufirst%3DR.%2BO.%26aulast%3DSeeliger%26aufirst%3DM.%2BA.%26aulast%3DShaw%26aufirst%3DD.%2BE.%26atitle%3DHow%2520does%2520a%2520drug%2520molecule%2520find%2520its%2520target%2520binding%2520site%253F%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2011%26volume%3D133%26spage%3D9181%26epage%3D9183%26doi%3D10.1021%2Fja202726y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eastwood, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arkhipov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dror, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jumper, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuriyan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, D. E.</span></span> <span> </span><span class="NLM_article-title">Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>149</i></span>,  <span class="NLM_fpage">860</span>â <span class="NLM_lpage">870</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1016%2Fj.cell.2012.02.063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=22579287" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BC38XntFaju7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=149&publication_year=2012&pages=860-870&author=Y.+Shanauthor=M.+P.+Eastwoodauthor=X.+Zhangauthor=E.+T.+Kimauthor=A.+Arkhipovauthor=R.+O.+Drorauthor=J.+Jumperauthor=J.+Kuriyanauthor=D.+E.+Shaw&title=Oncogenic+mutations+counteract+intrinsic+disorder+in+the+EGFR+kinase+and+promote+receptor+dimerization"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization</span></div><div class="casAuthors">Shan, Yibing; Eastwood, Michael P.; Zhang, Xuewu; Kim, Eric T.; Arkhipov, Anton; Dror, Ron O.; Jumper, John; Kuriyan, John; Shaw, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">149</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">860-870</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The mutation and overexpression of the epidermal growth factor receptor (EGFR) are assocd. with the development of a variety of cancers, making this prototypical dimerization-activated receptor tyrosine kinase a prominent target of cancer drugs.  Using long-timescale mol. dynamics simulations, we find that the N lobe dimerization interface of the wild-type EGFR kinase domain is intrinsically disordered and that it becomes ordered only upon dimerization.  Our simulations suggest, moreover, that some cancer-linked mutations distal to the dimerization interface, particularly the widespread L834R mutation (also referred to as L858R), facilitate EGFR dimerization by suppressing this local disorder.  Corroborating these findings, our biophys. expts. and kinase enzymic assays indicate that the L834R mutation causes abnormally high activity primarily by promoting EGFR dimerization rather than by allowing activation without dimerization.  We also find that phosphorylation of EGFR kinase domain at Tyr845 may suppress the intrinsic disorder, suggesting a mol. mechanism for autonomous EGFR signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZhEY912uUTrVg90H21EOLACvtfcHk0lghClW8VZ0FmA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XntFaju7k%253D&md5=8ab973e5a5626ac495d176322f30d2b7</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2012.02.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2012.02.063%26sid%3Dliteratum%253Aachs%26aulast%3DShan%26aufirst%3DY.%26aulast%3DEastwood%26aufirst%3DM.%2BP.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DKim%26aufirst%3DE.%2BT.%26aulast%3DArkhipov%26aufirst%3DA.%26aulast%3DDror%26aufirst%3DR.%2BO.%26aulast%3DJumper%26aufirst%3DJ.%26aulast%3DKuriyan%26aufirst%3DJ.%26aulast%3DShaw%26aufirst%3DD.%2BE.%26atitle%3DOncogenic%2520mutations%2520counteract%2520intrinsic%2520disorder%2520in%2520the%2520EGFR%2520kinase%2520and%2520promote%2520receptor%2520dimerization%26jtitle%3DCell%26date%3D2012%26volume%3D149%26spage%3D860%26epage%3D870" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gureasko, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuriyan, J.</span></span> <span> </span><span class="NLM_article-title">An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">1137</span>â <span class="NLM_lpage">1149</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2006.05.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1016%2Fj.cell.2006.05.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=16777603" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BD28XmsVOms7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2006&pages=1137-1149&author=X.+Zhangauthor=J.+Gureaskoauthor=K.+Shenauthor=P.+A.+Coleauthor=J.+Kuriyan&title=An+allosteric+mechanism+for+activation+of+the+kinase+domain+of+epidermal+growth+factor+receptor&doi=10.1016%2Fj.cell.2006.05.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor</span></div><div class="casAuthors">Zhang, Xuewu; Gureasko, Jodi; Shen, Kui; Cole, Philip A.; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1137-1149</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The mechanism by which the epidermal growth factor receptor (EGFR) is activated upon dimerization has eluded definition.  We find that the EGFR kinase domain can be activated by increasing its local concn. or by mutating a leucine (L834R) in the activation loop, the phosphorylation of which is not required for activation.  This suggests that the kinase domain is intrinsically auto-inhibited, and an intermol. interaction promotes its activation.  Using further mutational anal. and crystallog. we demonstrate that the auto-inhibited conformation of the EGFR kinase domain resembles that of Src and cyclin-dependent kinases (CDKs).  EGFR activation results from the formation of an asym. dimer in which the C-terminal lobe of one kinase domain plays a role analogous to that of cyclin in activated CDK/cyclin complexes.  The CDK/cyclin-like complex formed by two kinase domains thus explains the activation of EGFR-family receptors by homo- or heterodimerization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQsRAzLF-wK7Vg90H21EOLACvtfcHk0lghClW8VZ0FmA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmsVOms7g%253D&md5=f7b6795851425346f588cbd682125c93</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2006.05.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2006.05.013%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DGureasko%26aufirst%3DJ.%26aulast%3DShen%26aufirst%3DK.%26aulast%3DCole%26aufirst%3DP.%2BA.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DAn%2520allosteric%2520mechanism%2520for%2520activation%2520of%2520the%2520kinase%2520domain%2520of%2520epidermal%2520growth%2520factor%2520receptor%26jtitle%3DCell%26date%3D2006%26volume%3D125%26spage%3D1137%26epage%3D1149%26doi%3D10.1016%2Fj.cell.2006.05.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arkhipov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, D. E.</span></span> <span> </span><span class="NLM_article-title">Transitions to catalytically inactive conformations in EGFR kinase</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">7270</span>â <span class="NLM_lpage">7275</span>, <span class="refDoi">Â DOI: 10.1073/pnas.1220843110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1073%2Fpnas.1220843110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=23576739" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BC3sXos1Oisbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=7270-7275&author=Y.+Shanauthor=A.+Arkhipovauthor=E.+T.+Kimauthor=A.+C.+Panauthor=D.+E.+Shaw&title=Transitions+to+catalytically+inactive+conformations+in+EGFR+kinase&doi=10.1073%2Fpnas.1220843110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Transitions to catalytically inactive conformations in EGFR kinase</span></div><div class="casAuthors">Shan, Yibing; Arkhipov, Anton; Kim, Eric T.; Pan, Albert C.; Shaw, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7270-7275, S7270/1-S7270/5</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) is a key protein in cellular signaling, and its kinase domain (EGFR kinase) is an intensely pursued target of small-mol. drugs.  Although both catalytically active and inactive conformations of EGFR kinase have been resolved crystallog., exptl. characterization of the transitions between these conformations remains difficult.  Here, using unbiased, all-atom mol. dynamics simulations, the authors obsd. EGFR kinase spontaneously transition from the active to the so-called "Src-like inactive" conformation by way of 2 sets of intermediate conformations: one corresponded to a previously identified locally disordered state and the other to previously undescribed "extended" conformations, marked by the opening of the ATP-binding site between the 2 lobes of the kinase domain.  The authors also simulated the protonation-dependent transition of EGFR kinase to another ["Asp-Phe-Gly-out" ("DFG-out")] inactive conformation and obsd. similar intermediate conformations.  A key element obsd. in the simulated transitions was local unfolding, or "cracking," which supported a prediction of energy landscape theory.  The authors used H/D exchange measurements to corroborate their simulations and found that the simulated intermediate conformations correlated better with the H/D exchange data than existing active or inactive EGFR kinase crystal structures.  The intermediate conformations revealed by the simulations of the transition process differed significantly from the existing crystal structures and may provide unique possibilities for structure-based drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqK9XT_1ortrLVg90H21EOLACvtfcHk0lhtnPdv5WrrvA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXos1Oisbk%253D&md5=91b0d30ac37d3dc030a9fd7e3f792295</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1220843110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1220843110%26sid%3Dliteratum%253Aachs%26aulast%3DShan%26aufirst%3DY.%26aulast%3DArkhipov%26aufirst%3DA.%26aulast%3DKim%26aufirst%3DE.%2BT.%26aulast%3DPan%26aufirst%3DA.%2BC.%26aulast%3DShaw%26aufirst%3DD.%2BE.%26atitle%3DTransitions%2520to%2520catalytically%2520inactive%2520conformations%2520in%2520EGFR%2520kinase%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2013%26volume%3D110%26spage%3D7270%26epage%3D7275%26doi%3D10.1073%2Fpnas.1220843110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carey, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garton, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haley, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sliwkowski, M. X.</span></span> <span> </span><span class="NLM_article-title">Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">8163</span>â <span class="NLM_lpage">8171</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-06-0453</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1158%2F0008-5472.CAN-06-0453" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=16912195" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BD28XotFWqtb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=8163-8171&author=K.+D.+Careyauthor=A.+J.+Gartonauthor=M.+S.+Romeroauthor=J.+Kahlerauthor=S.+Thomsonauthor=S.+Rossauthor=F.+Parkauthor=J.+D.+Haleyauthor=N.+Gibsonauthor=M.+X.+Sliwkowski&title=Kinetic+analysis+of+epidermal+growth+factor+receptor+somatic+mutant+proteins+shows+increased+sensitivity+to+the+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitor%2C+erlotinib&doi=10.1158%2F0008-5472.CAN-06-0453"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Kinetic Analysis of Epidermal Growth Factor Receptor Somatic Mutant Proteins Shows Increased Sensitivity to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Erlotinib</span></div><div class="casAuthors">Carey, Kendall D.; Garton, Andrew J.; Romero, Maria S.; Kahler, Jennifer; Thomson, Stuart; Ross, Sarajane; Park, Frances; Haley, John D.; Gibson, Neil; Sliwkowski, Mark X.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">8163-8171</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">We show that two commonly occurring epidermal growth factor receptor (EGFR) somatic mutations, L858R and an in-frame deletion mutant, Del(746-750), exhibit distinct enzymic properties relative to wild-type EGFR and are differentially sensitive to erlotinib.  Kinetic anal. of the purified intracellular domains of EGFR L858R and EGFR Del(746-750) reveals that both mutants are active but exhibit a higher KM for ATP and a lower Ki for erlotinib relative to wild-type receptor.  When expressed in NR6 cells, a cell line that does not express EGFR or other ErbB receptors, both mutations are ligand dependent for receptor activation, can activate downstream EGFR signaling pathways, and promote cell cycle progression.  As expected from the kinetic anal., the EGFR Del(746-752) is more sensitive to erlotinib inhibition than the EGFR L858R mutant.  Further characterization shows that these mutations promote ligand-dependent and anchorage-independent growth, and cells harboring these mutant receptors form tumors in immunocompromised mice.  Anal. of tumor lysates reveals that the tumorigenicity of the mutant EGFR cell lines may be due to a differential pattern of mutant EGFR autophosphorylation as compared with wild-type receptor.  Significant inhibition of tumor growth, in mice harboring wild-type EGFR receptors, is only obsd. at doses of erlotinib approaching the max. tolerated dose for the mouse.  In contrast, the growth of mutant tumors is inhibited by erlotinib treatment at approx. one third the max. tolerated dose.  These findings suggest that EGFR somatic mutations directly influence both erlotinib sensitivity and cellular transformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-kYT9GVzgo7Vg90H21EOLACvtfcHk0lhtnPdv5WrrvA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XotFWqtb0%253D&md5=0ea102a026666dc0cb9cf60a3de0e944</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-0453&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-0453%26sid%3Dliteratum%253Aachs%26aulast%3DCarey%26aufirst%3DK.%2BD.%26aulast%3DGarton%26aufirst%3DA.%2BJ.%26aulast%3DRomero%26aufirst%3DM.%2BS.%26aulast%3DKahler%26aufirst%3DJ.%26aulast%3DThomson%26aufirst%3DS.%26aulast%3DRoss%26aufirst%3DS.%26aulast%3DPark%26aufirst%3DF.%26aulast%3DHaley%26aufirst%3DJ.%2BD.%26aulast%3DGibson%26aufirst%3DN.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26atitle%3DKinetic%2520analysis%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520somatic%2520mutant%2520proteins%2520shows%2520increased%2520sensitivity%2520to%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitor%252C%2520erlotinib%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D8163%26epage%3D8171%26doi%3D10.1158%2F0008-5472.CAN-06-0453" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggon, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greulich, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span> <span> </span><span class="NLM_article-title">Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">217</span>â <span class="NLM_lpage">227</span>, <span class="refDoi">Â DOI: 10.1016/j.ccr.2006.12.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1016%2Fj.ccr.2006.12.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=17349580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVymtL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2007&pages=217-227&author=C.+H.+Yunauthor=T.+J.+Boggonauthor=Y.+Liauthor=M.+S.+Wooauthor=H.+Greulichauthor=M.+Meyersonauthor=M.+J.+Eck&title=Structures+of+lung+cancer-derived+EGFR+mutants+and+inhibitor+complexes%3A+mechanism+of+activation+and+insights+into+differential+inhibitor+sensitivity&doi=10.1016%2Fj.ccr.2006.12.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity</span></div><div class="casAuthors">Yun, Cai-Hong; Boggon, Titus J.; Li, Yiqun; Woo, Michele S.; Greulich, Heidi; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">217-227</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Mutations in the EGFR kinase are a cause of non-small-cell lung cancer.  To understand their mechanism of activation and effects on drug binding, we studied the kinetics of the L858R and G719S mutants and detd. their crystal structures with inhibitors including gefitinib, AEE788, and a staurosporine.  We find that the mutations activate the kinase by disrupting autoinhibitory interactions, and that they accelerate catalysis as much as 50-fold in vitro.  Structures of inhibitors in complex with both wild-type and mutant kinases reveal similar binding modes for gefitinib and AEE788, but a marked rotation of the staurosporine in the G719S mutant.  Strikingly, direct binding measurements show that gefitinib binds 20-fold more tightly to the L858R mutant than to the wild-type enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoogeLQ1CuEnLVg90H21EOLACvtfcHk0lhtnPdv5WrrvA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVymtL4%253D&md5=6bc3223df84d829d9cb2bb00fd88ca29</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2006.12.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2006.12.017%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DStructures%2520of%2520lung%2520cancer-derived%2520EGFR%2520mutants%2520and%2520inhibitor%2520complexes%253A%2520mechanism%2520of%2520activation%2520and%2520insights%2520into%2520differential%2520inhibitor%2520sensitivity%26jtitle%3DCancer%2520Cell%26date%3D2007%26volume%3D11%26spage%3D217%26epage%3D227%26doi%3D10.1016%2Fj.ccr.2006.12.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuzmic, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solowiej, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergqvist, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolanos, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almaden, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagata, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalvie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kath, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, B. W.</span></span> <span> </span><span class="NLM_article-title">Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">173</span>â <span class="NLM_lpage">178</span>, <span class="refDoi">Â DOI: 10.1073/pnas.1313733111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1073%2Fpnas.1313733111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=24347635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BC2cXps1eluw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=173-178&author=P.+A.+Schwartzauthor=P.+Kuzmicauthor=J.+Solowiejauthor=S.+Bergqvistauthor=B.+Bolanosauthor=C.+Almadenauthor=A.+Nagataauthor=K.+Ryanauthor=J.+Fengauthor=D.+Dalvieauthor=J.+C.+Kathauthor=M.+Xuauthor=R.+Waniauthor=B.+W.+Murray&title=Covalent+EGFR+inhibitor+analysis+reveals+importance+of+reversible+interactions+to+potency+and+mechanisms+of+drug+resistance&doi=10.1073%2Fpnas.1313733111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance</span></div><div class="casAuthors">Schwartz, Phillip A.; Kuzmic, Petr; Solowiej, James; Bergqvist, Simon; Bolanos, Ben; Almaden, Chau; Nagata, Asako; Ryan, Kevin; Feng, Junli; Dalvie, Deepak; Kath, John C.; Xu, Meirong; Wani, Revati; Murray, Brion William</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">173-178</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Covalent inhibition is a reemerging paradigm in kinase drug design, but the roles of inhibitor binding affinity and chem. reactivity in overall potency are not well-understood.  To characterize the underlying mol. processes at a microscopic level and det. the appropriate kinetic consts., specialized exptl. design and advanced numerical integration of differential equations are developed.  Previously uncharacterized investigational covalent drugs reported here are shown to be extremely effective epidermal growth factor receptor (EGFR) inhibitors (kinact/Ki in the range 105-107 M-1s-1), despite their low specific reactivity (kinact â¤ 2.1 Ã 10-3 s-1), which is compensated for by high binding affinities (Ki < 1 nM).  For inhibitors relying on reactivity to achieve potency, noncovalent enzyme-inhibitor complex partitioning between inhibitor dissocn. and bond formation is central.  Interestingly, reversible binding affinity of EGFR covalent inhibitors is highly correlated with antitumor cell potency.  Furthermore, cellular potency for a subset of covalent inhibitors can be accounted for solely through reversible interactions.  One reversible interaction is between EGFR-Cys797 nucleophile and the inhibitor's reactive group, which may also contribute to drug resistance.  Because covalent inhibitors target a cysteine residue, the effects of its oxidn. on enzyme catalysis and inhibitor pharmacol. are characterized.  Oxidn. of the EGFR cysteine nucleophile does not alter catalysis but has widely varied effects on inhibitor potency depending on the EGFR context (e.g., oncogenic mutations), type of oxidn. (sulfinylation or glutathiolation), and inhibitor architecture.  These methods, parameters, and insights provide a rational framework for assessing and designing effective covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTpPuRq8MwCLVg90H21EOLACvtfcHk0lgnOK0mb_ebbQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXps1eluw%253D%253D&md5=47197c5e7876a238eefb2e8e7de305ea</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1313733111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1313733111%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DP.%2BA.%26aulast%3DKuzmic%26aufirst%3DP.%26aulast%3DSolowiej%26aufirst%3DJ.%26aulast%3DBergqvist%26aufirst%3DS.%26aulast%3DBolanos%26aufirst%3DB.%26aulast%3DAlmaden%26aufirst%3DC.%26aulast%3DNagata%26aufirst%3DA.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DDalvie%26aufirst%3DD.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DWani%26aufirst%3DR.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26atitle%3DCovalent%2520EGFR%2520inhibitor%2520analysis%2520reveals%2520importance%2520of%2520reversible%2520interactions%2520to%2520potency%2520and%2520mechanisms%2520of%2520drug%2520resistance%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2014%26volume%3D111%26spage%3D173%26epage%3D178%26doi%3D10.1073%2Fpnas.1313733111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thress, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paweletz, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stetson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dougherty, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markovets, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vivancos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantarini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oxnard, G. R.</span></span> <span> </span><span class="NLM_article-title">Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">560</span>â <span class="NLM_lpage">562</span>, <span class="refDoi">Â DOI: 10.1038/nm.3854</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1038%2Fnm.3854" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=25939061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFemsbfJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=560-562&author=K.+S.+Thressauthor=C.+P.+Paweletzauthor=E.+Felipauthor=B.+C.+Choauthor=D.+Stetsonauthor=B.+Doughertyauthor=Z.+Laiauthor=A.+Markovetsauthor=A.+Vivancosauthor=Y.+Kuangauthor=D.+Ercanauthor=S.+E.+Matthewsauthor=M.+Cantariniauthor=J.+C.+Barrettauthor=P.+A.+Janneauthor=G.+R.+Oxnard&title=Acquired+EGFR+C797S+mutation+mediates+resistance+to+AZD9291+in+non-small+cell+lung+cancer+harboring+EGFR+T790M&doi=10.1038%2Fnm.3854"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M</span></div><div class="casAuthors">Thress, Kenneth S.; Paweletz, Cloud P.; Felip, Enriqueta; Cho, Byoung Chul; Stetson, Daniel; Dougherty, Brian; Lai, Zhongwu; Markovets, Aleksandra; Vivancos, Ana; Kuang, Yanan; Ercan, Dalia; Matthews, Sarah E.; Cantarini, Mireille; Barrett, J. Carl; Janne, Pasi A.; Oxnard, Geoffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">560-562</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Here we studied cell-free plasma DNA (cfDNA) collected from subjects with advanced lung cancer whose tumors had developed resistance to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) AZD9291.  We first performed next-generation sequencing of cfDNA from seven subjects and detected an acquired EGFR C797S mutation in one; expression of this mutant EGFR construct in a cell line rendered it resistant to AZD9291.  We then performed droplet digital PCR on serial cfDNA specimens collected from 15 AZD9291-treated subjects.  All were pos. for the T790M mutation before treatment, but upon developing AZD9291 resistance three mol. subtypes emerged: six cases acquired the C797S mutation, five cases maintained the T790M mutation but did not acquire the C797S mutation and four cases lost the T790M mutation despite the presence of the underlying EGFR activating mutation.  Our findings provide insight into the diversity of mechanisms through which tumors acquire resistance to AZD9291 and highlight the need for therapies that are able to overcome resistance mediated by the EGFR C797S mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTggAW5fpGrbVg90H21EOLACvtfcHk0ljeDWo4_PfG-A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFemsbfJ&md5=adac4cb6c7057855aff61fd62890d010</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnm.3854&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3854%26sid%3Dliteratum%253Aachs%26aulast%3DThress%26aufirst%3DK.%2BS.%26aulast%3DPaweletz%26aufirst%3DC.%2BP.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DStetson%26aufirst%3DD.%26aulast%3DDougherty%26aufirst%3DB.%26aulast%3DLai%26aufirst%3DZ.%26aulast%3DMarkovets%26aufirst%3DA.%26aulast%3DVivancos%26aufirst%3DA.%26aulast%3DKuang%26aufirst%3DY.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DMatthews%26aufirst%3DS.%2BE.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DBarrett%26aufirst%3DJ.%2BC.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DOxnard%26aufirst%3DG.%2BR.%26atitle%3DAcquired%2520EGFR%2520C797S%2520mutation%2520mediates%2520resistance%2520to%2520AZD9291%2520in%2520non-small%2520cell%2520lung%2520cancer%2520harboring%2520EGFR%2520T790M%26jtitle%3DNat.%2520Med.%26date%3D2015%26volume%3D21%26spage%3D560%26epage%3D562%26doi%3D10.1038%2Fnm.3854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capelletti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span> <span> </span><span class="NLM_article-title">EGFR mutations and resistance to Irreversible pyrimidine based EGFR inhibitors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">3913</span>â <span class="NLM_lpage">3923</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-14-2789</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1158%2F1078-0432.CCR-14-2789" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=25948633" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVCrsLfE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=3913-3923&author=D.+Ercanauthor=H.+G.+Choiauthor=C.+H.+Yunauthor=M.+Capellettiauthor=T.+Xieauthor=M.+J.+Eckauthor=N.+S.+Grayauthor=P.+A.+Janne&title=EGFR+mutations+and+resistance+to+Irreversible+pyrimidine+based+EGFR+inhibitors&doi=10.1158%2F1078-0432.CCR-14-2789"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors</span></div><div class="casAuthors">Ercan, Dalia; Choi, Hwan Geun; Yun, Cai-Hong; Capelletti, Marzia; Xie, Ting; Eck, Michael J.; Gray, Nathanael S.; Jaenne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">3913-3923</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Mutant selective irreversible pyrimidine-based EGFR kinase inhibitors, including WZ4002, CO-1686, and AZD9291, are effective in preclin. models and in lung cancer patients harboring the EGFR T790M gefitinib/erlotinib resistance mutation.  However, little is known about how cancers develop acquired resistance to this class of EGFR inhibitors.  We sought to identify and study EGFR mutations that confer resistance to this class of agents.  Exptl. Design: We performed an N-ethyl-N-nitrosourea (ENU) mutagenesis screen in EGFR-mutant (sensitizing alone or with concurrent EGFR T790M) Ba/F3 cells and selected drug-resistant clones.  We evaluated the sensitivity of EGFR inhibitors in models harboring drug-resistant EGFR mutations.  Results: We identified 3 major drug resistance mutations.  EGFR L718Q, L844V, and C797S cause resistance to both WZ4002 and CO-1686 while, in contrast, only EGFR C797S leads to AZD9291 resistance.  Cells contg. an EGFR-sensitizing mutation, Del 19 or L858R, in conjunction with L718Q, L844V, or C797S retain sensitivity to quinazoline-based EGFR inhibitors, gefitinib and afatinib.  The C797S mutation, in the presence of Del 19 or L858R and T790M, causes resistance to all current EGFR inhibitors, but L858R/T790M/C797S remains partially sensitive to cetuximab which leads to disruption of EGFR dimerization.  Conclusions: Our findings provide insights into resistance mechanisms to irreversible pyrimidine-based EGFR inhibitors and identify specific genomic contexts in which sensitivity is retained to existing clin. EGFR inhibitors.  These findings will guide the development of new strategies to inhibit EGFR.  Clin Cancer Res; 21(17); 3913-23. Â©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEcpT5h6UJorVg90H21EOLACvtfcHk0ljeDWo4_PfG-A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVCrsLfE&md5=9c2916156cb18726ff2f2d2881345548</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-2789&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-2789%26sid%3Dliteratum%253Aachs%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DChoi%26aufirst%3DH.%2BG.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DXie%26aufirst%3DT.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DEGFR%2520mutations%2520and%2520resistance%2520to%2520Irreversible%2520pyrimidine%2520based%2520EGFR%2520inhibitors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D3913%26epage%3D3923%26doi%3D10.1158%2F1078-0432.CCR-14-2789" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hornak, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strockbine, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roitberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmerling, C.</span></span> <span> </span><span class="NLM_article-title">Comparison of multiple Amber force fields and development of improved protein backbone parameters</span>. <i>Proteins</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">712</span>â <span class="NLM_lpage">725</span>, <span class="refDoi">Â DOI: 10.1002/prot.21123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1002%2Fprot.21123" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=16981200" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFWqt7fM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2006&pages=712-725&author=V.+Hornakauthor=R.+Abelauthor=A.+Okurauthor=B.+Strockbineauthor=A.+Roitbergauthor=C.+Simmerling&title=Comparison+of+multiple+Amber+force+fields+and+development+of+improved+protein+backbone+parameters&doi=10.1002%2Fprot.21123"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of multiple Amber force fields and development of improved protein backbone parameters</span></div><div class="casAuthors">Hornak, Viktor; Abel, Robert; Okur, Asim; Strockbine, Bentley; Roitberg, Adrian; Simmerling, Carlos</div><div class="citationInfo"><span class="NLM_cas:title">Proteins: Structure, Function, and Bioinformatics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">712-725</span>CODEN:
                <span class="NLM_cas:coden">PSFBAF</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The ff94 force field that is commonly assocd. with the Amber simulation package is one of the most widely used parameter sets for biomol. simulation.  After a decade of extensive use and testing, limitations in this force field, such as over-stabilization of Î±-helixes, were reported by the authors and other researchers.  This led to a no. of attempts to improve these parameters, resulting in a variety of "Amber" force fields and significant difficulty in detg. which should be used for a particular application.  The authors show that several of these continue to suffer from inadequate balance between different secondary structure elements.  In addn., the approach used in most of these studies neglected to account for the existence in Amber of two sets of backbone .vphi./Ï dihedral terms.  This led to parameter sets that provide unreasonable conformational preferences for glycine.  The authors report here an effort to improve the .vphi./Ï dihedral terms in the ff99 energy function.  Dihedral term parameters are based on fitting the energies of multiple conformations of glycine and alanine tetrapeptides from high level ab initio quantum mech. calcns.  The new parameters for backbone dihedrals replace those in the existing ff99 force field.  This parameter set, which the authors denote ff99SB, achieves a better balance of secondary structure elements as judged by improved distribution of backbone dihedrals for glycine and alanine with respect to PDB survey data.  It also accomplishes improved agreement with published exptl. data for conformational preferences of short alanine peptides and better accord with exptl. NMR relaxation data of test protein systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmoASzza-Gd7Vg90H21EOLACvtfcHk0lh_GBarzhrkPg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFWqt7fM&md5=de683a26eca9e83ae524726e97ac22fa</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1002%2Fprot.21123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprot.21123%26sid%3Dliteratum%253Aachs%26aulast%3DHornak%26aufirst%3DV.%26aulast%3DAbel%26aufirst%3DR.%26aulast%3DOkur%26aufirst%3DA.%26aulast%3DStrockbine%26aufirst%3DB.%26aulast%3DRoitberg%26aufirst%3DA.%26aulast%3DSimmerling%26aufirst%3DC.%26atitle%3DComparison%2520of%2520multiple%2520Amber%2520force%2520fields%2520and%2520development%2520of%2520improved%2520protein%2520backbone%2520parameters%26jtitle%3DProteins%26date%3D2006%26volume%3D65%26spage%3D712%26epage%3D725%26doi%3D10.1002%2Fprot.21123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lindorff-Larsen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piana, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maragakis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klepeis, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dror, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, D. E.</span></span> <span> </span><span class="NLM_article-title">Improved side-chain torsion potentials for the Amber ff99SB protein force field</span>. <i>Proteins</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">1950</span>â <span class="NLM_lpage">1958</span>, <span class="refDoi">Â DOI: 10.1002/prot.22711</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1002%2Fprot.22711" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=20408171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvFegtLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2010&pages=1950-1958&author=K.+Lindorff-Larsenauthor=S.+Pianaauthor=K.+Palmoauthor=P.+Maragakisauthor=J.+L.+Klepeisauthor=R.+O.+Drorauthor=D.+E.+Shaw&title=Improved+side-chain+torsion+potentials+for+the+Amber+ff99SB+protein+force+field&doi=10.1002%2Fprot.22711"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Improved side-chain torsion potentials for the Amber ff99SB protein force field</span></div><div class="casAuthors">Lindorff-Larsen, Kresten; Piana, Stefano; Palmo, Kim; Maragakis, Paul; Klepeis, John L.; Dror, Ron O.; Shaw, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Proteins: Structure, Function, and Bioinformatics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1950-1958</span>CODEN:
                <span class="NLM_cas:coden">PSFBAF</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Recent advances in hardware and software have enabled increasingly long mol. dynamics (MD) simulations of biomols., exposing certain limitations in the accuracy of the force fields used for such simulations and spurring efforts to refine these force fields.  Recent modifications to the Amber and CHARMM protein force fields, for example, have improved the backbone torsion potentials, remedying deficiencies in earlier versions.  Here, the authors further advance simulation accuracy by improving the amino acid side-chain torsion potentials of the Amber ff99SB force field.  First, the authors used simulations of model alpha-helical systems to identify the four residue types whose rotamer distribution differed the most from expectations based on Protein Data Bank statistics.  Second, the authors optimized the side-chain torsion potentials of these residues to match new, high-level quantum-mech. calcns.  Finally, the authors used microsecond-timescale MD simulations in explicit solvent to validate the resulting force field against a large set of exptl. NMR measurements that directly probe side-chain conformations.  The new force field, which the authors have termed Amber ff99SB-ILDN, exhibits considerably better agreement with the NMR data.  Proteins 2010. Â© 2010 Wiley-Liss, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNFHrYs9024bVg90H21EOLACvtfcHk0lh_GBarzhrkPg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvFegtLo%253D&md5=447a9004026e2b93f0f7beff165daa09</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2Fprot.22711&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprot.22711%26sid%3Dliteratum%253Aachs%26aulast%3DLindorff-Larsen%26aufirst%3DK.%26aulast%3DPiana%26aufirst%3DS.%26aulast%3DPalmo%26aufirst%3DK.%26aulast%3DMaragakis%26aufirst%3DP.%26aulast%3DKlepeis%26aufirst%3DJ.%2BL.%26aulast%3DDror%26aufirst%3DR.%2BO.%26aulast%3DShaw%26aufirst%3DD.%2BE.%26atitle%3DImproved%2520side-chain%2520torsion%2520potentials%2520for%2520the%2520Amber%2520ff99SB%2520protein%2520force%2520field%26jtitle%3DProteins%26date%3D2010%26volume%3D78%26spage%3D1950%26epage%3D1958%26doi%3D10.1002%2Fprot.22711" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Best, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hummer, G.</span></span> <span> </span><span class="NLM_article-title">Optimized molecular dynamics force fields applied to the helix-coil transition of polypeptides</span>. <i>J. Phys. Chem. B</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">9004</span>â <span class="NLM_lpage">9015</span>, <span class="refDoi">Â DOI: 10.1021/jp901540t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jp901540t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BD1MXntVGjsLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2009&pages=9004-9015&author=R.+B.+Bestauthor=G.+Hummer&title=Optimized+molecular+dynamics+force+fields+applied+to+the+helix-coil+transition+of+polypeptides&doi=10.1021%2Fjp901540t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Optimized molecular dynamics force fields applied to the helix-coil transition of polypeptides</span></div><div class="casAuthors">Best, Robert B.; Hummer, Gerhard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physical Chemistry B</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">9004-9015</span>CODEN:
                <span class="NLM_cas:coden">JPCBFK</span>;
        ISSN:<span class="NLM_cas:issn">1520-6106</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Obtaining the correct balance of secondary structure propensities is a central priority in protein force-field development.  Given that current force fields differ significantly in their Î±-helical propensities, a correction to match exptl. results would be highly desirable.  We have detd. simple backbone energy corrections for two force fields to reproduce the fraction of helix measured in short peptides at 300 K.  As validation, we show that the optimized force fields produce results in excellent agreement with NMR expts. for folded proteins and short peptides not used in the optimization.  However, despite the agreement at ambient conditions, the dependence of the helix content on temp. is too weak, a problem shared with other force fields.  A fit of the Lifson-Roig helix-coil theory shows that both the enthalpy and entropy of helix formation are too small: the helix extension parameter w agrees well with expt., but its entropic and enthalpic components are both only about half the resp. exptl. ests.  Our structural and thermodn. analyses point toward the phys. origins of these shortcomings in current force fields, and suggest ways to address them in future force-field development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6YKyHMhZcXLVg90H21EOLACvtfcHk0lh_GBarzhrkPg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXntVGjsLs%253D&md5=0fead55a8bc1c9269f92184ba27fc443</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjp901540t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjp901540t%26sid%3Dliteratum%253Aachs%26aulast%3DBest%26aufirst%3DR.%2BB.%26aulast%3DHummer%26aufirst%3DG.%26atitle%3DOptimized%2520molecular%2520dynamics%2520force%2520fields%2520applied%2520to%2520the%2520helix-coil%2520transition%2520of%2520polypeptides%26jtitle%3DJ.%2520Phys.%2520Chem.%2520B%26date%3D2009%26volume%3D113%26spage%3D9004%26epage%3D9015%26doi%3D10.1021%2Fjp901540t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandrasekhar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madura, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Impey, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, M. L.</span></span> <span> </span><span class="NLM_article-title">Comparison of simple potential functions for simulating liquid water</span>. <i>J. Chem. Phys.</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">926</span>â <span class="NLM_lpage">935</span>, <span class="refDoi">Â DOI: 10.1063/1.445869</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1063%2F1.445869" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADyaL3sXksF2htL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=1983&pages=926-935&author=W.+L.+Jorgensenauthor=J.+Chandrasekharauthor=J.+D.+Maduraauthor=R.+W.+Impeyauthor=M.+L.+Klein&title=Comparison+of+simple+potential+functions+for+simulating+liquid+water&doi=10.1063%2F1.445869"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of simple potential functions for simulating liquid water</span></div><div class="casAuthors">Jorgensen, William L.; Chandrasekhar, Jayaraman; Madura, Jeffry D.; Impey, Roger W.; Klein, Michael L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Physics</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">926-35</span>CODEN:
                <span class="NLM_cas:coden">JCPSA6</span>;
        ISSN:<span class="NLM_cas:issn">0021-9606</span>.
    </div><div class="casAbstract">Classical Monte Carlo simulations were carried out for liq. H2O in the NPT ensemble at 25Â° and 1 atm using 6 of the simpler intermol. potential functions for the dimer.  Comparisons were made with exptl. thermodn. and structural data including the neutron diffraction results of Thiessen and Narten (1982).  The computed densities and potential energies agree with expt. except for the original Bernal-Fowler model, which yields an 18% overest. of the d. and poor structural results.  The discrepancy may be due to the correction terms needed in processing the neutron data or to an effect uniformly neglected in the computations.  Comparisons were made for the self-diffusion coeffs. obtained from mol. dynamics simulations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpK4QUFMvwYFrVg90H21EOLACvtfcHk0litXT10xykh_A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXksF2htL4%253D&md5=a1161334e381746be8c9b15a5e56f704</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1063%2F1.445869&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1063%252F1.445869%26sid%3Dliteratum%253Aachs%26aulast%3DJorgensen%26aufirst%3DW.%2BL.%26aulast%3DChandrasekhar%26aufirst%3DJ.%26aulast%3DMadura%26aufirst%3DJ.%2BD.%26aulast%3DImpey%26aufirst%3DR.%2BW.%26aulast%3DKlein%26aufirst%3DM.%2BL.%26atitle%3DComparison%2520of%2520simple%2520potential%2520functions%2520for%2520simulating%2520liquid%2520water%26jtitle%3DJ.%2520Chem.%2520Phys.%26date%3D1983%26volume%3D79%26spage%3D926%26epage%3D935%26doi%3D10.1063%2F1.445869" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldwell, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kollman, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Case, D. A.</span></span> <span> </span><span class="NLM_article-title">Development and testing of a general amber force field</span>. <i>J. Comput. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1157</span>â <span class="NLM_lpage">1174</span>, <span class="refDoi">Â DOI: 10.1002/jcc.20035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1002%2Fjcc.20035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=15116359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksFakurc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2004&pages=1157-1174&author=J.+Wangauthor=R.+M.+Wolfauthor=J.+W.+Caldwellauthor=P.+A.+Kollmanauthor=D.+A.+Case&title=Development+and+testing+of+a+general+amber+force+field&doi=10.1002%2Fjcc.20035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Development and testing of a general Amber force field</span></div><div class="casAuthors">Wang, Junmei; Wolf, Romain M.; Caldwell, James W.; Kollman, Peter A.; Case, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1157-1174</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">We describe here a general Amber force field (GAFF) for org. mols.  GAFF is designed to be compatible with existing Amber force fields for proteins and nucleic acids, and has parameters for most org. and pharmaceutical mols. that are composed of H, C, N, O, S, P, and halogens.  It uses a simple functional form and a limited no. of atom types, but incorporates both empirical and heuristic models to est. force consts. and partial at. charges.  The performance of GAFF in test cases is encouraging.  In test I, 74 crystallog. structures were compared to GAFF minimized structures, with a root-mean-square displacement of 0.26 Ã, which is comparable to that of the Tripos 5.2 force field (0.25 Ã) and better than those of MMFF 94 and CHARMm (0.47 and 0.44 Ã, resp.).  In test II, gas phase minimizations were performed on 22 nucleic acid base pairs, and the minimized structures and intermol. energies were compared to MP2/6-31G* results.  The RMS of displacements and relative energies were 0.25 Ã and 1.2 kcal/mol, resp.  These data are comparable to results from Parm99/RESP (0.16 Ã and 1.18 kcal/mol, resp.), which were parameterized to these base pairs.  Test III looked at the relative energies of 71 conformational pairs that were used in development of the Parm99 force field.  The RMS error in relative energies (compared to expt.) is about 0.5 kcal/mol.  GAFF can be applied to wide range of mols. in an automatic fashion, making it suitable for rational drug design and database searching.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfW8Gsf8IiW7Vg90H21EOLACvtfcHk0litXT10xykh_A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksFakurc%253D&md5=2992017a8cf51f89290ae2562403b115</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1002%2Fjcc.20035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.20035%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWolf%26aufirst%3DR.%2BM.%26aulast%3DCaldwell%26aufirst%3DJ.%2BW.%26aulast%3DKollman%26aufirst%3DP.%2BA.%26aulast%3DCase%26aufirst%3DD.%2BA.%26atitle%3DDevelopment%2520and%2520testing%2520of%2520a%2520general%2520amber%2520force%2520field%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D2004%26volume%3D25%26spage%3D1157%26epage%3D1174%26doi%3D10.1002%2Fjcc.20035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bergdorf, M.</span>; <span class="NLM_string-name">Baxter, S.</span>; <span class="NLM_string-name">Rendleman, C. A.</span>; <span class="NLM_string-name">Shaw, D. E.</span></span> <i>Desmond/GPU Performance as of October 2015</i>; D. E. Shaw Research Technical Report DESRES/TR--2015-01, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=M.+Bergdorf&author=S.+Baxter&author=C.+A.+Rendleman&author=D.+E.+Shaw&title=Desmond%2FGPU+Performance+as+of+October+2015"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26aulast%3DBergdorf%26aufirst%3DM.%26jtitle%3DDesmond%252FGPU%2520Performance%2520as%2520of%2520October%25202015%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, D. E.</span></span> In  <i>Anton 2: Raising the Bar for Performance and Programmability in a Special-Purpose Molecular Dynamics Supercomputer, SC14</i>. International Conference for High Performance Computing, Networking, Storage and Analysis, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=D.+E.+Shaw&title=Anton+2%3A+Raising+the+Bar+for+Performance+and+Programmability+in+a+Special-Purpose+Molecular+Dynamics+Supercomputer%2C+SC14"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DD.%2BE.%26jtitle%3DAnton%25202%253A%2520Raising%2520the%2520Bar%2520for%2520Performance%2520and%2520Programmability%2520in%2520a%2520Special-Purpose%2520Molecular%2520Dynamics%2520Supercomputer%252C%2520SC14%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lippert, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Predescu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ierardi, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackenzie, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eastwood, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dror, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, D. E.</span></span> <span> </span><span class="NLM_article-title">Accurate and efficient integration for molecular dynamics simulations at constant temperature and pressure</span>. <i>J. Chem. Phys.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>139</i></span>, <span class="NLM_elocation-id">164106</span> <span class="refDoi">Â DOI: 10.1063/1.4825247</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1063%2F1.4825247" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=24182003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1Kisb%252FL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2013&author=R.+A.+Lippertauthor=C.+Predescuauthor=D.+J.+Ierardiauthor=K.+M.+Mackenzieauthor=M.+P.+Eastwoodauthor=R.+O.+Drorauthor=D.+E.+Shaw&title=Accurate+and+efficient+integration+for+molecular+dynamics+simulations+at+constant+temperature+and+pressure&doi=10.1063%2F1.4825247"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Accurate and efficient integration for molecular dynamics simulations at constant temperature and pressure</span></div><div class="casAuthors">Lippert, Ross A.; Predescu, Cristian; Ierardi, Douglas J.; MacKenzie, Kenneth M.; Eastwood, Michael P.; Dror, Ron O.; Shaw, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Physics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">139</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">164106/1-164106/11</span>CODEN:
                <span class="NLM_cas:coden">JCPSA6</span>;
        ISSN:<span class="NLM_cas:issn">0021-9606</span>.
    
            (<span class="NLM_cas:orgname">American Institute of Physics</span>)
        </div><div class="casAbstract">In mol. dynamics simulations, control over temp. and pressure is typically achieved by augmenting the original system with addnl. dynamical variables to create a thermostat and a barostat, resp.  These variables generally evolve on timescales much longer than those of particle motion, but typical integrator implementations update the addnl. variables along with the particle positions and momenta at each time step.  We present a framework that replaces the traditional integration procedure with sep. barostat, thermostat, and Newtonian particle motion updates, allowing thermostat and barostat updates to be applied infrequently.  Such infrequent updates provide a particularly substantial performance advantage for simulations parallelized across many computer processors, because thermostat and barostat updates typically require communication among all processors.  Infrequent updates can also improve accuracy by alleviating certain sources of error assocd. with limited-precision arithmetic.  In addn., sepg. the barostat, thermostat, and particle motion update steps reduces certain truncation errors, bringing the time-av. pressure closer to its target value.  Finally, this framework, which we have implemented on both general-purpose and special-purpose hardware, reduces software complexity and improves software modularity.  (c) 2013 American Institute of Physics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoW51ZULlZFvrVg90H21EOLACvtfcHk0ljr4NXdELUceQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1Kisb%252FL&md5=0bd59b4b73b6999b9311306f4c32f3c1</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1063%2F1.4825247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1063%252F1.4825247%26sid%3Dliteratum%253Aachs%26aulast%3DLippert%26aufirst%3DR.%2BA.%26aulast%3DPredescu%26aufirst%3DC.%26aulast%3DIerardi%26aufirst%3DD.%2BJ.%26aulast%3DMackenzie%26aufirst%3DK.%2BM.%26aulast%3DEastwood%26aufirst%3DM.%2BP.%26aulast%3DDror%26aufirst%3DR.%2BO.%26aulast%3DShaw%26aufirst%3DD.%2BE.%26atitle%3DAccurate%2520and%2520efficient%2520integration%2520for%2520molecular%2520dynamics%2520simulations%2520at%2520constant%2520temperature%2520and%2520pressure%26jtitle%3DJ.%2520Chem.%2520Phys.%26date%3D2013%26volume%3D139%26doi%3D10.1063%2F1.4825247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoover, W. G.</span></span> <span> </span><span class="NLM_article-title">Canonical dynamics: Equilibrium phase-space distributions</span>. <i>Phys. Rev. A</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">1695</span>â <span class="NLM_lpage">1697</span>, <span class="refDoi">Â DOI: 10.1103/PhysRevA.31.1695</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1103%2FPhysRevA.31.1695" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=9895674" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A280%3ADC%252BC2sjotlWltA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1985&pages=1695-1697&author=W.+G.+Hoover&title=Canonical+dynamics%3A+Equilibrium+phase-space+distributions&doi=10.1103%2FPhysRevA.31.1695"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Canonical dynamics: Equilibrium phase-space distributions</span></div><div class="casAuthors">Hoover</div><div class="citationInfo"><span class="NLM_cas:title">Physical review. A, General physics</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1695-1697</span>
        ISSN:<span class="NLM_cas:issn">0556-2791</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSFX8fOxXRWv36CEoQgWY10fW6udTcc2eYAD-jWhDzz0Lntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sjotlWltA%253D%253D&md5=99a2477835b37592226a5d18a760685c</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1103%2FPhysRevA.31.1695&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1103%252FPhysRevA.31.1695%26sid%3Dliteratum%253Aachs%26aulast%3DHoover%26aufirst%3DW.%2BG.%26atitle%3DCanonical%2520dynamics%253A%2520Equilibrium%2520phase-space%2520distributions%26jtitle%3DPhys.%2520Rev.%2520A%26date%3D1985%26volume%3D31%26spage%3D1695%26epage%3D1697%26doi%3D10.1103%2FPhysRevA.31.1695" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martyna, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tobias, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, M. L.</span></span> <span> </span><span class="NLM_article-title">Constant pressure molecular dynamics algorithms</span>. <i>J. Chem. Phys.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">4177</span>â <span class="NLM_lpage">4189</span>, <span class="refDoi">Â DOI: 10.1063/1.467468</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1063%2F1.467468" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADyaK2cXmtFeht7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=1994&pages=4177-4189&author=G.+J.+Martynaauthor=D.+J.+Tobiasauthor=M.+L.+Klein&title=Constant+pressure+molecular+dynamics+algorithms&doi=10.1063%2F1.467468"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Constant pressure molecular dynamics algorithms</span></div><div class="casAuthors">Martyna, Glenn J.; Tobias, Douglas J.; Klein, Michael L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Physics</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">4177-89</span>CODEN:
                <span class="NLM_cas:coden">JCPSA6</span>;
        ISSN:<span class="NLM_cas:issn">0021-9606</span>.
    </div><div class="casAbstract">Modularly invariant equations of motion are derived that generate the isothermal-isobaric ensemble as their phase space avs.  Isotropic vol. fluctuations and fully flexible simulation cells as well as a hybrid scheme that naturally combines the two motions are considered.  The resulting methods are tested on two problems, a particle in a one-dimensional periodic potential and a spherical model of C60 in the solid/fluid phase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3YN7wMRJpjrVg90H21EOLACvtfcHk0ljr4NXdELUceQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXmtFeht7o%253D&md5=c14bd79c6398b0b30541e3cbe92851b0</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1063%2F1.467468&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1063%252F1.467468%26sid%3Dliteratum%253Aachs%26aulast%3DMartyna%26aufirst%3DG.%2BJ.%26aulast%3DTobias%26aufirst%3DD.%2BJ.%26aulast%3DKlein%26aufirst%3DM.%2BL.%26atitle%3DConstant%2520pressure%2520molecular%2520dynamics%2520algorithms%26jtitle%3DJ.%2520Chem.%2520Phys.%26date%3D1994%26volume%3D101%26spage%3D4177%26epage%3D4189%26doi%3D10.1063%2F1.467468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Predescu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lerer, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippert, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Towles, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossman, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dirks, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, D. E.</span></span> <span> </span><span class="NLM_article-title">The u-series: A separable decomposition for electrostatics computation with improved accuracy</span>. <i>J. Chem. Phys.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>152</i></span>, <span class="NLM_elocation-id">084113</span> <span class="refDoi">Â DOI: 10.1063/1.5129393</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1063%2F1.5129393" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=32113352" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BB3cXktlaktrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=2020&author=C.+Predescuauthor=A.+K.+Lererauthor=R.+A.+Lippertauthor=B.+Towlesauthor=J.+P.+Grossmanauthor=R.+M.+Dirksauthor=D.+E.+Shaw&title=The+u-series%3A+A+separable+decomposition+for+electrostatics+computation+with+improved+accuracy&doi=10.1063%2F1.5129393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">The u-series: A separable decomposition for electrostatics computation with improved accuracy</span></div><div class="casAuthors">Predescu, Cristian; Lerer, Adam K.; Lippert, Ross A.; Towles, Brian; Grossman, J. P.; Dirks, Robert M.; Shaw, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Physics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">152</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">084113/1-084113/12</span>CODEN:
                <span class="NLM_cas:coden">JCPSA6</span>;
        ISSN:<span class="NLM_cas:issn">0021-9606</span>.
    
            (<span class="NLM_cas:orgname">American Institute of Physics</span>)
        </div><div class="casAbstract">The evaluation of electrostatic energy for a set of point charges in a periodic lattice is a computationally expensive part of mol. dynamics simulations (and other applications) because of the long-range nature of the Coulomb interaction.  A std. approach is to decomp. the Coulomb potential into a near part, typically evaluated by direct summation up to a cutoff radius, and a far part, typically evaluated in Fourier space.  In practice, all decompn. approaches involve approxns. - such as cutting off the near-part direct sum - but it may be possible to find new decompns. with improved trade-offs between accuracy and performance.  Here, we present the u-series, a new decompn. of the Coulomb potential that is more accurate than the std. (Ewald) decompn. for a given amt. of computational effort and achieves the same accuracy as the Ewald decompn. with approx. half the computational effort.  These improvements, which we demonstrate numerically using a lipid membrane system, arise because the u-series is smooth on the entire real axis and exact up to the cutoff radius.  Addnl. performance improvements over the Ewald decompn. may be possible in certain situations because the far part of the u-series is a sum of Gaussians and can thus be evaluated using algorithms that require a separable convolution kernel; we describe one such algorithm that reduces communication latency at the expense of communication bandwidth and computation, a trade-off that may be advantageous on modern massively parallel supercomputers.  (c) 2020 American Institute of Physics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpSUTM2JpQDbVg90H21EOLACvtfcHk0lg17t0crkViXw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXktlaktrg%253D&md5=5520109d55a7ceb66fbc2167da773d4c</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1063%2F1.5129393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1063%252F1.5129393%26sid%3Dliteratum%253Aachs%26aulast%3DPredescu%26aufirst%3DC.%26aulast%3DLerer%26aufirst%3DA.%2BK.%26aulast%3DLippert%26aufirst%3DR.%2BA.%26aulast%3DTowles%26aufirst%3DB.%26aulast%3DGrossman%26aufirst%3DJ.%2BP.%26aulast%3DDirks%26aufirst%3DR.%2BM.%26aulast%3DShaw%26aufirst%3DD.%2BE.%26atitle%3DThe%2520u-series%253A%2520A%2520separable%2520decomposition%2520for%2520electrostatics%2520computation%2520with%2520improved%2520accuracy%26jtitle%3DJ.%2520Chem.%2520Phys.%26date%3D2020%26volume%3D152%26doi%3D10.1063%2F1.5129393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neese, F.</span></span> <span> </span><span class="NLM_article-title">The ORCA program system</span>. <i>Wiley Interdiscip. Rev.: Comput. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">73</span>â <span class="NLM_lpage">78</span>, <span class="refDoi">Â DOI: 10.1002/wcms.81</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1002%2Fwcms.81" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvFGls7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=73-78&author=F.+Neese&title=The+ORCA+program+system&doi=10.1002%2Fwcms.81"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">The ORCA program system</span></div><div class="casAuthors">Neese, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Wiley Interdisciplinary Reviews: Computational Molecular Science</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">73-78</span>CODEN:
                <span class="NLM_cas:coden">WIRCAH</span>;
        ISSN:<span class="NLM_cas:issn">1759-0884</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  ORCA is a general-purpose quantum chem. program package that features virtually all modern electronic structure methods (d. functional theory, many-body perturbation and coupled cluster theories, and multireference and semiempirical methods).  It is designed with the aim of generality, extendibility, efficiency, and user friendliness.  Its main field of application is larger mols., transition metal complexes, and their spectroscopic properties.  ORCA uses std. Gaussian basis functions and is fully parallelized.  The article provides an overview of its current possibilities and documents its efficiency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq39ez8fWMbr7Vg90H21EOLACvtfcHk0lg17t0crkViXw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvFGls7s%253D&md5=a753e33a6f9a326553295596f5c754e5</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1002%2Fwcms.81&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fwcms.81%26sid%3Dliteratum%253Aachs%26aulast%3DNeese%26aufirst%3DF.%26atitle%3DThe%2520ORCA%2520program%2520system%26jtitle%3DWiley%2520Interdiscip.%2520Rev.%253A%2520Comput.%2520Mol.%2520Sci.%26date%3D2012%26volume%3D2%26spage%3D73%26epage%3D78%26doi%3D10.1002%2Fwcms.81" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parrish, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burns, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmonett, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DePrince, A. E.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohenstein, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bozkaya, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sokolov, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Remigio, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richard, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonthier, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAlexander, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saitow, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritchard, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaefer, H. F.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patkowski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valeev, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evangelista, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turney, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherrill, C. D.</span></span> <span> </span><span class="NLM_article-title">Psi4 1.1: An Open-Source Electronic Structure Program Emphasizing Automation, Advanced Libraries, and Interoperability</span>. <i>J. Chem. Theory Comput.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">3185</span>â <span class="NLM_lpage">3197</span>, <span class="refDoi">Â DOI: 10.1021/acs.jctc.7b00174</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jctc.7b00174" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnsV2ju7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=3185-3197&author=R.+M.+Parrishauthor=L.+A.+Burnsauthor=D.+G.+A.+Smithauthor=A.+C.+Simmonettauthor=A.+E.+DePrinceauthor=E.+G.+Hohensteinauthor=U.+Bozkayaauthor=A.+Y.+Sokolovauthor=R.+Di+Remigioauthor=R.+M.+Richardauthor=J.+F.+Gonthierauthor=A.+M.+Jamesauthor=H.+R.+McAlexanderauthor=A.+Kumarauthor=M.+Saitowauthor=X.+Wangauthor=B.+P.+Pritchardauthor=P.+Vermaauthor=H.+F.+Schaeferauthor=K.+Patkowskiauthor=R.+A.+Kingauthor=E.+F.+Valeevauthor=F.+A.+Evangelistaauthor=J.+M.+Turneyauthor=T.+D.+Crawfordauthor=C.+D.+Sherrill&title=Psi4+1.1%3A+An+Open-Source+Electronic+Structure+Program+Emphasizing+Automation%2C+Advanced+Libraries%2C+and+Interoperability&doi=10.1021%2Facs.jctc.7b00174"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">PSI4 1.1: An Open-Source Electronic Structure Program Emphasizing Automation, Advanced Libraries, and Interoperability</span></div><div class="casAuthors">Parrish, Robert M.; Burns, Lori A.; Smith, Daniel G. A.; Simmonett, Andrew C.; DePrince, A. Eugene; Hohenstein, Edward G.; Bozkaya, Ugur; Sokolov, Alexander Yu.; Di Remigio, Roberto; Richard, Ryan M.; Gonthier, Jerome F.; James, Andrew M.; McAlexander, Harley R.; Kumar, Ashutosh; Saitow, Masaaki; Wang, Xiao; Pritchard, Benjamin P.; Verma, Prakash; Schaefer, Henry F.; Patkowski, Konrad; King, Rollin A.; Valeev, Edward F.; Evangelista, Francesco A.; Turney, Justin M.; Crawford, T. Daniel; Sherrill, C. David</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Theory and Computation</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3185-3197</span>CODEN:
                <span class="NLM_cas:coden">JCTCCE</span>;
        ISSN:<span class="NLM_cas:issn">1549-9618</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Psi4 is an ab initio electronic structure program providing methods such as Hartree-Fock, d. functional theory, CI, and coupled-cluster theory.  The 1.1 release represents a major update meant to automate complex tasks, such as geometry optimization using complete-basis-set extrapolation or focal-point methods.  Conversion of the top-level code to a Python module means that Psi4 can now be used in complex workflows alongside other Python tools.  Several new features have been added with the aid of libraries providing easy access to techniques such as d. fitting, Cholesky decompn., and Laplace denominators.  The build system has been completely rewritten to simplify interoperability with independent, reusable software components for quantum chem.  Finally, a wide range of new theor. methods and analyses have been added to the code base, including functional-group and open-shell symmetry adapted perturbation theory (F-SAPT and O-SAPT), d.-fitted coupled cluster with frozen natural orbitals [DF-FNO-CCSD(T)], orbital-optimized perturbation and coupled-cluster methods (e.g., OO-MP2 and OO-CCSD), d.-fitted MC-SCF (DF-MCSCF), d. cumulant functional theory (DCT), algebraic-diagrammatic construction [ADC(2)] excited states, improvements to the geometry optimizer, and the "X2C" approach to relativistic corrections, among many other improvements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqX9YFhWdEVKbVg90H21EOLACvtfcHk0lg17t0crkViXw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnsV2ju7k%253D&md5=68be5ece3075b2184a4c804e50f4eca3</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Facs.jctc.7b00174&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jctc.7b00174%26sid%3Dliteratum%253Aachs%26aulast%3DParrish%26aufirst%3DR.%2BM.%26aulast%3DBurns%26aufirst%3DL.%2BA.%26aulast%3DSmith%26aufirst%3DD.%2BG.%2BA.%26aulast%3DSimmonett%26aufirst%3DA.%2BC.%26aulast%3DDePrince%26aufirst%3DA.%2BE.%26aulast%3DHohenstein%26aufirst%3DE.%2BG.%26aulast%3DBozkaya%26aufirst%3DU.%26aulast%3DSokolov%26aufirst%3DA.%2BY.%26aulast%3DDi%2BRemigio%26aufirst%3DR.%26aulast%3DRichard%26aufirst%3DR.%2BM.%26aulast%3DGonthier%26aufirst%3DJ.%2BF.%26aulast%3DJames%26aufirst%3DA.%2BM.%26aulast%3DMcAlexander%26aufirst%3DH.%2BR.%26aulast%3DKumar%26aufirst%3DA.%26aulast%3DSaitow%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DPritchard%26aufirst%3DB.%2BP.%26aulast%3DVerma%26aufirst%3DP.%26aulast%3DSchaefer%26aufirst%3DH.%2BF.%26aulast%3DPatkowski%26aufirst%3DK.%26aulast%3DKing%26aufirst%3DR.%2BA.%26aulast%3DValeev%26aufirst%3DE.%2BF.%26aulast%3DEvangelista%26aufirst%3DF.%2BA.%26aulast%3DTurney%26aufirst%3DJ.%2BM.%26aulast%3DCrawford%26aufirst%3DT.%2BD.%26aulast%3DSherrill%26aufirst%3DC.%2BD.%26atitle%3DPsi4%25201.1%253A%2520An%2520Open-Source%2520Electronic%2520Structure%2520Program%2520Emphasizing%2520Automation%252C%2520Advanced%2520Libraries%252C%2520and%2520Interoperability%26jtitle%3DJ.%2520Chem.%2520Theory%2520Comput.%26date%3D2017%26volume%3D13%26spage%3D3185%26epage%3D3197%26doi%3D10.1021%2Facs.jctc.7b00174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanan, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryan, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burdick, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dotson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heald, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lainchbury, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purkey, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaefer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seward, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sideris, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeap, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zilberleyb, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heffron, T. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of selective and noncovalent diaminopyrimidine-based inhibitors of epidermal growth factor receptor containing the T790M resistance mutation</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">10176</span>â <span class="NLM_lpage">10191</span>, <span class="refDoi">Â DOI: 10.1021/jm501578n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501578n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVyrur3O" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=10176-10191&author=E.+J.+Hananauthor=C.+Eigenbrotauthor=M.+C.+Bryanauthor=D.+J.+Burdickauthor=B.+K.+Chanauthor=Y.+Chenauthor=J.+Dotsonauthor=R.+A.+Healdauthor=P.+S.+Jacksonauthor=H.+Laauthor=M.+D.+Lainchburyauthor=S.+Malekauthor=H.+E.+Purkeyauthor=G.+Schaeferauthor=S.+Schmidtauthor=E.+M.+Sewardauthor=S.+Siderisauthor=C.+Tamauthor=S.+Wangauthor=S.+K.+Yeapauthor=I.+Yenauthor=J.+Yinauthor=C.+Yuauthor=I.+Zilberleybauthor=T.+P.+Heffron&title=Discovery+of+selective+and+noncovalent+diaminopyrimidine-based+inhibitors+of+epidermal+growth+factor+receptor+containing+the+T790M+resistance+mutation&doi=10.1021%2Fjm501578n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Selective and Noncovalent Diaminopyrimidine-Based Inhibitors of Epidermal Growth Factor Receptor Containing the T790M Resistance Mutation</span></div><div class="casAuthors">Hanan, Emily J.; Eigenbrot, Charles; Bryan, Marian C.; Burdick, Daniel J.; Chan, Bryan K.; Chen, Yuan; Dotson, Jennafer; Heald, Robert A.; Jackson, Philip S.; La, Hank; Lainchbury, Michael D.; Malek, Shiva; Purkey, Hans E.; Schaefer, Gabriele; Schmidt, Stephen; Seward, Eileen M.; Sideris, Steve; Tam, Christine; Wang, Shumei; Yeap, Siew Kuen; Yen, Ivana; Yin, Jianping; Yu, Christine; Zilberleyb, Inna; Heffron, Timothy P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10176-10191</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Activating mutations within the epidermal growth factor receptor (EGFR) kinase domain, commonly L858R or deletions within exon 19, increase EGFR-driven cell proliferation and survival and are correlated with impressive responses to the EGFR inhibitors erlotinib and gefitinib in nonsmall cell lung cancer patients.  Approx. 60% of acquired resistance to these agents is driven by a single secondary mutation within the EGFR kinase domain, specifically substitution of the gatekeeper residue threonine-790 with methionine (T790M).  Due to dose-limiting toxicities assocd. with inhibition of wild-type EGFR (wtEGFR), we sought inhibitors of T790M-contg. EGFR mutants with selectivity over wtEGFR.  We describe the evolution of HTS hits derived from Jak2/Tyk2 inhibitors into selective EGFR inhibitors.  X-ray crystal structures revealed two distinct binding modes and enabled the design of a selective series of novel diaminopyrimidine-based inhibitors with good potency against T790M-contg. mutants of EGFR, high selectivity over wtEGFR, broad kinase selectivity, and desirable physicochem. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHIAeWoyjC2LVg90H21EOLACvtfcHk0ljDW_HSqbk-GA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVyrur3O&md5=b17adf4b49cebb2f2cea77015e1f6e4b</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm501578n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501578n%26sid%3Dliteratum%253Aachs%26aulast%3DHanan%26aufirst%3DE.%2BJ.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DBryan%26aufirst%3DM.%2BC.%26aulast%3DBurdick%26aufirst%3DD.%2BJ.%26aulast%3DChan%26aufirst%3DB.%2BK.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DHeald%26aufirst%3DR.%2BA.%26aulast%3DJackson%26aufirst%3DP.%2BS.%26aulast%3DLa%26aufirst%3DH.%26aulast%3DLainchbury%26aufirst%3DM.%2BD.%26aulast%3DMalek%26aufirst%3DS.%26aulast%3DPurkey%26aufirst%3DH.%2BE.%26aulast%3DSchaefer%26aufirst%3DG.%26aulast%3DSchmidt%26aufirst%3DS.%26aulast%3DSeward%26aufirst%3DE.%2BM.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DTam%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DYeap%26aufirst%3DS.%2BK.%26aulast%3DYen%26aufirst%3DI.%26aulast%3DYin%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DZilberleyb%26aufirst%3DI.%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26atitle%3DDiscovery%2520of%2520selective%2520and%2520noncovalent%2520diaminopyrimidine-based%2520inhibitors%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520containing%2520the%2520T790M%2520resistance%2520mutation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D10176%26epage%3D10191%26doi%3D10.1021%2Fjm501578n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Minor, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cymborowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otwinowski, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chruszcz, M.</span></span> <span> </span><span class="NLM_article-title">HKL-3000: the integration of data reduction and structure solution--from diffraction images to an initial model in minutes</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">859</span>â <span class="NLM_lpage">866</span>, <span class="refDoi">Â DOI: 10.1107/S0907444906019949</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1107%2FS0907444906019949" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=16855301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BD28XntVWksL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2006&pages=859-866&author=W.+Minorauthor=M.+Cymborowskiauthor=Z.+Otwinowskiauthor=M.+Chruszcz&title=HKL-3000%3A+the+integration+of+data+reduction+and+structure+solution%2D%2Dfrom+diffraction+images+to+an+initial+model+in+minutes&doi=10.1107%2FS0907444906019949"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">HKL-3000: the integration of data reduction and structure solution - from diffraction images to an initial model in minutes</span></div><div class="casAuthors">Minor, Wladek; Cymborowski, Marcin; Otwinowski, Zbyszek; Chruszcz, Maksymilian</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">D62</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">859-866</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A new approach that integrates data collection, data redn., phasing and model building significantly accelerates the process of structure detn. and on av. minimizes the no. of data sets and synchrotron time required for structure soln.  Initial testing of the HKL-3000 system (the beta version was named HKL-2000_ph) with more than 140 novel structure detns. has proven its high value for MAD/SAD expts.  The heuristics for choosing the best computational strategy at different data resoln. limits of phasing signal and crystal diffraction are being optimized.  The typical end result is an interpretable electron-d. map with a partially built structure and, in some cases, an almost complete refined model.  The current development is oriented towards very fast structure soln. in order to provide feedback during the diffraction expt.  Work is also proceeding towards improving the quality of phasing calcn. and model building.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0c0DYtjFP7rVg90H21EOLACvtfcHk0ljDW_HSqbk-GA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XntVWksL8%253D&md5=2cd2fe288f954837abb4acae4c008a2f</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1107%2FS0907444906019949&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444906019949%26sid%3Dliteratum%253Aachs%26aulast%3DMinor%26aufirst%3DW.%26aulast%3DCymborowski%26aufirst%3DM.%26aulast%3DOtwinowski%26aufirst%3DZ.%26aulast%3DChruszcz%26aufirst%3DM.%26atitle%3DHKL-3000%253A%2520the%2520integration%2520of%2520data%2520reduction%2520and%2520structure%2520solution--from%2520diffraction%2520images%2520to%2520an%2520initial%2520model%2520in%2520minutes%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2006%26volume%3D62%26spage%3D859%26epage%3D866%26doi%3D10.1107%2FS0907444906019949" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosse-Kunstleve, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winn, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storoni, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, R. J.</span></span> <span> </span><span class="NLM_article-title">Phaser crystallographic software</span>. <i>J. Appl. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">658</span>â <span class="NLM_lpage">674</span>, <span class="refDoi">Â DOI: 10.1107/S0021889807021206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1107%2FS0021889807021206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=19461840" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnslWqsLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2007&pages=658-674&author=A.+J.+McCoyauthor=R.+W.+Grosse-Kunstleveauthor=P.+D.+Adamsauthor=M.+D.+Winnauthor=L.+C.+Storoniauthor=R.+J.+Read&title=Phaser+crystallographic+software&doi=10.1107%2FS0021889807021206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Phaser crystallographic software</span></div><div class="casAuthors">McCoy, Airlie J.; Grosse-Kunstleve, Ralf W.; Adams, Paul D.; Winn, Martyn D.; Storoni, Laurent C.; Read, Randy J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">658-674</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">0021-8898</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Phaser is a program for phasing macromol. crystal structures by both mol. replacement and exptl. phasing methods.  The novel phasing algorithms implemented in Phaser have been developed using max. likelihood and multivariate statistics.  For mol. replacement, the new algorithms have proved to be significantly better than traditional methods in discriminating correct solns. from noise, and for single-wavelength anomalous dispersion exptl. phasing, the new algorithms, which account for correlations between F+ and F-, give better phases (lower mean phase error with respect to the phases given by the refined structure) than those that use mean F and anomalous differences ÎF.  One of the design concepts of Phaser was that it be capable of a high degree of automation.  To this end, Phaser (written in C++) can be called directly from Python, although it can also be called using traditional CCP4 keyword-style input.  Phaser is a platform for future development of improved phasing methods and their release, including source code, to the crystallog. community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPeVyjN_FMGbVg90H21EOLACvtfcHk0ljDW_HSqbk-GA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnslWqsLk%253D&md5=c63b722ae97e0a74e6a5a079d388f09f</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1107%2FS0021889807021206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0021889807021206%26sid%3Dliteratum%253Aachs%26aulast%3DMcCoy%26aufirst%3DA.%2BJ.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DAdams%26aufirst%3DP.%2BD.%26aulast%3DWinn%26aufirst%3DM.%2BD.%26aulast%3DStoroni%26aufirst%3DL.%2BC.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26atitle%3DPhaser%2520crystallographic%2520software%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D2007%26volume%3D40%26spage%3D658%26epage%3D674%26doi%3D10.1107%2FS0021889807021206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">BrÃ¼nger, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clore, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeLano, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gros, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosse-Kunstleve, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuszewski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilges, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannu, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warren, G. L.</span></span> <span> </span><span class="NLM_article-title">Crystallography & NMR system: A new software suite for macromolecular structure determination</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">905</span>â <span class="NLM_lpage">921</span>, <span class="refDoi">Â DOI: 10.1107/S0907444998003254</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1107%2FS0907444998003254" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=9757107" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A280%3ADyaK1cvjslKhsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=1998&pages=905-921&author=A.+T.+Br%C3%BCngerauthor=P.+D.+Adamsauthor=G.+M.+Cloreauthor=W.+L.+DeLanoauthor=P.+Grosauthor=R.+W.+Grosse-Kunstleveauthor=J.+S.+Jiangauthor=J.+Kuszewskiauthor=M.+Nilgesauthor=N.+S.+Pannuauthor=R.+J.+Readauthor=L.+M.+Riceauthor=T.+Simonsonauthor=G.+L.+Warren&title=Crystallography+%26+NMR+system%3A+A+new+software+suite+for+macromolecular+structure+determination&doi=10.1107%2FS0907444998003254"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Crystallography & NMR system: A new software suite for macromolecular structure determination</span></div><div class="casAuthors">Brunger A T; Adams P D; Clore G M; DeLano W L; Gros P; Grosse-Kunstleve R W; Jiang J S; Kuszewski J; Nilges M; Pannu N S; Read R J; Rice L M; Simonson T; Warren G L</div><div class="citationInfo"><span class="NLM_cas:title">Acta crystallographica. Section D, Biological crystallography</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">Pt 5</span>),
    <span class="NLM_cas:pages">905-21</span>
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    </div><div class="casAbstract">A new software suite, called Crystallography & NMR System (CNS), has been developed for macromolecular structure determination by X-ray crystallography or solution nuclear magnetic resonance (NMR) spectroscopy.  In contrast to existing structure-determination programs, the architecture of CNS is highly flexible, allowing for extension to other structure-determination methods, such as electron microscopy and solid-state NMR spectroscopy.  CNS has a hierarchical structure: a high-level hypertext markup language (HTML) user interface, task-oriented user input files, module files, a symbolic structure-determination language (CNS language), and low-level source code.  Each layer is accessible to the user.  The novice user may just use the HTML interface, while the more advanced user may use any of the other layers.  The source code will be distributed, thus source-code modification is possible.  The CNS language is sufficiently powerful and flexible that many new algorithms can be easily implemented in the CNS language without changes to the source code.  The CNS language allows the user to perform operations on data structures, such as structure factors, electron-density maps, and atomic properties.  The power of the CNS language has been demonstrated by the implementation of a comprehensive set of crystallographic procedures for phasing, density modification and refinement.  User-friendly task-oriented input files are available for nearly all aspects of macromolecular structure determination by X-ray crystallography and solution NMR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRAeLCFcGBdlx0LsK7uFuY7fW6udTcc2eaW5me0GCqqPrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1cvjslKhsw%253D%253D&md5=37afee1b07ac44d3f3730a39061b4e79</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1107%2FS0907444998003254&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444998003254%26sid%3Dliteratum%253Aachs%26aulast%3DBr%25C3%25BCnger%26aufirst%3DA.%2BT.%26aulast%3DAdams%26aufirst%3DP.%2BD.%26aulast%3DClore%26aufirst%3DG.%2BM.%26aulast%3DDeLano%26aufirst%3DW.%2BL.%26aulast%3DGros%26aufirst%3DP.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DJiang%26aufirst%3DJ.%2BS.%26aulast%3DKuszewski%26aufirst%3DJ.%26aulast%3DNilges%26aufirst%3DM.%26aulast%3DPannu%26aufirst%3DN.%2BS.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26aulast%3DRice%26aufirst%3DL.%2BM.%26aulast%3DSimonson%26aufirst%3DT.%26aulast%3DWarren%26aufirst%3DG.%2BL.%26atitle%3DCrystallography%2520%2526%2520NMR%2520system%253A%2520A%2520new%2520software%2520suite%2520for%2520macromolecular%2520structure%2520determination%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D1998%26volume%3D54%26spage%3D905%26epage%3D921%26doi%3D10.1107%2FS0907444998003254" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Emsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohkamp, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowtan, K.</span></span> <span> </span><span class="NLM_article-title">Features and development of Coot</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">486</span>â <span class="NLM_lpage">501</span>, <span class="refDoi">Â DOI: 10.1107/S0907444910007493</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1107%2FS0907444910007493" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=20383002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=486-501&author=P.+Emsleyauthor=B.+Lohkampauthor=W.+G.+Scottauthor=K.+Cowtan&title=Features+and+development+of+Coot&doi=10.1107%2FS0907444910007493"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Features and development of Coot</span></div><div class="casAuthors">Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">486-501</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Coot is a mol.-graphics application for model building and validation of biol. macromols.  The program displays electron-d. maps and at. models and allows model manipulations such as idealization, real-space refinement, manual rotation/translation, rigid-body fitting, ligand search, solvation, mutations, rotamers and Ramachandran idealization.  Furthermore, tools are provided for model validation as well as interfaces to external programs for refinement, validation and graphics.  The software is designed to be easy to learn for novice users, which is achieved by ensuring that tools for common tasks are 'discoverable' through familiar user-interface elements (menus and toolbars) or by intuitive behavior (mouse controls).  Recent developments have focused on providing tools for expert users, with customisable key bindings, extensions and an extensive scripting interface.  The software is under rapid development, but has already achieved very widespread use within the crystallog. community.  The current state of the software is presented, with a description of the facilities available and of some of the underlying methods employed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAKBKszbqb_7Vg90H21EOLACvtfcHk0ljsCzODKw_HGw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D&md5=67262cbfc60004de5ef962d5c043c910</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1107%2FS0907444910007493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444910007493%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DLohkamp%26aufirst%3DB.%26aulast%3DScott%26aufirst%3DW.%2BG.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DFeatures%2520and%2520development%2520of%2520Coot%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D486%26epage%3D501%26doi%3D10.1107%2FS0907444910007493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adams, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afonine, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunkoczi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Echols, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Headd, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapral, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosse-Kunstleve, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriarty, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oeffner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terwilliger, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zwart, P. H.</span></span> <span> </span><span class="NLM_article-title">PHENIX: a comprehensive Python-based system for macromolecular structure solution</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">213</span>â <span class="NLM_lpage">221</span>, <span class="refDoi">Â DOI: 10.1107/S0907444909052925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1107%2FS0907444909052925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=20124702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1Sisbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=213-221&author=P.+D.+Adamsauthor=P.+V.+Afonineauthor=G.+Bunkocziauthor=V.+B.+Chenauthor=I.+W.+Davisauthor=N.+Echolsauthor=J.+J.+Headdauthor=L.+W.+Hungauthor=G.+J.+Kapralauthor=R.+W.+Grosse-Kunstleveauthor=A.+J.+McCoyauthor=N.+W.+Moriartyauthor=R.+Oeffnerauthor=R.+J.+Readauthor=D.+C.+Richardsonauthor=J.+S.+Richardsonauthor=T.+C.+Terwilligerauthor=P.+H.+Zwart&title=PHENIX%3A+a+comprehensive+Python-based+system+for+macromolecular+structure+solution&doi=10.1107%2FS0907444909052925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">PHENIX: a comprehensive Python-based system for macromolecular structure solution</span></div><div class="casAuthors">Adams, Paul D.; Afonine, Pavel V.; Bunkoczi, Gabor; Chen, Vincent B.; Davis, Ian W.; Echols, Nathaniel; Headd, Jeffrey J.; Hung, Li Wei; Kapral, Gary J.; Grosse-Kunstleve, Ralf W.; McCoy, Airlie J.; Moriarty, Nigel W.; Oeffner, Robert; Read, Randy J.; Richardson, David C.; Richardson, Jane S.; Terwilliger, Thomas C.; Zwart, Peter H.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">213-221</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">A review.  Macromol. X-ray crystallog. is routinely applied to understand biol. processes at a mol. level.  However, significant time and effort are still required to solve and complete many of these structures because of the need for manual interpretation of complex numerical data using many software packages and the repeated use of interactive three-dimensional graphics.  PHENIX has been developed to provide a comprehensive system for macromol. crystallog. structure soln. with an emphasis on the automation of all procedures.  This has relied on the development of algorithms that minimize or eliminate subjective input, the development of algorithms that automate procedures that are traditionally performed by hand and, finally, the development of a framework that allows a tight integration between the algorithms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm_HgKRpa-ObVg90H21EOLACvtfcHk0lhw2FDgNWTEPg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1Sisbc%253D&md5=67b439ff4bd61c659cae37ca4209b7bc</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1107%2FS0907444909052925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909052925%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DP.%2BD.%26aulast%3DAfonine%26aufirst%3DP.%2BV.%26aulast%3DBunkoczi%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DV.%2BB.%26aulast%3DDavis%26aufirst%3DI.%2BW.%26aulast%3DEchols%26aufirst%3DN.%26aulast%3DHeadd%26aufirst%3DJ.%2BJ.%26aulast%3DHung%26aufirst%3DL.%2BW.%26aulast%3DKapral%26aufirst%3DG.%2BJ.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DMcCoy%26aufirst%3DA.%2BJ.%26aulast%3DMoriarty%26aufirst%3DN.%2BW.%26aulast%3DOeffner%26aufirst%3DR.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26aulast%3DRichardson%26aufirst%3DD.%2BC.%26aulast%3DRichardson%26aufirst%3DJ.%2BS.%26aulast%3DTerwilliger%26aufirst%3DT.%2BC.%26aulast%3DZwart%26aufirst%3DP.%2BH.%26atitle%3DPHENIX%253A%2520a%2520comprehensive%2520Python-based%2520system%2520for%2520macromolecular%2520structure%2520solution%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D213%26epage%3D221%26doi%3D10.1107%2FS0907444909052925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">SchÃ¼ttelkopf, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Aalten, D. M.</span></span> <span> </span><span class="NLM_article-title">PRODRG: a tool for high-throughput crystallography of protein-ligand complexes</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1355</span>â <span class="NLM_lpage">1363</span>, <span class="refDoi">Â DOI: 10.1107/S0907444904011679</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1107%2FS0907444904011679" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=15272157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlvVegtbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2004&pages=1355-1363&author=A.+W.+Sch%C3%BCttelkopfauthor=D.+M.+van+Aalten&title=PRODRG%3A+a+tool+for+high-throughput+crystallography+of+protein-ligand+complexes&doi=10.1107%2FS0907444904011679"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">PRODRG: a tool for high-throughput crystallography of protein-ligand complexes</span></div><div class="casAuthors">Schuettelkopf, Alexander W.; van Aalten, Daan M. F.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">D60</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1355-1363</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">The small-mol. topol. generator PRODRG is described, which takes input from existing coordinates or various two-dimensional formats and automatically generates coordinates and mol. topologies suitable for x-ray refinement of protein-ligand complexes.  Test results are described for automatic generation of topologies followed by energy minimization for a subset of compds. from the Cambridge Structural Database, which shows that, within the limits of the empirical GROMOS87 force field used, structures with good geometries are generated.  X-ray refinement in X-PLOR/CNS, REFMAC and SHELX using PRODRG-generated topologies produces results comparable to refinement with topologies from the std. libraries.  However, tests with distorted starting coordinates show that PRODRG topologies perform better, both in terms of ligand geometry and of crystallog. R factors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbflrch0bs97Vg90H21EOLACvtfcHk0lhw2FDgNWTEPg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlvVegtbY%253D&md5=f9bfdb14be7b04ea5c0db67feb39f72a</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1107%2FS0907444904011679&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444904011679%26sid%3Dliteratum%253Aachs%26aulast%3DSch%25C3%25BCttelkopf%26aufirst%3DA.%2BW.%26aulast%3Dvan%2BAalten%26aufirst%3DD.%2BM.%26atitle%3DPRODRG%253A%2520a%2520tool%2520for%2520high-throughput%2520crystallography%2520of%2520protein-ligand%2520complexes%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2004%26volume%3D60%26spage%3D1355%26epage%3D1363%26doi%3D10.1107%2FS0907444904011679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 13 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Yonggang Meng, Bin Yu, He Huang, Youmei Peng, Ertong Li, Yongfang Yao, Chuanjun Song, Wenquan Yu, Kaikai Zhu, Kai Wang, Dongxu Yi, Jinfa Du, <span class="NLM_string-name hlFld-ContribAuthor">Junbiao Chang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Dosimertinib, a Highly Potent, Selective, and Orally Efficacious Deuterated EGFR Targeting Clinical Candidate for the Treatment of Non-Small-Cell Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (2)
                                     , 925-937. <a href="https://doi.org/10.1021/acs.jmedchem.0c02005" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c02005%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BDosimertinib%25252C%252Ba%252BHighly%252BPotent%25252C%252BSelective%25252C%252Band%252BOrally%252BEfficacious%252BDeuterated%252BEGFR%252BTargeting%252BClinical%252BCandidate%252Bfor%252Bthe%252BTreatment%252Bof%252BNon-Small-Cell%252BLung%252BCancer%26aulast%3DMeng%26aufirst%3DYonggang%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D19112020%26date%3D18012021%26volume%3D64%26issue%3D2%26spage%3D925%26epage%3D937" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Krishnan Anand, Naeem Sheik Abdul, Terisha Ghazi, Muthusamy Ramesh, Gaurav Gupta, Murtaza M. Tambuwala, Harish Dureja, Sachin Kumar Singh, Dinesh Kumar Chellappan, Kamal Dua, Boomi Pandi, Muthupandian Saravanan, <span class="NLM_string-name hlFld-ContribAuthor">Anil Amichund Chuturgoon</span>. </span><span class="cited-content_cbyCitation_article-title">Induction of Caspase-Mediated Apoptosis in HepG2 Liver Carcinoma Cells Using MutagenâAntioxidant Conjugated Self-Assembled Novel Carbazole Nanoparticles and In Silico Modeling Studies. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2021,</strong> <em>6 </em>
                                    (1)
                                     , 265-277. <a href="https://doi.org/10.1021/acsomega.0c04461" title="DOI URL">https://doi.org/10.1021/acsomega.0c04461</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.0c04461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.0c04461%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DInduction%252Bof%252BCaspase-Mediated%252BApoptosis%252Bin%252BHepG2%252BLiver%252BCarcinoma%252BCells%252BUsing%252BMutagen%2525E2%252580%252593Antioxidant%252BConjugated%252BSelf-Assembled%252BNovel%252BCarbazole%252BNanoparticles%252Band%252BIn%252BSilico%252BModeling%252BStudies%26aulast%3DAnand%26aufirst%3DKrishnan%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D11092020%26date%3D09122020%26date%3D21122020%26volume%3D6%26issue%3D1%26spage%3D265%26epage%3D277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Janina Niggenaber, Leonie Heyden, Tobias Grabe, Matthias P. MÃ¼ller, Jonas Lategahn, <span class="NLM_string-name hlFld-ContribAuthor">Daniel Rauh</span>. </span><span class="cited-content_cbyCitation_article-title">Complex Crystal Structures of EGFR with Third-Generation Kinase Inhibitors and Simultaneously Bound Allosteric Ligands. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (12)
                                     , 2484-2490. <a href="https://doi.org/10.1021/acsmedchemlett.0c00472" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.0c00472</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.0c00472&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.0c00472%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DComplex%252BCrystal%252BStructures%252Bof%252BEGFR%252Bwith%252BThird-Generation%252BKinase%252BInhibitors%252Band%252BSimultaneously%252BBound%252BAllosteric%252BLigands%26aulast%3DNiggenaber%26aufirst%3DJanina%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D26082020%26date%3D28092020%26date%3D05112020%26volume%3D11%26issue%3D12%26spage%3D2484%26epage%3D2490" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xian  Zhou</span>, <span class="hlFld-ContribAuthor ">Xuexin  Feng</span>, <span class="hlFld-ContribAuthor ">Dachi  Wang</span>, <span class="hlFld-ContribAuthor ">Deheng  Chen</span>, <span class="hlFld-ContribAuthor ">Gaoxing  Wu</span>, <span class="hlFld-ContribAuthor ">Ziqin  Yan</span>, <span class="hlFld-ContribAuthor ">Xilin  Lyu</span>, <span class="hlFld-ContribAuthor ">Huan  Wang</span>, <span class="hlFld-ContribAuthor ">Jin-Ming  Yang</span>, <span class="hlFld-ContribAuthor ">Yujun  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and bioactivity studies of covalent inhibitors derived from (-)-Chaetominine. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Structure</span><span> <strong>2021,</strong> <em>1241 </em>, 130694. <a href="https://doi.org/10.1016/j.molstruc.2021.130694" title="DOI URL">https://doi.org/10.1016/j.molstruc.2021.130694</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molstruc.2021.130694&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molstruc.2021.130694%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Structure%26atitle%3DSynthesis%252Band%252Bbioactivity%252Bstudies%252Bof%252Bcovalent%252Binhibitors%252Bderived%252Bfrom%252B%252528-%252529-Chaetominine%26aulast%3DZhou%26aufirst%3DXian%26date%3D2021%26volume%3D1241%26spage%3D130694" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ismail M.M.  Othman</span>, <span class="hlFld-ContribAuthor ">Zahra M.  Alamshany</span>, <span class="hlFld-ContribAuthor ">Nada Y.  Tashkandi</span>, <span class="hlFld-ContribAuthor ">Mohamed A.M.  Gad-Elkareem</span>, <span class="hlFld-ContribAuthor ">Manal M.  Anwar</span>, <span class="hlFld-ContribAuthor ">Eman S.  Nossier</span>. </span><span class="cited-content_cbyCitation_article-title">New pyrimidine and pyrazole-based compounds as potential EGFR inhibitors: Synthesis, anticancer, antimicrobial evaluation and computational studies. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>114 </em>, 105078. <a href="https://doi.org/10.1016/j.bioorg.2021.105078" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.105078</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.105078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.105078%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DNew%252Bpyrimidine%252Band%252Bpyrazole-based%252Bcompounds%252Bas%252Bpotential%252BEGFR%252Binhibitors%25253A%252BSynthesis%25252C%252Banticancer%25252C%252Bantimicrobial%252Bevaluation%252Band%252Bcomputational%252Bstudies%26aulast%3DOthman%26aufirst%3DIsmail%2BM.M.%26date%3D2021%26volume%3D114%26spage%3D105078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">David E.  Heppner</span>, <span class="hlFld-ContribAuthor ">Michael J.  Eck</span>. </span><span class="cited-content_cbyCitation_article-title">A structural perspective on targeting the
              RTK
              /Ras/
              MAP
              kinase pathway in cancer. </span><span class="cited-content_cbyCitation_journal-name">Protein Science</span><span> <strong>2021,</strong> <em>30 </em>
                                    (8)
                                     , 1535-1553. <a href="https://doi.org/10.1002/pro.4125" title="DOI URL">https://doi.org/10.1002/pro.4125</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/pro.4125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fpro.4125%26sid%3Dliteratum%253Aachs%26jtitle%3DProtein%2520Science%26atitle%3DA%252Bstructural%252Bperspective%252Bon%252Btargeting%252Bthe%252BRTK%252B%25252FRas%25252F%252BMAP%252Bkinase%252Bpathway%252Bin%252Bcancer%26aulast%3DHeppner%26aufirst%3DDavid%2BE.%26date%3D2021%26date%3D2021%26volume%3D30%26issue%3D8%26spage%3D1535%26epage%3D1553" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhihui  Zhou</span>, <span class="hlFld-ContribAuthor ">Jie  He</span>, <span class="hlFld-ContribAuthor ">Feiyi  Yang</span>, <span class="hlFld-ContribAuthor ">Qingshan  Pan</span>, <span class="hlFld-ContribAuthor ">Zunhua  Yang</span>, <span class="hlFld-ContribAuthor ">Pengwu  Zheng</span>, <span class="hlFld-ContribAuthor ">Shan  Xu</span>, <span class="hlFld-ContribAuthor ">Wufu  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and evaluation of anti-proliferative activity of 2-aryl-4-aminoquinazoline derivatives as EGFR inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>112 </em>, 104848. <a href="https://doi.org/10.1016/j.bioorg.2021.104848" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.104848</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.104848&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.104848%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bevaluation%252Bof%252Banti-proliferative%252Bactivity%252Bof%252B2-aryl-4-aminoquinazoline%252Bderivatives%252Bas%252BEGFR%252Binhibitors%26aulast%3DZhou%26aufirst%3DZhihui%26date%3D2021%26volume%3D112%26spage%3D104848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Florian  Wittlinger</span>, <span class="hlFld-ContribAuthor ">Stefan A.  Laufer</span>. </span><span class="cited-content_cbyCitation_article-title">The pre-clinical discovery and development of osimertinib used to treat non-small cell lung cancer. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Discovery</span><span> <strong>2021,</strong> <em>40 </em>, 1-13. <a href="https://doi.org/10.1080/17460441.2021.1936496" title="DOI URL">https://doi.org/10.1080/17460441.2021.1936496</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17460441.2021.1936496&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17460441.2021.1936496%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Discovery%26atitle%3DThe%252Bpre-clinical%252Bdiscovery%252Band%252Bdevelopment%252Bof%252Bosimertinib%252Bused%252Bto%252Btreat%252Bnon-small%252Bcell%252Blung%252Bcancer%26aulast%3DWittlinger%26aufirst%3DFlorian%26date%3D2021%26date%3D2021%26volume%3D40%26spage%3D1%26epage%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Debasis  Das</span>, <span class="hlFld-ContribAuthor ">Jingbing  Wang</span>, <span class="hlFld-ContribAuthor ">Jian  Hong</span>. </span><span class="cited-content_cbyCitation_article-title">NextâGeneration Kinase Inhibitors Targeting Specific Biomarkers in NonâSmall Cell Lung Cancer (NSCLC): A Recent Overview. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2021,</strong> <em>71 </em><a href="https://doi.org/10.1002/cmdc.202100166" title="DOI URL">https://doi.org/10.1002/cmdc.202100166</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202100166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202100166%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DNext%2525E2%252580%252590Generation%252BKinase%252BInhibitors%252BTargeting%252BSpecific%252BBiomarkers%252Bin%252BNon%2525E2%252580%252590Small%252BCell%252BLung%252BCancer%252B%252528NSCLC%252529%25253A%252BA%252BRecent%252BOverview%26aulast%3DDas%26aufirst%3DDebasis%26date%3D2021%26date%3D2021%26volume%3D71" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuran  Qiu</span>, <span class="hlFld-ContribAuthor ">Xiaolan  Yin</span>, <span class="hlFld-ContribAuthor ">Xinyi  Li</span>, <span class="hlFld-ContribAuthor ">Yuanhao  Wang</span>, <span class="hlFld-ContribAuthor ">Qiang  Fu</span>, <span class="hlFld-ContribAuthor ">Renhua  Huang</span>, <span class="hlFld-ContribAuthor ">Shaoyong  Lu</span>. </span><span class="cited-content_cbyCitation_article-title">Untangling Dual-Targeting Therapeutic Mechanism of Epidermal Growth Factor Receptor (EGFR) Based on Reversed Allosteric Communication. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceutics</span><span> <strong>2021,</strong> <em>13 </em>
                                    (5)
                                     , 747. <a href="https://doi.org/10.3390/pharmaceutics13050747" title="DOI URL">https://doi.org/10.3390/pharmaceutics13050747</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/pharmaceutics13050747&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fpharmaceutics13050747%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceutics%26atitle%3DUntangling%252BDual-Targeting%252BTherapeutic%252BMechanism%252Bof%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252B%252528EGFR%252529%252BBased%252Bon%252BReversed%252BAllosteric%252BCommunication%26aulast%3DQiu%26aufirst%3DYuran%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D5%26spage%3D747" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaojing  Du</span>, <span class="hlFld-ContribAuthor ">Biwei  Yang</span>, <span class="hlFld-ContribAuthor ">Quanlin  An</span>, <span class="hlFld-ContribAuthor ">Yehuda G.  Assaraf</span>, <span class="hlFld-ContribAuthor ">Xin  Cao</span>, <span class="hlFld-ContribAuthor ">Jinglin  Xia</span>. </span><span class="cited-content_cbyCitation_article-title">Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors. </span><span class="cited-content_cbyCitation_journal-name">The Innovation</span><span> <strong>2021,</strong> <em>2 </em>
                                    (2)
                                     , 100103. <a href="https://doi.org/10.1016/j.xinn.2021.100103" title="DOI URL">https://doi.org/10.1016/j.xinn.2021.100103</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.xinn.2021.100103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.xinn.2021.100103%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Innovation%26atitle%3DAcquired%252Bresistance%252Bto%252Bthird-generation%252BEGFR-TKIs%252Band%252Bemerging%252Bnext-generation%252BEGFR%252Binhibitors%26aulast%3DDu%26aufirst%3DXiaojing%26date%3D2021%26volume%3D2%26issue%3D2%26spage%3D100103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daoxing  Chen</span>, <span class="hlFld-ContribAuthor ">Liting  Zhang</span>, <span class="hlFld-ContribAuthor ">Yanan  Liu</span>, <span class="hlFld-ContribAuthor ">Jiali  Song</span>, <span class="hlFld-ContribAuthor ">Jingwen  Guo</span>, <span class="hlFld-ContribAuthor ">Longxin  Wang</span>, <span class="hlFld-ContribAuthor ">Qinqin  Xia</span>, <span class="hlFld-ContribAuthor ">Xiaohui  Zheng</span>, <span class="hlFld-ContribAuthor ">Yuepiao  Cai</span>, <span class="hlFld-ContribAuthor ">Chenglv  Hong</span>. </span><span class="cited-content_cbyCitation_article-title">Insight into the impact of EGFR L792Y/F/H mutations on sensitivity to osimertinib: an
              in silico
              study. </span><span class="cited-content_cbyCitation_journal-name">New Journal of Chemistry</span><span> <strong>2021,</strong> <em>45 </em>
                                    (10)
                                     , 4756-4765. <a href="https://doi.org/10.1039/D0NJ05570K" title="DOI URL">https://doi.org/10.1039/D0NJ05570K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0NJ05570K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0NJ05570K%26sid%3Dliteratum%253Aachs%26jtitle%3DNew%2520Journal%2520of%2520Chemistry%26atitle%3DInsight%252Binto%252Bthe%252Bimpact%252Bof%252BEGFR%252BL792Y%25252FF%25252FH%252Bmutations%252Bon%252Bsensitivity%252Bto%252Bosimertinib%25253A%252Ban%252Bin%252Bsilico%252Bstudy%26aulast%3DChen%26aufirst%3DDaoxing%26date%3D2021%26date%3D2021%26volume%3D45%26issue%3D10%26spage%3D4756%26epage%3D4765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Leonard  Sung</span>. </span><span class="cited-content_cbyCitation_article-title">Covalent drugs in development for immune-mediated diseases. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 33-74. <a href="https://doi.org/10.1016/bs.armc.2021.03.001" title="DOI URL">https://doi.org/10.1016/bs.armc.2021.03.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.armc.2021.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.armc.2021.03.001%26sid%3Dliteratum%253Aachs%26atitle%3DCovalent%252Bdrugs%252Bin%252Bdevelopment%252Bfor%252Bimmune-mediated%252Bdiseases%26aulast%3DSung%26aufirst%3DLeonard%26date%3D2021%26spage%3D33%26epage%3D74%26pub%3DElsevier%26atitle%3DThe%252BDesign%252Bof%252BCovalent-Based%252BInhibitors%26date%3D2021%26volume%3D56" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00891/20200806/images/medium/jm0c00891_0007.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00891/20200806/images/large/jm0c00891_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00891&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00891/20200806/images/medium/jm0c00891_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00891/20200806/images/large/jm0c00891_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Compounds discussed in this report.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00891/20200806/images/large/jm0c00891_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00891&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00891/20200806/images/medium/jm0c00891_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00891/20200806/images/large/jm0c00891_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. MD simulations of AZD9291 binding to EGFR L858R and L858R/T790M. (Note that because the cancer mutation L858R is included in all simulations, L858R/T790M simulations are labeled âT790Mâ and L858R simulations are labeled âT790â in all panels.) (a) Spontaneous binding of AZD9291 to EGFR L858R in a simulation. Equally spaced snapshots from a 10 Î¼s simulation are superimposed on EGFR. AZD9291 is colored from red to green, representing the time progression. The opening of the binding site (as measured by the CÎ± distance between Ala 722, at the tip of the P-loop, and Ala 839, at the C-terminal of the catalytic loop) is shown by a dashed line. The root-mean-square deviation (RMSD) of AZD9291 with respect to the crystal structure of AZD9291-bound EGFR kinase (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZAU">4ZAU</a>) is plotted. (b) Spontaneous binding of AZD9291 with EGFR L858R/T790M in a simulation. The ligand RMSD of AZD9291 with respect to our crystal structure of AZD9291-bound T790M is plotted (bottom). The opening of the binding site is shown (middle), as is the AZD9291 dihedral angle that distinguishes the flipped and unflipped ligand conformations (top). As shown, the ligand was in the unflipped conformation when it first entered the binding site. (c) Left, the unflipped EGFR binding pose of AZD9291 in the binding simulations of L858R, in which Thr 790 is not mutated, compared with the crystal structure of the AZD9291-bound WT (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZAU">4ZAU</a>); right, the flipped EGFR binding pose from the binding simulations of L858R/T790M compared with our crystal structure of the AZD9291-bound T790M EGFR mutant (T790M/ccAZD9291). (d) Plots of the NHâO distances of the hinge hydrogen bonds (i.e., hydrogen bonds between AZD9291 and residues of the hinge of EGFR), where the stability of the hinge hydrogen bonds indicates a stable binding pose. The simulations that reached stable binding poses are shown in color and the others in gray. The top panel includes seventeen 10 Î¼s binding simulations of AZD9291 to EGFR L858R/T790M (8 of which reached the bound state), and the bottom panel includes 17 similar binding simulations to EGFR L858R (8 of which reached the bound state). The black arrows indicate binding events in which AZD9291 adopted an unflipped pose, and the red arrows indicate binding events in which it adopted a flipped pose. (e) Distribution of the dihedral angle associated with the flipping of AZD9291. The blue histogram was calculated based on 5 Î¼s of simulations of AZD9291 in solution, whereas the red histogram is based on aggregation of the portion of AZD9291 binding simulations to T790M/L858R in which a stable binding pose had been reached; the green histogram is based on the binding simulations of AZD9291 to L858R. Although the latter two histograms indicate that the T790M mutation favors the flipped binding pose, the histograms are likely unconverged and are meaningful only qualitatively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00891/20200806/images/large/jm0c00891_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00891&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00891/20200806/images/medium/jm0c00891_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00891/20200806/images/large/jm0c00891_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Plots of the Cys797(SG)-AZD9291 warhead distances in binding simulations of AZD9291 to EGFR L858R/T790M (labeled T790M) and EGFR L858R (labeled T790); smaller distances may indicate more productive binding modes (i.e., those conducive to covalent bond formation). The black arrows indicate binding events in which AZD9291 adopted an unflipped pose, and the red arrows indicate binding events in which it adopted a flipped pose. (See Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.0c00891/suppl_file/jm0c00891_si_001.pdf" class="ext-link">Figure S1</a> for the plots for the rest of the 16 ligand-binding simulations.).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00891/20200806/images/large/jm0c00891_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00891&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00891/20200806/images/medium/jm0c00891_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00891/20200806/images/large/jm0c00891_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Crystal structures of EGFR mutants in complex with AZD9291. The overall structures (upper subpanel) and the close views of the ATP-binding sites (lower subpanel) are shown for T790M/skAZD9291 (a), T790M/ccAZD9291 (b and c), L858R/skAZD9291 (d), WT/ccAZD9291 (e), and WT/skAZD9291 by Yosaatmadja et al. (f). Panel (c) shows the 2Fo-Fc electron density maps (blue meshes, contoured at 1.2Ï) and Fo-Fc electron density maps (green meshes, contoured at 3.0Ï) for the extra AZD9291 molecules (top) and the AZD9291 molecule in the ATP-binding site (bottom) in the T790M/ccAZD9291 crystal structure. These maps are omit maps, i.e., they were calculated after simulated annealing refinement (starting from 300 K) of the coordinates omitting the three AZD9291 molecules. The black dashes indicate hydrogen bonds between the compound and EGFR.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00891/20200806/images/large/jm0c00891_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00891&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00891/20200806/images/medium/jm0c00891_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00891/20200806/images/large/jm0c00891_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Comparison of AZD9291 binding poses observed in the co-crystallization and soaked complex crystal structures. (a) Superimposition of T790M/ccAZD9291 (slate) with T790M/skAZD9291 (lime). (b) Superimposition of T790M/ccAZD9291 (slate) with WT/ccAZD9291 (cyan). Note that the C-helix in the T790M/skAZD9291 structure is in the Î±C-in position (a), while in the WT/ccAZD9291 structure it takes the Î±C-out conformation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00891/20200806/images/large/jm0c00891_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00891&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00891/20200806/images/medium/jm0c00891_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00891/20200806/images/large/jm0c00891_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Extra binding site of AZD9291 to EGFR T790M in T790M/ccAZD9291 and the unusual conformation of EGFR in this structure. (a) Superimposition of T790M/ccAZD9291 (slate) on apo-T790M (active conformation of T790M, shown in yellow-orange, drawn from PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIT">2JIT</a>). (b) Superimposition of T790M/ccAZD9291 (slate) on V948R (inactive conformation of EGFR, shown in cyan, drawn from PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2GS7">2GS7</a>). (c) Conformation of the C-terminal end of A-loop in T790M/ccAZD9291 and its interaction with the N-lobe residues. (d) Classic asymmetric dimer described by Zhang et al.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> The donor and receiver EGFRs are shown in pink and cyan, respectively. (e) Altered asymmetric dimer observed in T790M/ccAZD9291. An enlarged close view of AZD9291 binding at the extra site is shown on the right. The black dashes indicate the polar interactions between Asp974 and AZD9291(2). AZD9291(3) is not shown for a better view of AZD9291(2). The P-loop, A-loop, and C-helix in panels (d) and (e) are shown in blue, orange, and red, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00891/20200806/images/large/jm0c00891_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00891&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i21">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72162" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72162" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 46 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paez, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tracy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greulich, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabriel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaye, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindeman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggon, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naoki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujii, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span> <span> </span><span class="NLM_article-title">EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>304</i></span>,  <span class="NLM_fpage">1497</span>â <span class="NLM_lpage">1500</span>, <span class="refDoi">Â DOI: 10.1126/science.1099314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1126%2Fscience.1099314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=15118125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVGmsbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=304&publication_year=2004&pages=1497-1500&author=J.+G.+Paezauthor=P.+A.+Janneauthor=J.+C.+Leeauthor=S.+Tracyauthor=H.+Greulichauthor=S.+Gabrielauthor=P.+Hermanauthor=F.+J.+Kayeauthor=N.+Lindemanauthor=T.+J.+Boggonauthor=K.+Naokiauthor=H.+Sasakiauthor=Y.+Fujiiauthor=M.+J.+Eckauthor=W.+R.+Sellersauthor=B.+E.+Johnsonauthor=M.+Meyerson&title=EGFR+mutations+in+lung+cancer%3A+correlation+with+clinical+response+to+gefitinib+therapy&doi=10.1126%2Fscience.1099314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy</span></div><div class="casAuthors">Paez, J. Guillermo; Jaenne, Pasi A.; Lee, Jeffrey C.; Tracy, Sean; Greulich, Heidi; Gabriel, Stacey; Herman, Paula; Kaye, Frederic J.; Lindeman, Neal; Boggon, Titus J.; Naoki, Katsuhiko; Sasaki, Hidefumi; Fujii, Yoshitaka; Eck, Michael J.; Sellers, William R.; Johnson, Bruce E.; Meyerson, Matthew</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">304</span>
        (<span class="NLM_cas:issue">5676</span>),
    <span class="NLM_cas:pages">1497-1500</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Receptor tyrosine kinase genes were sequenced in non-small cell lung cancer (NSCLC) and matched normal tissue.  Somatic mutations of the epidermal growth factor receptor gene EGFR were found in 15 of 58 unselected tumors from Japan and 1 of 61 from the United States.  Treatment with the EGFR kinase inhibitor gefitinib (Iressa) causes tumor regression in some patients with NSCLC, more frequently in Japan.  EGFR mutations were found in addnl. lung cancer samples from U.S. patients who responded to gefitinib therapy and in a lung adenocarcinoma cell line that was hypersensitive to growth inhibition by gefitinib, but not in gefitinib-insensitive tumors or cell lines.  These results suggest that EGFR mutations may predict sensitivity to gefitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGxLJH5f3Kb7Vg90H21EOLACvtfcHk0ljpnGaRhGKUjA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVGmsbs%253D&md5=6df1b11bf9b3c284fbe000e34c61ebac</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1126%2Fscience.1099314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1099314%26sid%3Dliteratum%253Aachs%26aulast%3DPaez%26aufirst%3DJ.%2BG.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DTracy%26aufirst%3DS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DGabriel%26aufirst%3DS.%26aulast%3DHerman%26aufirst%3DP.%26aulast%3DKaye%26aufirst%3DF.%2BJ.%26aulast%3DLindeman%26aufirst%3DN.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DNaoki%26aufirst%3DK.%26aulast%3DSasaki%26aufirst%3DH.%26aulast%3DFujii%26aufirst%3DY.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DMeyerson%26aufirst%3DM.%26atitle%3DEGFR%2520mutations%2520in%2520lung%2520cancer%253A%2520correlation%2520with%2520clinical%2520response%2520to%2520gefitinib%2520therapy%26jtitle%3DScience%26date%3D2004%26volume%3D304%26spage%3D1497%26epage%3D1500%26doi%3D10.1126%2Fscience.1099314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sordella, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurubhagavatula, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okimoto, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brannigan, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haserlat, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Supko, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haluska, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louis, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christiani, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Settleman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haber, D. A.</span></span> <span> </span><span class="NLM_article-title">Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>350</i></span>,  <span class="NLM_fpage">2129</span>â <span class="NLM_lpage">2139</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa040938</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1056%2FNEJMoa040938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=15118073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BD2cXktF2js7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=2004&pages=2129-2139&author=T.+J.+Lynchauthor=D.+W.+Bellauthor=R.+Sordellaauthor=S.+Gurubhagavatulaauthor=R.+A.+Okimotoauthor=B.+W.+Branniganauthor=P.+L.+Harrisauthor=S.+M.+Haserlatauthor=J.+G.+Supkoauthor=F.+G.+Haluskaauthor=D.+N.+Louisauthor=D.+C.+Christianiauthor=J.+Settlemanauthor=D.+A.+Haber&title=Activating+mutations+in+the+epidermal+growth+factor+receptor+underlying+responsiveness+of+non-small-cell+lung+cancer+to+gefitinib&doi=10.1056%2FNEJMoa040938"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Lynch, Thomas J.; Bell, Daphne W.; Sordella, Raffaella; Gurubhagavatula, Sarada; Okimoto, Ross A.; Brannigan, Brian W.; Harris, Patricia L.; Haserlat, Sara M.; Supko, Jeffrey G.; Haluska, Frank G.; Louis, David N.; Christiani, David C.; Settleman, Jeff; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">350</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2129-2139</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Most patients with non-small-cell lung cancer have no response to the tyrosine kinase inhibitor gefitinib, which targets the epidermal growth factor receptor (EGFR).  However, about 10% of patients have a rapid and often dramatic clin. response.  The mol. mechanisms underlying sensitivity to gefitinib are unknown.  We searched for mutations in the EGFR gene in primary tumors from patients with non-small-cell lung cancer who had a response to gefitinib, those who did not have a response, and those who had not been exposed to gefitinib.  The functional consequences of identified mutations were evaluated after the mutant proteins were expressed in cultured cells.  Somatic mutations were identified in the tyrosine kinase domain of the EGFR gene in eight of nine patients with gefitinib-responsive lung cancer, as compared with none of the seven patients with no response (P < 0.001).  Mutations were either small, in-frame deletions or amino acid substitutions clustered around the ATP-binding pocket of the tyrosine kinase domain.  Similar mutations were detected in tumors from 2 of 25 patients with primary non-small-cell lung cancer who had not been exposed to gefitinib (8%).  All mutations were heterozygous, and identical mutations were obsd. in multiple patients, suggesting an additive specific gain of function.  In vitro, EGFR mutants demonstrated enhanced tyrosine kinase activity in response to epidermal growth factor and increased sensitivity to inhibition by gefitinib.  A subgroup of patients with non-small-cell lung cancer have specific mutations in the EGFR gene, which correlate with clin. responsiveness to the tyrosine kinase inhibitor gefitinib.  These mutations lead to increased growth factor signaling and confer susceptibility to the inhibitor.  Screening for such mutations in lung cancers may identify patients who will have a response to gefitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXwWGeAQrNTLVg90H21EOLACvtfcHk0liEdE4oQ1sh1Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXktF2js7c%253D&md5=fad70aa0f32ad4105ad6f3db98135bf9</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa040938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa040938%26sid%3Dliteratum%253Aachs%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DGurubhagavatula%26aufirst%3DS.%26aulast%3DOkimoto%26aufirst%3DR.%2BA.%26aulast%3DBrannigan%26aufirst%3DB.%2BW.%26aulast%3DHarris%26aufirst%3DP.%2BL.%26aulast%3DHaserlat%26aufirst%3DS.%2BM.%26aulast%3DSupko%26aufirst%3DJ.%2BG.%26aulast%3DHaluska%26aufirst%3DF.%2BG.%26aulast%3DLouis%26aufirst%3DD.%2BN.%26aulast%3DChristiani%26aufirst%3DD.%2BC.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DActivating%2520mutations%2520in%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520underlying%2520responsiveness%2520of%2520non-small-cell%2520lung%2520cancer%2520to%2520gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2004%26volume%3D350%26spage%3D2129%26epage%3D2139%26doi%3D10.1056%2FNEJMoa040938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zakowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doherty, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Politi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkaria, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heelan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulton, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mardis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kupfer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kris, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varmus, H.</span></span> <span> </span><span class="NLM_article-title">EGF receptor gene mutations are common in lung cancers from ânever smokersâ and are associated with sensitivity of tumors to gefitinib and erlotinib</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">13306</span>â <span class="NLM_lpage">13311</span>, <span class="refDoi">Â DOI: 10.1073/pnas.0405220101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1073%2Fpnas.0405220101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=15329413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnvFems70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=13306-13311&author=W.+Paoauthor=V.+Millerauthor=M.+Zakowskiauthor=J.+Dohertyauthor=K.+Politiauthor=I.+Sarkariaauthor=B.+Singhauthor=R.+Heelanauthor=V.+Ruschauthor=L.+Fultonauthor=E.+Mardisauthor=D.+Kupferauthor=R.+Wilsonauthor=M.+Krisauthor=H.+Varmus&title=EGF+receptor+gene+mutations+are+common+in+lung+cancers+from+%E2%80%9Cnever+smokers%E2%80%9D+and+are+associated+with+sensitivity+of+tumors+to+gefitinib+and+erlotinib&doi=10.1073%2Fpnas.0405220101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib</span></div><div class="casAuthors">Pao, William; Miller, Vincent; Zakowski, Maureen; Doherty, Jennifer; Politi, Katerina; Sarkaria, Inderpal; Singh, Bhuvanesh; Heelan, Robert; Rusch, Valerie; Fulton, Lucinda; Mardis, Elaine; Kupfer, Doris; Wilson, Richard; Kris, Mark; Varmus, Harold</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">13306-13311</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Somatic mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene are reportedly assocd. with sensitivity of lung cancers to gefitinib (Iressa), kinase inhibitor.  In-frame deletions occur in exon 19, whereas point mutations occur frequently in codon 858 (exon 21).  We found from sequencing the EGFR TK domain that 7 of 10 gefitinib-sensitive tumors had similar types of alterations; no mutations were found in eight gefitinib-refractory tumors (P = 0.004).  Five of seven tumors sensitive to erlotinib (Tarceva), a related kinase inhibitor for which the clin. relevant target is undocumented, had analogous somatic mutations, as opposed to none of 10 erlotinib-refractory tumors (P = 0.003).  Because most mutation-pos. tumors were adenocarcinomas from patients who smoked <100 cigarettes in a lifetime ("never smokers"), we screened EGFR exons 2-28 in 15 adenocarcinomas resected from untreated never smokers.  Seven tumors had TK domain mutations, in contrast to 4 of 81 non-small cell lung cancers resected from untreated former or current smokers (P = 0.0001).  Immunoblotting of lysates from cells transiently transfected with various EGFR constructs demonstrated that, compared to wild-type protein, an exon 19 deletion mutant induced diminished levels of phosphotyrosine, whereas the phosphorylation at tyrosine 1092 of an exon 21 point mutant was inhibited at 10-fold lower concns. of drug.  Collectively, these data show that adenocarcinomas from never smokers comprise a distinct subset of lung cancers, frequently contg. mutations within the TK domain of EGFR that are assocd. with gefitinib and erlotinib sensitivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovevWonTGqELVg90H21EOLACvtfcHk0liEdE4oQ1sh1Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnvFems70%253D&md5=38f491968552501b7463a688fa0e62ff</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0405220101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0405220101%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%26aulast%3DZakowski%26aufirst%3DM.%26aulast%3DDoherty%26aufirst%3DJ.%26aulast%3DPoliti%26aufirst%3DK.%26aulast%3DSarkaria%26aufirst%3DI.%26aulast%3DSingh%26aufirst%3DB.%26aulast%3DHeelan%26aufirst%3DR.%26aulast%3DRusch%26aufirst%3DV.%26aulast%3DFulton%26aufirst%3DL.%26aulast%3DMardis%26aufirst%3DE.%26aulast%3DKupfer%26aufirst%3DD.%26aulast%3DWilson%26aufirst%3DR.%26aulast%3DKris%26aufirst%3DM.%26aulast%3DVarmus%26aufirst%3DH.%26atitle%3DEGF%2520receptor%2520gene%2520mutations%2520are%2520common%2520in%2520lung%2520cancers%2520from%2520%25E2%2580%259Cnever%2520smokers%25E2%2580%259D%2520and%2520are%2520associated%2520with%2520sensitivity%2520of%2520tumors%2520to%2520gefitinib%2520and%2520erlotinib%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2004%26volume%3D101%26spage%3D13306%26epage%3D13311%26doi%3D10.1073%2Fpnas.0405220101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggon, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dayaram, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocher, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tenen, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halmos, B.</span></span> <span> </span><span class="NLM_article-title">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>352</i></span>,  <span class="NLM_fpage">786</span>â <span class="NLM_lpage">792</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa044238</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1056%2FNEJMoa044238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=15728811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=786-792&author=S.+Kobayashiauthor=T.+J.+Boggonauthor=T.+Dayaramauthor=P.+A.+Janneauthor=O.+Kocherauthor=M.+Meyersonauthor=B.+E.+Johnsonauthor=M.+J.+Eckauthor=D.+G.+Tenenauthor=B.+Halmos&title=EGFR+mutation+and+resistance+of+non-small-cell+lung+cancer+to+gefitinib&doi=10.1056%2FNEJMoa044238"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Kobayashi, Susumu; Boggon, Titus J.; Dayaram, Tajhal; Jaenne, Pasi A.; Kocher, Olivier; Meyerson, Matthew; Johnson, Bruce E.; Eck, Michael J.; Tenen, Daniel G.; Halmos, Balizs</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">786-792</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Mutations of the epidermal growth factor receptor (EGFR) gene were identified in specimens from patients with non-small-cell lung cancer who have a response to anilinoquinazoline EGFR inhibitors.  Despite the dramatic responses to such inhibitors, most patients ultimately have a relapse.  The mechanism of the drug resistance is unknown.  Here the authors report the case of a patient with EGFR-mutant, gefitinib-responsive, advanced non-small-cell lung cancer who had a relapse after 2 years of complete remission during treatment with gefitinib.  The DNA sequence of the EGFR gene in his tumor biopsy specimen at relapse revealed the presence of a second point mutation, resulting in threonine-to-methionine amino acid change at position 790 of EGFR.  Structural modeling and biochem. studies showed that this second mutation led to gefitinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8XXhT1hrbe7Vg90H21EOLACvtfcHk0ljhS9IxdVhfJg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D&md5=808223ad566e2a3748977727cc5a9846</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa044238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa044238%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DDayaram%26aufirst%3DT.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DKocher%26aufirst%3DO.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DTenen%26aufirst%3DD.%2BG.%26aulast%3DHalmos%26aufirst%3DB.%26atitle%3DEGFR%2520mutation%2520and%2520resistance%2520of%2520non-small-cell%2520lung%2520cancer%2520to%2520gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26spage%3D786%26epage%3D792%26doi%3D10.1056%2FNEJMoa044238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Politi, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somwar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zakowski, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kris, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varmus, H.</span></span> <span> </span><span class="NLM_article-title">Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain</span>. <i>PLoS Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>2</i></span>, <span class="NLM_elocation-id">e73</span> <span class="refDoi">Â DOI: 10.1371/journal.pmed.0020073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1371%2Fjournal.pmed.0020073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=15737014" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A280%3ADC%252BD2MzjtVehsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&author=W.+Paoauthor=V.+A.+Millerauthor=K.+A.+Politiauthor=G.+J.+Rielyauthor=R.+Somwarauthor=M.+F.+Zakowskiauthor=M.+G.+Krisauthor=H.+Varmus&title=Acquired+resistance+of+lung+adenocarcinomas+to+gefitinib+or+erlotinib+is+associated+with+a+second+mutation+in+the+EGFR+kinase+domain&doi=10.1371%2Fjournal.pmed.0020073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain</span></div><div class="casAuthors">Pao William; Miller Vincent A; Politi Katerina A; Riely Gregory J; Somwar Romel; Zakowski Maureen F; Kris Mark G; Varmus Harold</div><div class="citationInfo"><span class="NLM_cas:title">PLoS medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e73</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Lung adenocarcinomas from patients who respond to the tyrosine kinase inhibitors gefitinib (Iressa) or erlotinib (Tarceva) usually harbor somatic gain-of-function mutations in exons encoding the kinase domain of the epidermal growth factor receptor (EGFR).  Despite initial responses, patients eventually progress by unknown mechanisms of "acquired" resistance.  METHODS AND FINDINGS:  We show that in two of five patients with acquired resistance to gefitinib or erlotinib, progressing tumors contain, in addition to a primary drug-sensitive mutation in EGFR, a secondary mutation in exon 20, which leads to substitution of methionine for threonine at position 790 (T790M) in the kinase domain.  Tumor cells from a sixth patient with a drug-sensitive EGFR mutation whose tumor progressed on adjuvant gefitinib after complete resection also contained the T790M mutation.  This mutation was not detected in untreated tumor samples.  Moreover, no tumors with acquired resistance had KRAS mutations, which have been associated with primary resistance to these drugs.  Biochemical analyses of transfected cells and growth inhibition studies with lung cancer cell lines demonstrate that the T790M mutation confers resistance to EGFR mutants usually sensitive to either gefitinib or erlotinib.  Interestingly, a mutation analogous to T790M has been observed in other kinases with acquired resistance to another kinase inhibitor, imatinib (Gleevec).  CONCLUSION:  In patients with tumors bearing gefitinib- or erlotinib-sensitive EGFR mutations, resistant subclones containing an additional EGFR mutation emerge in the presence of drug.  This observation should help guide the search for more effective therapy against a specific subset of lung cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcREkXMV3u1nwwMthz5_Rx5rfW6udTcc2earY2vwwnmKL7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MzjtVehsw%253D%253D&md5=3e626105e0dea2a38997156ae513f56b</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pmed.0020073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pmed.0020073%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPoliti%26aufirst%3DK.%2BA.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DSomwar%26aufirst%3DR.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DVarmus%26aufirst%3DH.%26atitle%3DAcquired%2520resistance%2520of%2520lung%2520adenocarcinomas%2520to%2520gefitinib%2520or%2520erlotinib%2520is%2520associated%2520with%2520a%2520second%2520mutation%2520in%2520the%2520EGFR%2520kinase%2520domain%26jtitle%3DPLoS%2520Med.%26date%3D2005%26volume%3D2%26doi%3D10.1371%2Fjournal.pmed.0020073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Balak, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somwar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zakowski, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouerfelli, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kris, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladanyi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span> <span> </span><span class="NLM_article-title">Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">6494</span>â <span class="NLM_lpage">6501</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-06-1570</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1158%2F1078-0432.CCR-06-1570" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=17085664" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFKitbrI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=6494-6501&author=M.+N.+Balakauthor=Y.+Gongauthor=G.+J.+Rielyauthor=R.+Somwarauthor=A.+R.+Liauthor=M.+F.+Zakowskiauthor=A.+Chiangauthor=G.+Yangauthor=O.+Ouerfelliauthor=M.+G.+Krisauthor=M.+Ladanyiauthor=V.+A.+Millerauthor=W.+Pao&title=Novel+D761Y+and+common+secondary+T790M+mutations+in+epidermal+growth+factor+receptor-mutant+lung+adenocarcinomas+with+acquired+resistance+to+kinase+inhibitors&doi=10.1158%2F1078-0432.CCR-06-1570"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor-Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors</span></div><div class="casAuthors">Balak, Marissa N.; Gong, Yixuan; Riely, Gregory J.; Somwar, Romel; Li, Allan R.; Zakowski, Maureen F.; Chiang, Anne; Yang, Guangli; Ouerfelli, Ouathek; Kris, Mark G.; Ladanyi, Marc; Miller, Vincent A.; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6494-6501</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: In patients whose lung adenocarcinomas harbor epidermal growth factor receptor (EGFR) tyrosine kinase domain mutations, acquired resistance to the tyrosine kinase inhibitors (TKI) gefitinib (Iressa) and erlotinib (Tarceva) has been assocd. with a second-site EGFR mutation, which leads to substitution of methionine for threonine at position 790 (T790M).  We aimed to elucidate the frequency and nature of secondary EGFR mutations in patients with acquired resistance to TKI monotherapy.  Exptl. Design: Tumor cells from patients with acquired resistance were examd. for secondary EGFR kinase domain mutations by mol. analyses.  RESULTS: Eight of 16 patients (50% obsd. rate; 95% confidence interval, 25-75%) had tumor cells with second-site EGFR mutations.  Seven mutations were T790M and one was a novel D761Y mutation found in a brain metastasis.  When combined with a drug-sensitive L858R mutation, the D761Y mutation modestly reduced the sensitivity of mutant EGFR to TKIs in both surrogate kinase and cell viability assays.  In an autopsy case, the T790M mutation was found in multiple visceral metastases but not in a brain lesion.  CONCLUSIONS: The T790M mutation is common in patients with acquired resistance.  The limited spectrum of TKI-resistant mutations in EGFR, which binds to erlotinib in the active conformation, contrasts with a wider range of second-site mutations seen with acquired resistance to imatinib, which binds to ABL and KIT, resp., in closed conformations.  Collectively, our data suggest that the type and nature of kinase inhibitor resistance mutations may be influenced by both anat. site and mode of binding to the kinase target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmeHDQldYeDLVg90H21EOLACvtfcHk0ljhS9IxdVhfJg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFKitbrI&md5=e817eb717673081d89ec3d58a04a7d4d</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-1570&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-1570%26sid%3Dliteratum%253Aachs%26aulast%3DBalak%26aufirst%3DM.%2BN.%26aulast%3DGong%26aufirst%3DY.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DSomwar%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DA.%2BR.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DChiang%26aufirst%3DA.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DOuerfelli%26aufirst%3DO.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DNovel%2520D761Y%2520and%2520common%2520secondary%2520T790M%2520mutations%2520in%2520epidermal%2520growth%2520factor%2520receptor-mutant%2520lung%2520adenocarcinomas%2520with%2520acquired%2520resistance%2520to%2520kinase%2520inhibitors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D6494%26epage%3D6501%26doi%3D10.1158%2F1078-0432.CCR-06-1570" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mengwasser, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toms, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greulich, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span> <span> </span><span class="NLM_article-title">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">2070</span>â <span class="NLM_lpage">2075</span>, <span class="refDoi">Â DOI: 10.1073/pnas.0709662105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1073%2Fpnas.0709662105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=18227510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2070-2075&author=C.+H.+Yunauthor=K.+E.+Mengwasserauthor=A.+V.+Tomsauthor=M.+S.+Wooauthor=H.+Greulichauthor=K.+K.+Wongauthor=M.+Meyersonauthor=M.+J.+Eck&title=The+T790M+mutation+in+EGFR+kinase+causes+drug+resistance+by+increasing+the+affinity+for+ATP&doi=10.1073%2Fpnas.0709662105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span></div><div class="casAuthors">Yun, Cai-Hong; Mengwasser, Kristen E.; Toms, Angela V.; Woo, Michele S.; Greulich, Heidi; Wong, Kwok-Kin; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2070-2075</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to small mol. tyrosine kinase inhibitors (TKIs), but the efficacy of these agents is often limited because of the emergence of drug resistance conferred by a second mutation, T790M.  Threonine 790 is the "gatekeeper" residue, an important determinant of inhibitor specificity in the ATP binding pocket.  The T790M mutation has been thought to cause resistance by sterically blocking binding of TKIs such as gefitinib and erlotinib, but this explanation is difficult to reconcile with the fact that it remains sensitive to structurally similar irreversible inhibitors.  Here, we show by using a direct binding assay that T790M mutants retain low-nanomolar affinity for gefitinib.  Furthermore, we show that the T790M mutation activates WT EGFR and that introduction of the T790M mutation increases the ATP affinity of the oncogenic L858R mutant by more than an order of magnitude.  The increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance.  Crystallog. anal. of the T790M mutant shows how it can adapt to accommodate tight binding of diverse inhibitors, including the irreversible inhibitor HKI-272, and also suggests a structural mechanism for catalytic activation.  We conclude that the T790M mutation is a "generic" resistance mutation that will reduce the potency of any ATP-competitive kinase inhibitor and that irreversible inhibitors overcome this resistance simply through covalent binding, not as a result of an alternative binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXXP7TBlyrdrVg90H21EOLACvtfcHk0lg0p8k3Wov0dQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D&md5=f5f5d791a65f73ca628d95e9922b8ea8</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0709662105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0709662105%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DMengwasser%26aufirst%3DK.%2BE.%26aulast%3DToms%26aufirst%3DA.%2BV.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520T790M%2520mutation%2520in%2520EGFR%2520kinase%2520causes%2520drug%2520resistance%2520by%2520increasing%2520the%2520affinity%2520for%2520ATP%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2008%26volume%3D105%26spage%3D2070%26epage%3D2075%26doi%3D10.1073%2Fpnas.0709662105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capelletti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortot, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chirieac, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacob, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padera, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engen, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span> <span> </span><span class="NLM_article-title">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>462</i></span>,  <span class="NLM_fpage">1070</span>â <span class="NLM_lpage">1074</span>, <span class="refDoi">Â DOI: 10.1038/nature08622</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1038%2Fnature08622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=20033049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2009&pages=1070-1074&author=W.+Zhouauthor=D.+Ercanauthor=L.+Chenauthor=C.+H.+Yunauthor=D.+Liauthor=M.+Capellettiauthor=A.+B.+Cortotauthor=L.+Chirieacauthor=R.+E.+Iacobauthor=R.+Paderaauthor=J.+R.+Engenauthor=K.+K.+Wongauthor=M.+J.+Eckauthor=N.+S.+Grayauthor=P.+A.+Janne&title=Novel+mutant-selective+EGFR+kinase+inhibitors+against+EGFR+T790M&doi=10.1038%2Fnature08622"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span></div><div class="casAuthors">Zhou, Wenjun; Ercan, Dalia; Chen, Liang; Yun, Cai-Hong; Li, Danan; Capelletti, Marzia; Cortot, Alexis B.; Chirieac, Lucian; Iacob, Roxana E.; Padera, Robert; Engen, John R.; Wong, Kwok-Kin; Eck, Michael J.; Gray, Nathanael S.; Janne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">462</span>
        (<span class="NLM_cas:issue">7276</span>),
    <span class="NLM_cas:pages">1070-1074</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR-mutant non-small-cell lung cancer (NSCLC) is limited by the development of drug-resistance mutations, including the gatekeeper T790M mutation.  Strategies targeting EGFR T790M with irreversible inhibitors have had limited success and are assocd. with toxicity due to concurrent inhibition of wild-type EGFR.  All current EGFR inhibitors possess a structurally related quinazoline-based core scaffold and were identified as ATP-competitive inhibitors of wild-type EGFR.  Here we identify a covalent pyrimidine EGFR inhibitor by screening an irreversible kinase inhibitor library specifically against EGFR T790M.  These agents are 30- to 100-fold more potent against EGFR T790M, and up to 100-fold less potent against wild-type EGFR, than quinazoline-based EGFR inhibitors in vitro.  They are also effective in murine models of lung cancer driven by EGFR T790M.  Co-crystn. studies reveal a structural basis for the increased potency and mutant selectivity of these agents.  These mutant-selective irreversible EGFR kinase inhibitors may be clin. more effective and better tolerated than quinazoline-based inhibitors.  Our findings demonstrate that functional pharmacol. screens against clin. important mutant kinases represent a powerful strategy to identify new classes of mutant-selective kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcksZlIe-1bbVg90H21EOLACvtfcHk0lg0p8k3Wov0dQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI&md5=9b5d41a2be401c67a4b9f04a41cf1725</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnature08622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08622%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DCortot%26aufirst%3DA.%2BB.%26aulast%3DChirieac%26aufirst%3DL.%26aulast%3DIacob%26aufirst%3DR.%2BE.%26aulast%3DPadera%26aufirst%3DR.%26aulast%3DEngen%26aufirst%3DJ.%2BR.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DNovel%2520mutant-selective%2520EGFR%2520kinase%2520inhibitors%2520against%2520EGFR%2520T790M%26jtitle%3DNature%26date%3D2009%26volume%3D462%26spage%3D1070%26epage%3D1074%26doi%3D10.1038%2Fnature08622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walter, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sjin, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haringsma, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubrovskiy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labenski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheets, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St Martin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karp, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Kalken, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaturvedi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nacht, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petter, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westlin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaw-Tsai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raponi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Dyke, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Etter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmons, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harding, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, A.</span></span> <span> </span><span class="NLM_article-title">Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1404</span>â <span class="NLM_lpage">1415</span>, <span class="refDoi">Â DOI: 10.1158/2159-8290.CD-13-0314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1158%2F2159-8290.CD-13-0314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=24065731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvV2rtLvN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=1404-1415&author=A.+O.+Walterauthor=R.+T.+Sjinauthor=H.+J.+Haringsmaauthor=K.+Ohashiauthor=J.+Sunauthor=K.+Leeauthor=A.+Dubrovskiyauthor=M.+Labenskiauthor=Z.+Zhuauthor=Z.+Wangauthor=M.+Sheetsauthor=T.+St+Martinauthor=R.+Karpauthor=D.+van+Kalkenauthor=P.+Chaturvediauthor=D.+Niuauthor=M.+Nachtauthor=R.+C.+Petterauthor=W.+Westlinauthor=K.+Linauthor=S.+Jaw-Tsaiauthor=M.+Raponiauthor=T.+Van+Dykeauthor=J.+Etterauthor=Z.+Weaverauthor=W.+Paoauthor=J.+Singhauthor=A.+D.+Simmonsauthor=T.+C.+Hardingauthor=A.+Allen&title=Discovery+of+a+mutant-selective+covalent+inhibitor+of+EGFR+that+overcomes+T790M-mediated+resistance+in+NSCLC&doi=10.1158%2F2159-8290.CD-13-0314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC</span></div><div class="casAuthors">Walter, Annette O.; Sjin, Robert Tjin Tham; Haringsma, Henry J.; Ohashi, Kadoaki; Sun, Jing; Lee, Kwangho; Dubrovskiy, Aleksandr; Labenski, Matthew; Zhu, Zhendong; Wang, Zhigang; Sheets, Michael; St. Martin, Thia; Karp, Russell; van Kalken, Dan; Chaturvedi, Prasoon; Niu, Deqiang; Nacht, Mariana; Petter, Russell C.; Westlin, William; Lin, Kevin; Jaw-Tsai, Sarah; Raponi, Mitch; Van Dyke, Terry; Etter, Jeff; Weaver, Zoe; Pao, William; Singh, Juswinder; Simmons, Andrew D.; Harding, Thomas C.; Allen, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1404-1415</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Patients with non-small cell lung cancer (NSCLC) with activating EGF receptor (EGFR) mutations initially respond to first-generation reversible EGFR tyrosine kinase inhibitors.  However, clin. efficacy is limited by acquired resistance, frequently driven by the EGFRT790M mutation.  CO-1686 is a novel, irreversible, and orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR, including T790M, while exhibiting minimal activity toward the wild-type (WT) receptor.  Oral administration of CO-1686 as single agent induces tumor regression in EGFR-mutated NSCLC tumor xenograft and transgenic models.  Minimal activity of CO-1686 against the WT EGFR receptor was obsd.  In NSCLC cells with acquired resistance to CO-1686 in vitro, there was no evidence of addnl. mutations or amplification of the EGFR gene, but resistant cells exhibited signs of epithelial-mesenchymal transition and demonstrated increased sensitivity to AKT inhibitors.  These results suggest that CO-1686 may offer a novel therapeutic option for patients with mutant EGFR NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR0CDWQZ5wn7Vg90H21EOLACvtfcHk0lhJislgCXsDYA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvV2rtLvN&md5=3d111f4bf958f2fda6890fbc0e1d99f5</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-13-0314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-13-0314%26sid%3Dliteratum%253Aachs%26aulast%3DWalter%26aufirst%3DA.%2BO.%26aulast%3DSjin%26aufirst%3DR.%2BT.%26aulast%3DHaringsma%26aufirst%3DH.%2BJ.%26aulast%3DOhashi%26aufirst%3DK.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DDubrovskiy%26aufirst%3DA.%26aulast%3DLabenski%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DSt%2BMartin%26aufirst%3DT.%26aulast%3DKarp%26aufirst%3DR.%26aulast%3Dvan%2BKalken%26aufirst%3DD.%26aulast%3DChaturvedi%26aufirst%3DP.%26aulast%3DNiu%26aufirst%3DD.%26aulast%3DNacht%26aufirst%3DM.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DWestlin%26aufirst%3DW.%26aulast%3DLin%26aufirst%3DK.%26aulast%3DJaw-Tsai%26aufirst%3DS.%26aulast%3DRaponi%26aufirst%3DM.%26aulast%3DVan%2BDyke%26aufirst%3DT.%26aulast%3DEtter%26aufirst%3DJ.%26aulast%3DWeaver%26aufirst%3DZ.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DSimmons%26aufirst%3DA.%2BD.%26aulast%3DHarding%26aufirst%3DT.%2BC.%26aulast%3DAllen%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520a%2520mutant-selective%2520covalent%2520inhibitor%2520of%2520EGFR%2520that%2520overcomes%2520T790M-mediated%2520resistance%2520in%2520NSCLC%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D1404%26epage%3D1415%26doi%3D10.1158%2F2159-8290.CD-13-0314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghiorghiu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberlein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nebhan, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitzler, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orme, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finlay, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Red Brewer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichihara, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Kadhimi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowlinson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinowska, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantarini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranson, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span> <span> </span><span class="NLM_article-title">AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1046</span>â <span class="NLM_lpage">1061</span>, <span class="refDoi">Â DOI: 10.1158/2159-8290.CD-14-0337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1158%2F2159-8290.CD-14-0337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=24893891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=1046-1061&author=D.+A.+Crossauthor=S.+E.+Ashtonauthor=S.+Ghiorghiuauthor=C.+Eberleinauthor=C.+A.+Nebhanauthor=P.+J.+Spitzlerauthor=J.+P.+Ormeauthor=M.+R.+Finlayauthor=R.+A.+Wardauthor=M.+J.+Mellorauthor=G.+Hughesauthor=A.+Rahiauthor=V.+N.+Jacobsauthor=M.+Red+Brewerauthor=E.+Ichiharaauthor=J.+Sunauthor=H.+Jinauthor=P.+Ballardauthor=K.+Al-Kadhimiauthor=R.+Rowlinsonauthor=T.+Klinowskaauthor=G.+H.+Richmondauthor=M.+Cantariniauthor=D.+W.+Kimauthor=M.+R.+Ransonauthor=W.+Pao&title=AZD9291%2C+an+irreversible+EGFR+TKI%2C+overcomes+T790M-mediated+resistance+to+EGFR+inhibitors+in+lung+cancer&doi=10.1158%2F2159-8290.CD-14-0337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer</span></div><div class="casAuthors">Cross, Darren A. E.; Ashton, Susan E.; Ghiorghiu, Serban; Eberlein, Cath; Nebhan, Caroline A.; Spitzler, Paula J.; Orme, Jonathon P.; Finlay, M. Raymond V.; Ward, Richard A.; Mellor, Martine J.; Hughes, Gareth; Rahi, Amar; Jacobs, Vivien N.; Brewer, Monica Red; Ichihara, Eiki; Sun, Jing; Jin, Hailing; Ballard, Peter; Al-Kadhimi, Katherine; Rowlinson, Rachel; Klinowska, Teresa; Richmond, Graham H. P.; Cantarini, Mireille; Kim, Dong-Wan; Ranson, Malcolm R.; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1046-1061</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A third-generation EGFR inhibitor selectively targets EGFR mutants, including T790M, but not wild-type EGFR, and induces durable antitumor responses in preclin. models and patients with NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDo3e2pAh8YbVg90H21EOLACvtfcHk0lhJislgCXsDYA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP&md5=f72e56f9463236ddc89eef32a4ab61b3</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0337%26sid%3Dliteratum%253Aachs%26aulast%3DCross%26aufirst%3DD.%2BA.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DNebhan%26aufirst%3DC.%2BA.%26aulast%3DSpitzler%26aufirst%3DP.%2BJ.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DHughes%26aufirst%3DG.%26aulast%3DRahi%26aufirst%3DA.%26aulast%3DJacobs%26aufirst%3DV.%2BN.%26aulast%3DRed%2BBrewer%26aufirst%3DM.%26aulast%3DIchihara%26aufirst%3DE.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DAl-Kadhimi%26aufirst%3DK.%26aulast%3DRowlinson%26aufirst%3DR.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DRichmond%26aufirst%3DG.%2BH.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DRanson%26aufirst%3DM.%2BR.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DAZD9291%252C%2520an%2520irreversible%2520EGFR%2520TKI%252C%2520overcomes%2520T790M-mediated%2520resistance%2520to%2520EGFR%2520inhibitors%2520in%2520lung%2520cancer%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26spage%3D1046%26epage%3D1061%26doi%3D10.1158%2F2159-8290.CD-14-0337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planchard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horn, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haggstrom, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frewer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantarini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickinson, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghiorghiu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranson, M.</span></span> <span> </span><span class="NLM_article-title">AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>372</i></span>,  <span class="NLM_fpage">1689</span>â <span class="NLM_lpage">1699</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa1411817</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1056%2FNEJMoa1411817" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=25923549" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A280%3ADC%252BC2Mjpt1yltA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2015&pages=1689-1699&author=P.+A.+Janneauthor=J.+C.+Yangauthor=D.+W.+Kimauthor=D.+Planchardauthor=Y.+Oheauthor=S.+S.+Ramalingamauthor=M.+J.+Ahnauthor=S.+W.+Kimauthor=W.+C.+Suauthor=L.+Hornauthor=D.+Haggstromauthor=E.+Felipauthor=J.+H.+Kimauthor=P.+Frewerauthor=M.+Cantariniauthor=K.+H.+Brownauthor=P.+A.+Dickinsonauthor=S.+Ghiorghiuauthor=M.+Ranson&title=AZD9291+in+EGFR+inhibitor-resistant+non-small-cell+lung+cancer&doi=10.1056%2FNEJMoa1411817"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer</span></div><div class="casAuthors">Janne Pasi A; Yang James Chih-Hsin; Kim Dong-Wan; Planchard David; Ohe Yuichiro; Ramalingam Suresh S; Ahn Myung-Ju; Kim Sang-We; Su Wu-Chou; Horn Leora; Haggstrom Daniel; Felip Enriqueta; Kim Joo-Hang; Frewer Paul; Cantarini Mireille; Brown Kathryn H; Dickinson Paul A; Ghiorghiu Serban; Ranson Malcolm</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1689-99</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The EGFR T790M mutation is the most common mechanism of drug resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in patients who have lung cancer with an EGFR mutation (EGFR-mutated lung cancer).  In preclinical models, the EGFR inhibitor AZD9291 has been shown to be effective against both EGFR tyrosine kinase inhibitor-sensitizing and T790M resistance mutations.  METHODS:  We administered AZD9291 at doses of 20 to 240 mg once daily in patients with advanced lung cancer who had radiologically documented disease progression after previous treatment with EGFR tyrosine kinase inhibitors.  The study included dose-escalation cohorts and dose-expansion cohorts.  In the expansion cohorts, prestudy tumor biopsies were required for central determination of EGFR T790M status.  Patients were assessed for safety, pharmacokinetics, and efficacy.  RESULTS:  A total of 253 patients were treated.  Among 31 patients enrolled in the dose-escalation cohorts, no dose-limiting toxic effects occurred at the doses evaluated.  An additional 222 patients were treated in five expansion cohorts.  The most common all-cause adverse events were diarrhea, rash, nausea, and decreased appetite.  The overall objective tumor response rate was 51% (95% confidence interval [CI], 45 to 58).  Among 127 patients with centrally confirmed EGFR T790M who could be evaluated for response, the response rate was 61% (95% CI, 52 to 70).  In contrast, among 61 patients without centrally detectable EGFR T790M who could be evaluated for response, the response rate was 21% (95% CI, 12 to 34).  The median progression-free survival was 9.6 months (95% CI, 8.3 to not reached) in EGFR T790M-positive patients and 2.8 months (95% CI, 2.1 to 4.3) in EGFR T790M-negative patients.  CONCLUSIONS:  AZD9291 was highly active in patients with lung cancer with the EGFR T790M mutation who had had disease progression during prior therapy with EGFR tyrosine kinase inhibitors. (Funded by AstraZeneca; ClinicalTrials.gov number, NCT01802632.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQME11ovAjH3SnGiHuhFGv8fW6udTcc2eZ3nPQWS5HUSrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mjpt1yltA%253D%253D&md5=7304f406bb2e568fb08b6d524d027389</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1411817&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1411817%26sid%3Dliteratum%253Aachs%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DPlanchard%26aufirst%3DD.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26aulast%3DAhn%26aufirst%3DM.%2BJ.%26aulast%3DKim%26aufirst%3DS.%2BW.%26aulast%3DSu%26aufirst%3DW.%2BC.%26aulast%3DHorn%26aufirst%3DL.%26aulast%3DHaggstrom%26aufirst%3DD.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DFrewer%26aufirst%3DP.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DK.%2BH.%26aulast%3DDickinson%26aufirst%3DP.%2BA.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DRanson%26aufirst%3DM.%26atitle%3DAZD9291%2520in%2520EGFR%2520inhibitor-resistant%2520non-small-cell%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D372%26spage%3D1689%26epage%3D1699%26doi%3D10.1056%2FNEJMoa1411817" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sequist, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakelee, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadgeel, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varga, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadimitrakopoulou, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oxnard, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dziadziuszko, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aisner, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doebele, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galasso, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garon, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heist, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Logan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neal, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendenhall, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piotrowska, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wozniak, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raponi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlovich, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaw-Tsai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isaacson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Despain, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matheny, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolfe, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D. R.</span></span> <span> </span><span class="NLM_article-title">Rociletinib in EGFR-mutated non-small-cell lung cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>372</i></span>,  <span class="NLM_fpage">1700</span>â <span class="NLM_lpage">1709</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa1413654</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1056%2FNEJMoa1413654" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=25923550" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A280%3ADC%252BC2Mjpt1yltQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2015&pages=1700-1709&author=L.+V.+Sequistauthor=J.+C.+Soriaauthor=J.+W.+Goldmanauthor=H.+A.+Wakeleeauthor=S.+M.+Gadgeelauthor=A.+Vargaauthor=V.+Papadimitrakopoulouauthor=B.+J.+Solomonauthor=G.+R.+Oxnardauthor=R.+Dziadziuszkoauthor=D.+L.+Aisnerauthor=R.+C.+Doebeleauthor=C.+Galassoauthor=E.+B.+Garonauthor=R.+S.+Heistauthor=J.+Loganauthor=J.+W.+Nealauthor=M.+A.+Mendenhallauthor=S.+Nicholsauthor=Z.+Piotrowskaauthor=A.+J.+Wozniakauthor=M.+Raponiauthor=C.+A.+Karlovichauthor=S.+Jaw-Tsaiauthor=J.+Isaacsonauthor=D.+Despainauthor=S.+L.+Mathenyauthor=L.+Rolfeauthor=A.+R.+Allenauthor=D.+R.+Camidge&title=Rociletinib+in+EGFR-mutated+non-small-cell+lung+cancer&doi=10.1056%2FNEJMoa1413654"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Rociletinib in EGFR-mutated non-small-cell lung cancer</span></div><div class="casAuthors">Sequist Lecia V; Soria Jean-Charles; Goldman Jonathan W; Wakelee Heather A; Gadgeel Shirish M; Varga Andrea; Papadimitrakopoulou Vassiliki; Solomon Benjamin J; Oxnard Geoffrey R; Dziadziuszko Rafal; Aisner Dara L; Doebele Robert C; Galasso Cathy; Garon Edward B; Heist Rebecca S; Logan Jennifer; Neal Joel W; Mendenhall Melody A; Nichols Suzanne; Piotrowska Zofia; Wozniak Antoinette J; Raponi Mitch; Karlovich Chris A; Jaw-Tsai Sarah; Isaacson Jeffrey; Despain Darrin; Matheny Shannon L; Rolfe Lindsey; Allen Andrew R; Camidge D Ross</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1700-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Non-small-cell lung cancer (NSCLC) with a mutation in the gene encoding epidermal growth factor receptor (EGFR) is sensitive to approved EGFR inhibitors, but resistance develops, mediated by the T790M EGFR mutation in most cases.  Rociletinib (CO-1686) is an EGFR inhibitor active in preclinical models of EGFR-mutated NSCLC with or without T790M.  METHODS:  In this phase 1-2 study, we administered rociletinib to patients with EGFR-mutated NSCLC who had disease progression during previous treatment with an existing EGFR inhibitor.  In the expansion (phase 2) part of the study, patients with T790M-positive disease received rociletinib at a dose of 500 mg twice daily, 625 mg twice daily, or 750 mg twice daily.  Key objectives were assessment of safety, side-effect profile, pharmacokinetics, and preliminary antitumor activity of rociletinib.  Tumor biopsies to identify T790M were performed during screening.  Treatment was administered in continuous 21-day cycles.  RESULTS:  A total of 130 patients were enrolled.  The first 57 patients to be enrolled received the free-base form of rociletinib (150 mg once daily to 900 mg twice daily).  The remaining patients received the hydrogen bromide salt (HBr) form (500 mg twice daily to 1000 mg twice daily).  A maximum tolerated dose (the highest dose associated with a rate of dose-limiting toxic effects of less than 33%) was not identified.  The only common dose-limiting adverse event was hyperglycemia.  In an efficacy analysis that included patients who received free-base rociletinib at a dose of 900 mg twice daily or the HBr form at any dose, the objective response rate among the 46 patients with T790M-positive disease who could be evaluated was 59% (95% confidence interval [CI], 45 to 73), and the rate among the 17 patients with T790M-negative disease who could be evaluated was 29% (95% CI, 8 to 51).  CONCLUSIONS:  Rociletinib was active in patients with EGFR-mutated NSCLC associated with the T790M resistance mutation. (Funded by Clovis Oncology; ClinicalTrials.gov number, NCT01526928.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQME11ovAjH3ZPq5LRczm8ffW6udTcc2eZ3nPQWS5HUSrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mjpt1yltQ%253D%253D&md5=5a5d21d36c081a5ef0f9e650d5cc84b9</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1413654&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1413654%26sid%3Dliteratum%253Aachs%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26aulast%3DGoldman%26aufirst%3DJ.%2BW.%26aulast%3DWakelee%26aufirst%3DH.%2BA.%26aulast%3DGadgeel%26aufirst%3DS.%2BM.%26aulast%3DVarga%26aufirst%3DA.%26aulast%3DPapadimitrakopoulou%26aufirst%3DV.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DOxnard%26aufirst%3DG.%2BR.%26aulast%3DDziadziuszko%26aufirst%3DR.%26aulast%3DAisner%26aufirst%3DD.%2BL.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26aulast%3DGalasso%26aufirst%3DC.%26aulast%3DGaron%26aufirst%3DE.%2BB.%26aulast%3DHeist%26aufirst%3DR.%2BS.%26aulast%3DLogan%26aufirst%3DJ.%26aulast%3DNeal%26aufirst%3DJ.%2BW.%26aulast%3DMendenhall%26aufirst%3DM.%2BA.%26aulast%3DNichols%26aufirst%3DS.%26aulast%3DPiotrowska%26aufirst%3DZ.%26aulast%3DWozniak%26aufirst%3DA.%2BJ.%26aulast%3DRaponi%26aufirst%3DM.%26aulast%3DKarlovich%26aufirst%3DC.%2BA.%26aulast%3DJaw-Tsai%26aufirst%3DS.%26aulast%3DIsaacson%26aufirst%3DJ.%26aulast%3DDespain%26aufirst%3DD.%26aulast%3DMatheny%26aufirst%3DS.%2BL.%26aulast%3DRolfe%26aufirst%3DL.%26aulast%3DAllen%26aufirst%3DA.%2BR.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26atitle%3DRociletinib%2520in%2520EGFR-mutated%2520non-small-cell%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D372%26spage%3D1700%26epage%3D1709%26doi%3D10.1056%2FNEJMoa1413654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greig, S. L.</span></span> <span> </span><span class="NLM_article-title">Osimertinib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">263</span>â <span class="NLM_lpage">273</span>, <span class="refDoi">Â DOI: 10.1007/s40265-015-0533-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1007%2Fs40265-015-0533-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=26729184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BC28XlvFymtA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=263-273&author=S.+L.+Greig&title=Osimertinib%3A+First+Global+Approval&doi=10.1007%2Fs40265-015-0533-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Osimertinib: First Global Approval</span></div><div class="casAuthors">Greig, Sarah L.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">263-273</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Osimertinib (Tagrisso, AZD9291) is an oral, third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) that is being developed by AstraZeneca for the treatment of advanced non-small cell lung cancer (NSCLC).  Osimertinib has been designed to target the EGFR T790M mutation that is often present in NSCLC patients with acquired EGFR TKI resistance, while sparing wild-type EGFR.  In Nov. 2015, the tablet formulation of osimertinib was granted accelerated approval in the USA for the treatment of patients with metastatic EGFR T790M mutation-pos. NSCLC (as detected by an FDA-approved test) who have progressed on or after EGFR TKI therapy.  Osimertinib has also been granted accelerated assessment status for this indication in the EU, and is in phase III development for first- and second-line and adjuvant treatment of advanced EGFR mutation-pos. NSCLC in several countries.  Phase I trials in patients with advanced solid tumors are also being conducted.  This article summarizes the milestones in the development of osimertinib leading to this first approval for NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD-OV6l6JC5rVg90H21EOLACvtfcHk0lgzD8jHfHReng"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlvFymtA%253D%253D&md5=fb46898918bdfe76320c26177710fb11</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0533-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0533-4%26sid%3Dliteratum%253Aachs%26aulast%3DGreig%26aufirst%3DS.%2BL.%26atitle%3DOsimertinib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2016%26volume%3D76%26spage%3D263%26epage%3D273%26doi%3D10.1007%2Fs40265-015-0533-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ayati, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moghimi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salarinejad, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safavi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pouramiri, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foroumadi, A.</span></span> <span> </span><span class="NLM_article-title">A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>99</i></span>, <span class="NLM_elocation-id">103811</span> <span class="refDoi">Â DOI: 10.1016/j.bioorg.2020.103811</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1016%2Fj.bioorg.2020.103811" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=32278207" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmvFWjt7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2020&author=A.+Ayatiauthor=S.+Moghimiauthor=S.+Salarinejadauthor=M.+Safaviauthor=B.+Pouramiriauthor=A.+Foroumadi&title=A+review+on+progression+of+epidermal+growth+factor+receptor+%28EGFR%29+inhibitors+as+an+efficient+approach+in+cancer+targeted+therapy&doi=10.1016%2Fj.bioorg.2020.103811"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy</span></div><div class="casAuthors">Ayati, Adileh; Moghimi, Setareh; Salarinejad, Somayeh; Safavi, Maliheh; Pouramiri, Behjat; Foroumadi, Alireza</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">103811</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The identification of mol. agents inhibiting specific functions in cancer cells progression is considered as one of the most successful plans in cancer treatment.  The epidermal growth factor receptor (EGFR) over-activation is obsd. in a vast no. of cancers, so, targeting EGFR and its downstream signaling cascades are regarded as a rational and valuable approach in cancer therapy.  Several synthetic EGFR tyrosine kinase inhibitors (TKIs) have been evaluated in recent years, mostly exhibited clin. efficacy in relevant models and categorized into first, second, third and fourth-generation.  However, studies are still ongoing to find more efficient EGFR inhibitors in light of the resistance to the current inhibitors.  In this review, the importance of targeting EGFR signaling pathway in cancer therapy and related epigenetic mutations are highlighted.  The recent advances on the discovery and development of different EGFR inhibitors and the use of various therapeutic strategies such as multi-targeting agents and combination therapies have also been reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVrJxSVWovxbVg90H21EOLACvtfcHk0liPM89mQVGwHw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmvFWjt7Y%253D&md5=3f0d8f98e46bc5b5bc5a6f29190f7881</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2020.103811&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2020.103811%26sid%3Dliteratum%253Aachs%26aulast%3DAyati%26aufirst%3DA.%26aulast%3DMoghimi%26aufirst%3DS.%26aulast%3DSalarinejad%26aufirst%3DS.%26aulast%3DSafavi%26aufirst%3DM.%26aulast%3DPouramiri%26aufirst%3DB.%26aulast%3DForoumadi%26aufirst%3DA.%26atitle%3DA%2520review%2520on%2520progression%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520inhibitors%2520as%2520an%2520efficient%2520approach%2520in%2520cancer%2520targeted%2520therapy%26jtitle%3DBioorg.%2520Chem.%26date%3D2020%26volume%3D99%26doi%3D10.1016%2Fj.bioorg.2020.103811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, E. S.</span></span> <span> </span><span class="NLM_article-title">Olmutinib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">1153</span>â <span class="NLM_lpage">1157</span>, <span class="refDoi">Â DOI: 10.1007/s40265-016-0606-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1007%2Fs40265-016-0606-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=27357069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFaitr%252FP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=1153-1157&author=E.+S.+Kim&title=Olmutinib%3A+First+Global+Approval&doi=10.1007%2Fs40265-016-0606-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Olmutinib: First Global Approval</span></div><div class="casAuthors">Kim, Esther S.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1153-1157</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Olmutinib (OlitaTM) is an oral, third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) that is being developed by Boehringer Ingelheim and Hanmi Pharmaceutical Co.  Ltd for the treatment of non-small cell lung cancer (NSCLC).  Third-generation EGFR TKIs with covalent binding to the receptors demonstrate irreversible enzymic inhibition of activating EGFR mutations and T790M mutation (a common reason for acquired EGFR TKI resistance), while sparing wild-type EGFR.  In Dec. 2015, olmutinib was granted breakthrough therapy designation in NSCLC by the US FDA.  In May 2016, olmutinib received its first global approval in South Korea for the treatment of patients with locally advanced or metastatic EGFR T790M mutation-pos. NSCLC.  This article summarizes the milestones in the development of olmutinib leading to this first approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriY-HbqvpWrrVg90H21EOLACvtfcHk0liPM89mQVGwHw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFaitr%252FP&md5=749828b58c3a4ce11f607c2dcfef6b9c</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1007%2Fs40265-016-0606-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-016-0606-z%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DE.%2BS.%26atitle%3DOlmutinib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2016%26volume%3D76%26spage%3D1153%26epage%3D1157%26doi%3D10.1007%2Fs40265-016-0606-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span> <span> </span><span class="NLM_article-title">Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1681</span>â <span class="NLM_lpage">1690</span>, <span class="refDoi">Â DOI: 10.1016/S1470-2045(19)30504-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1016%2FS1470-2045%2819%2930504-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=31587882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFCntb%252FJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=1681-1690&author=M.+J.+Ahnauthor=J.+Y.+Hanauthor=K.+H.+Leeauthor=S.+W.+Kimauthor=D.+W.+Kimauthor=Y.+G.+Leeauthor=E.+K.+Choauthor=J.+H.+Kimauthor=G.+W.+Leeauthor=J.+S.+Leeauthor=Y.+J.+Minauthor=J.+S.+Kimauthor=S.+S.+Leeauthor=H.+R.+Kimauthor=M.+H.+Hongauthor=J.+S.+Ahnauthor=J.+M.+Sunauthor=H.+T.+Kimauthor=D.+H.+Leeauthor=S.+Kimauthor=B.+C.+Cho&title=Lazertinib+in+patients+with+EGFR+mutation-positive+advanced+non-small-cell+lung+cancer%3A+results+from+the+dose+escalation+and+dose+expansion+parts+of+a+first-in-human%2C+open-label%2C+multicentre%2C+phase+1-2+study&doi=10.1016%2FS1470-2045%2819%2930504-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study</span></div><div class="casAuthors">Ahn, Myung-Ju; Han, Ji-Youn; Lee, Ki Hyeong; Kim, Sang-We; Kim, Dong-Wan; Lee, Yun-Gyoo; Cho, Eun Kyung; Kim, Joo-Hang; Lee, Gyeong-Won; Lee, Jong-Seok; Min, Young Joo; Kim, Jin-Soo; Lee, Sung Sook; Kim, Hye Ryun; Hong, Min Hee; Ahn, Jin Seok; Sun, Jong-Mu; Kim, Heung Tae; Lee, Dae Ho; Kim, Sohee; Cho, Byoung Chul</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1681-1690</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Patients with EGFR-mutated non-small-cell lung cancer (NSCLC) given EGFR tyrosine kinase inhibitors (TKIs) inevitably become resistant to first-generation or second-generation drugs.  We assessed the safety, tolerability, pharmacokinetics, and activity of lazertinib-an irreversible, third-generation, mutant-selective, EGFR TKI-in patients with advanced NSCLC progressing after EGFR TKI therapy.  This first-in-human, open-label, multicentre, phase 1-2 study had three parts: dose escalation, dose expansion, and dose extension; here, we report results on dose escalation and dose expansion.  The study was done in 14 hospitals in Korea.  Eligible patients were aged 20 years or older and had advanced NSCLC harbouring an activating EGFR mutation and progressing after first-generation or second-generation EGFR TKI treatment, a defined tumor T790M mutation status, an Eastern Cooperative Oncol. Group performance status of 0-1, at least one measurable extracranial lesion, defined according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, and adequate organ function.  Patients were enrolled to seven dose-escalation cohorts according to a rolling six design; five cohorts were expanded.  Patients were given oral lazertinib 20 mg, 40 mg, 80 mg, 120 mg, 160 mg, 240 mg, or 320 mg once daily continuously in 21-day cycles.  Primary endpoints were safety and tolerability and secondary endpoints included objective response in evaluable patients.  This study is registered with ClinicalTrials.gov, NCT03046992, and the phase 2 extension study is ongoing.  Between Feb 15, 2017, and May 28, 2018, 127 patients were enrolled into the dose escalation group (n=38) and dose expansion group (n=89).  No dose-limiting toxicities occurred.  There was no dose-dependent increase in adverse events.  The most commonly reported adverse events were grade 1-2 rash or acne (in 38 [30%] of 127 patients) and pruritus (in 34 [27%]).  Grade 3 or grade 4 adverse events occurred in 20 (16%) patients, with the most common being grade 3 pneumonia (four [3%]).  Treatment-related grade 3 or 4 adverse events occurred in four (3%) patients; treatment-related serious adverse events were reported in six patients (5%).  There were no adverse events with an outcome of death and no treatment-related deaths.  The proportion of patients achieving an objective response by independent central review assessment was 69 (54%; 95% CI 46-63) of 127.  Lazertinib had a tolerable safety profile and showed promosing clin. activity in patients with NSCLC progressing on or after EGFR TKI therapy.  Our findings provide a rationale for further clin. investigations.Yuhan Corporation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAxYXGWFPC0LVg90H21EOLACvtfcHk0liPM89mQVGwHw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFCntb%252FJ&md5=5d7c0d41b1c9273f4dd800b7a52ae08c</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2819%2930504-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252819%252930504-2%26sid%3Dliteratum%253Aachs%26aulast%3DAhn%26aufirst%3DM.%2BJ.%26aulast%3DHan%26aufirst%3DJ.%2BY.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3DKim%26aufirst%3DS.%2BW.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DLee%26aufirst%3DY.%2BG.%26aulast%3DCho%26aufirst%3DE.%2BK.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DLee%26aufirst%3DG.%2BW.%26aulast%3DLee%26aufirst%3DJ.%2BS.%26aulast%3DMin%26aufirst%3DY.%2BJ.%26aulast%3DKim%26aufirst%3DJ.%2BS.%26aulast%3DLee%26aufirst%3DS.%2BS.%26aulast%3DKim%26aufirst%3DH.%2BR.%26aulast%3DHong%26aufirst%3DM.%2BH.%26aulast%3DAhn%26aufirst%3DJ.%2BS.%26aulast%3DSun%26aufirst%3DJ.%2BM.%26aulast%3DKim%26aufirst%3DH.%2BT.%26aulast%3DLee%26aufirst%3DD.%2BH.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DCho%26aufirst%3DB.%2BC.%26atitle%3DLazertinib%2520in%2520patients%2520with%2520EGFR%2520mutation-positive%2520advanced%2520non-small-cell%2520lung%2520cancer%253A%2520results%2520from%2520the%2520dose%2520escalation%2520and%2520dose%2520expansion%2520parts%2520of%2520a%2520first-in-human%252C%2520open-label%252C%2520multicentre%252C%2520phase%25201-2%2520study%26jtitle%3DLancet%2520Oncol.%26date%3D2019%26volume%3D20%26spage%3D1681%26epage%3D1690%26doi%3D10.1016%2FS1470-2045%2819%2930504-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yosaatmadja, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silva, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickson, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smaill, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, J. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKeage, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Squire, C. J.</span></span> <span> </span><span class="NLM_article-title">Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed</span>. <i>J. Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>192</i></span>,  <span class="NLM_fpage">539</span>â <span class="NLM_lpage">544</span>, <span class="refDoi">Â DOI: 10.1016/j.jsb.2015.10.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1016%2Fj.jsb.2015.10.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=26522274" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslKksLbN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=192&publication_year=2015&pages=539-544&author=Y.+Yosaatmadjaauthor=S.+Silvaauthor=J.+M.+Dicksonauthor=A.+V.+Pattersonauthor=J.+B.+Smaillauthor=J.+U.+Flanaganauthor=M.+J.+McKeageauthor=C.+J.+Squire&title=Binding+mode+of+the+breakthrough+inhibitor+AZD9291+to+epidermal+growth+factor+receptor+revealed&doi=10.1016%2Fj.jsb.2015.10.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed</span></div><div class="casAuthors">Yosaatmadja, Yuliana; Silva, Shevan; Dickson, James M.; Patterson, Adam V.; Smaill, Jeff B.; Flanagan, Jack U.; McKeage, Mark J.; Squire, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Structural Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">192</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">539-544</span>CODEN:
                <span class="NLM_cas:coden">JSBIEM</span>;
        ISSN:<span class="NLM_cas:issn">1047-8477</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The discovery of genetic drivers of lung cancer in patient sub-groups has led to their use as predictive biomarkers and as targets for selective drug therapy.  Some of the most important lung cancer drivers are mutations in the EGFR gene, for example, the exon 19 deletions and the L858R variant that confer sensitivity to the front line drugs erlotinib and gefitinib; the acquired T790M variants confer drug resistance and a poor prognosis.  A challenge then in targeting EGFR is to produce drugs that inhibit both sensitizing variants and resistance variants, leaving wild type protein in healthy cells unaffected.  One such agent is AstraZeneca's "breakthrough" AZD9291 mol. that shows a 200-fold selectivity for T790M/L858R over wild type EGFR.  Our X-ray crystal structure reveals the binding mode of AZD9291 to the kinase domain of wild type EGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSZ-1Gcecv3LVg90H21EOLACvtfcHk0liQcbupPIxzqg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslKksLbN&md5=330ba9239615813dbe0009e29d2e0983</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.jsb.2015.10.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jsb.2015.10.018%26sid%3Dliteratum%253Aachs%26aulast%3DYosaatmadja%26aufirst%3DY.%26aulast%3DSilva%26aufirst%3DS.%26aulast%3DDickson%26aufirst%3DJ.%2BM.%26aulast%3DPatterson%26aufirst%3DA.%2BV.%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DFlanagan%26aufirst%3DJ.%2BU.%26aulast%3DMcKeage%26aufirst%3DM.%2BJ.%26aulast%3DSquire%26aufirst%3DC.%2BJ.%26atitle%3DBinding%2520mode%2520of%2520the%2520breakthrough%2520inhibitor%2520AZD9291%2520to%2520epidermal%2520growth%2520factor%2520receptor%2520revealed%26jtitle%3DJ.%2520Struct.%2520Biol.%26date%3D2015%26volume%3D192%26spage%3D539%26epage%3D544%26doi%3D10.1016%2Fj.jsb.2015.10.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eastwood, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dror, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeliger, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, D. E.</span></span> <span> </span><span class="NLM_article-title">How does a drug molecule find its target binding site?</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>133</i></span>,  <span class="NLM_fpage">9181</span>â <span class="NLM_lpage">9183</span>, <span class="refDoi">Â DOI: 10.1021/ja202726y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja202726y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtVWgtb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2011&pages=9181-9183&author=Y.+Shanauthor=E.+T.+Kimauthor=M.+P.+Eastwoodauthor=R.+O.+Drorauthor=M.+A.+Seeligerauthor=D.+E.+Shaw&title=How+does+a+drug+molecule+find+its+target+binding+site%3F&doi=10.1021%2Fja202726y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">How Does a Drug Molecule Find Its Target Binding Site?</span></div><div class="casAuthors">Shan, Yibing; Kim, Eric T.; Eastwood, Michael P.; Dror, Ron O.; Seeliger, Markus A.; Shaw, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">9181-9183</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Although the thermodn. principles that control the binding of drug mols. to their protein targets are well understood, detailed exptl. characterization of the process by which such binding occurs has proven challenging.  We conducted relatively long, unguided mol. dynamics simulations in which a ligand (the cancer drug dasatinib or the kinase inhibitor PP1) was initially placed at a random location within a box that also contained a protein (Src kinase) to which that ligand was known to bind.  In several of these simulations, the ligand correctly identified its target binding site, forming a complex virtually identical to the crystallog. detd. bound structure.  The simulated trajectories provide a continuous, at.-level view of the entire binding process, revealing persistent and noteworthy intermediate conformations and shedding light on the role of water mols.  The technique we employed, which does not assume any prior knowledge of the binding site's location, may prove particularly useful in the development of allosteric inhibitors that target previously undiscovered binding sites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfc8mwES5csLVg90H21EOLACvtfcHk0liQcbupPIxzqg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtVWgtb8%253D&md5=11847733dfeb27ed5ec1a565327b258c</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fja202726y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja202726y%26sid%3Dliteratum%253Aachs%26aulast%3DShan%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DE.%2BT.%26aulast%3DEastwood%26aufirst%3DM.%2BP.%26aulast%3DDror%26aufirst%3DR.%2BO.%26aulast%3DSeeliger%26aufirst%3DM.%2BA.%26aulast%3DShaw%26aufirst%3DD.%2BE.%26atitle%3DHow%2520does%2520a%2520drug%2520molecule%2520find%2520its%2520target%2520binding%2520site%253F%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2011%26volume%3D133%26spage%3D9181%26epage%3D9183%26doi%3D10.1021%2Fja202726y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eastwood, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arkhipov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dror, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jumper, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuriyan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, D. E.</span></span> <span> </span><span class="NLM_article-title">Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>149</i></span>,  <span class="NLM_fpage">860</span>â <span class="NLM_lpage">870</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1016%2Fj.cell.2012.02.063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=22579287" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BC38XntFaju7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=149&publication_year=2012&pages=860-870&author=Y.+Shanauthor=M.+P.+Eastwoodauthor=X.+Zhangauthor=E.+T.+Kimauthor=A.+Arkhipovauthor=R.+O.+Drorauthor=J.+Jumperauthor=J.+Kuriyanauthor=D.+E.+Shaw&title=Oncogenic+mutations+counteract+intrinsic+disorder+in+the+EGFR+kinase+and+promote+receptor+dimerization"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization</span></div><div class="casAuthors">Shan, Yibing; Eastwood, Michael P.; Zhang, Xuewu; Kim, Eric T.; Arkhipov, Anton; Dror, Ron O.; Jumper, John; Kuriyan, John; Shaw, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">149</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">860-870</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The mutation and overexpression of the epidermal growth factor receptor (EGFR) are assocd. with the development of a variety of cancers, making this prototypical dimerization-activated receptor tyrosine kinase a prominent target of cancer drugs.  Using long-timescale mol. dynamics simulations, we find that the N lobe dimerization interface of the wild-type EGFR kinase domain is intrinsically disordered and that it becomes ordered only upon dimerization.  Our simulations suggest, moreover, that some cancer-linked mutations distal to the dimerization interface, particularly the widespread L834R mutation (also referred to as L858R), facilitate EGFR dimerization by suppressing this local disorder.  Corroborating these findings, our biophys. expts. and kinase enzymic assays indicate that the L834R mutation causes abnormally high activity primarily by promoting EGFR dimerization rather than by allowing activation without dimerization.  We also find that phosphorylation of EGFR kinase domain at Tyr845 may suppress the intrinsic disorder, suggesting a mol. mechanism for autonomous EGFR signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZhEY912uUTrVg90H21EOLACvtfcHk0liEgM9ZgZDF_g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XntFaju7k%253D&md5=8ab973e5a5626ac495d176322f30d2b7</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2012.02.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2012.02.063%26sid%3Dliteratum%253Aachs%26aulast%3DShan%26aufirst%3DY.%26aulast%3DEastwood%26aufirst%3DM.%2BP.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DKim%26aufirst%3DE.%2BT.%26aulast%3DArkhipov%26aufirst%3DA.%26aulast%3DDror%26aufirst%3DR.%2BO.%26aulast%3DJumper%26aufirst%3DJ.%26aulast%3DKuriyan%26aufirst%3DJ.%26aulast%3DShaw%26aufirst%3DD.%2BE.%26atitle%3DOncogenic%2520mutations%2520counteract%2520intrinsic%2520disorder%2520in%2520the%2520EGFR%2520kinase%2520and%2520promote%2520receptor%2520dimerization%26jtitle%3DCell%26date%3D2012%26volume%3D149%26spage%3D860%26epage%3D870" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gureasko, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuriyan, J.</span></span> <span> </span><span class="NLM_article-title">An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">1137</span>â <span class="NLM_lpage">1149</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2006.05.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1016%2Fj.cell.2006.05.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=16777603" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BD28XmsVOms7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2006&pages=1137-1149&author=X.+Zhangauthor=J.+Gureaskoauthor=K.+Shenauthor=P.+A.+Coleauthor=J.+Kuriyan&title=An+allosteric+mechanism+for+activation+of+the+kinase+domain+of+epidermal+growth+factor+receptor&doi=10.1016%2Fj.cell.2006.05.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor</span></div><div class="casAuthors">Zhang, Xuewu; Gureasko, Jodi; Shen, Kui; Cole, Philip A.; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1137-1149</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The mechanism by which the epidermal growth factor receptor (EGFR) is activated upon dimerization has eluded definition.  We find that the EGFR kinase domain can be activated by increasing its local concn. or by mutating a leucine (L834R) in the activation loop, the phosphorylation of which is not required for activation.  This suggests that the kinase domain is intrinsically auto-inhibited, and an intermol. interaction promotes its activation.  Using further mutational anal. and crystallog. we demonstrate that the auto-inhibited conformation of the EGFR kinase domain resembles that of Src and cyclin-dependent kinases (CDKs).  EGFR activation results from the formation of an asym. dimer in which the C-terminal lobe of one kinase domain plays a role analogous to that of cyclin in activated CDK/cyclin complexes.  The CDK/cyclin-like complex formed by two kinase domains thus explains the activation of EGFR-family receptors by homo- or heterodimerization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQsRAzLF-wK7Vg90H21EOLACvtfcHk0ljevm0-yR5uZA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmsVOms7g%253D&md5=f7b6795851425346f588cbd682125c93</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2006.05.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2006.05.013%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DGureasko%26aufirst%3DJ.%26aulast%3DShen%26aufirst%3DK.%26aulast%3DCole%26aufirst%3DP.%2BA.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DAn%2520allosteric%2520mechanism%2520for%2520activation%2520of%2520the%2520kinase%2520domain%2520of%2520epidermal%2520growth%2520factor%2520receptor%26jtitle%3DCell%26date%3D2006%26volume%3D125%26spage%3D1137%26epage%3D1149%26doi%3D10.1016%2Fj.cell.2006.05.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arkhipov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, D. E.</span></span> <span> </span><span class="NLM_article-title">Transitions to catalytically inactive conformations in EGFR kinase</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">7270</span>â <span class="NLM_lpage">7275</span>, <span class="refDoi">Â DOI: 10.1073/pnas.1220843110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1073%2Fpnas.1220843110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=23576739" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BC3sXos1Oisbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=7270-7275&author=Y.+Shanauthor=A.+Arkhipovauthor=E.+T.+Kimauthor=A.+C.+Panauthor=D.+E.+Shaw&title=Transitions+to+catalytically+inactive+conformations+in+EGFR+kinase&doi=10.1073%2Fpnas.1220843110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Transitions to catalytically inactive conformations in EGFR kinase</span></div><div class="casAuthors">Shan, Yibing; Arkhipov, Anton; Kim, Eric T.; Pan, Albert C.; Shaw, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7270-7275, S7270/1-S7270/5</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) is a key protein in cellular signaling, and its kinase domain (EGFR kinase) is an intensely pursued target of small-mol. drugs.  Although both catalytically active and inactive conformations of EGFR kinase have been resolved crystallog., exptl. characterization of the transitions between these conformations remains difficult.  Here, using unbiased, all-atom mol. dynamics simulations, the authors obsd. EGFR kinase spontaneously transition from the active to the so-called "Src-like inactive" conformation by way of 2 sets of intermediate conformations: one corresponded to a previously identified locally disordered state and the other to previously undescribed "extended" conformations, marked by the opening of the ATP-binding site between the 2 lobes of the kinase domain.  The authors also simulated the protonation-dependent transition of EGFR kinase to another ["Asp-Phe-Gly-out" ("DFG-out")] inactive conformation and obsd. similar intermediate conformations.  A key element obsd. in the simulated transitions was local unfolding, or "cracking," which supported a prediction of energy landscape theory.  The authors used H/D exchange measurements to corroborate their simulations and found that the simulated intermediate conformations correlated better with the H/D exchange data than existing active or inactive EGFR kinase crystal structures.  The intermediate conformations revealed by the simulations of the transition process differed significantly from the existing crystal structures and may provide unique possibilities for structure-based drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqK9XT_1ortrLVg90H21EOLACvtfcHk0ljevm0-yR5uZA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXos1Oisbk%253D&md5=91b0d30ac37d3dc030a9fd7e3f792295</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1220843110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1220843110%26sid%3Dliteratum%253Aachs%26aulast%3DShan%26aufirst%3DY.%26aulast%3DArkhipov%26aufirst%3DA.%26aulast%3DKim%26aufirst%3DE.%2BT.%26aulast%3DPan%26aufirst%3DA.%2BC.%26aulast%3DShaw%26aufirst%3DD.%2BE.%26atitle%3DTransitions%2520to%2520catalytically%2520inactive%2520conformations%2520in%2520EGFR%2520kinase%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2013%26volume%3D110%26spage%3D7270%26epage%3D7275%26doi%3D10.1073%2Fpnas.1220843110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carey, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garton, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haley, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sliwkowski, M. X.</span></span> <span> </span><span class="NLM_article-title">Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">8163</span>â <span class="NLM_lpage">8171</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-06-0453</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1158%2F0008-5472.CAN-06-0453" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=16912195" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BD28XotFWqtb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=8163-8171&author=K.+D.+Careyauthor=A.+J.+Gartonauthor=M.+S.+Romeroauthor=J.+Kahlerauthor=S.+Thomsonauthor=S.+Rossauthor=F.+Parkauthor=J.+D.+Haleyauthor=N.+Gibsonauthor=M.+X.+Sliwkowski&title=Kinetic+analysis+of+epidermal+growth+factor+receptor+somatic+mutant+proteins+shows+increased+sensitivity+to+the+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitor%2C+erlotinib&doi=10.1158%2F0008-5472.CAN-06-0453"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Kinetic Analysis of Epidermal Growth Factor Receptor Somatic Mutant Proteins Shows Increased Sensitivity to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Erlotinib</span></div><div class="casAuthors">Carey, Kendall D.; Garton, Andrew J.; Romero, Maria S.; Kahler, Jennifer; Thomson, Stuart; Ross, Sarajane; Park, Frances; Haley, John D.; Gibson, Neil; Sliwkowski, Mark X.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">8163-8171</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">We show that two commonly occurring epidermal growth factor receptor (EGFR) somatic mutations, L858R and an in-frame deletion mutant, Del(746-750), exhibit distinct enzymic properties relative to wild-type EGFR and are differentially sensitive to erlotinib.  Kinetic anal. of the purified intracellular domains of EGFR L858R and EGFR Del(746-750) reveals that both mutants are active but exhibit a higher KM for ATP and a lower Ki for erlotinib relative to wild-type receptor.  When expressed in NR6 cells, a cell line that does not express EGFR or other ErbB receptors, both mutations are ligand dependent for receptor activation, can activate downstream EGFR signaling pathways, and promote cell cycle progression.  As expected from the kinetic anal., the EGFR Del(746-752) is more sensitive to erlotinib inhibition than the EGFR L858R mutant.  Further characterization shows that these mutations promote ligand-dependent and anchorage-independent growth, and cells harboring these mutant receptors form tumors in immunocompromised mice.  Anal. of tumor lysates reveals that the tumorigenicity of the mutant EGFR cell lines may be due to a differential pattern of mutant EGFR autophosphorylation as compared with wild-type receptor.  Significant inhibition of tumor growth, in mice harboring wild-type EGFR receptors, is only obsd. at doses of erlotinib approaching the max. tolerated dose for the mouse.  In contrast, the growth of mutant tumors is inhibited by erlotinib treatment at approx. one third the max. tolerated dose.  These findings suggest that EGFR somatic mutations directly influence both erlotinib sensitivity and cellular transformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-kYT9GVzgo7Vg90H21EOLACvtfcHk0ljevm0-yR5uZA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XotFWqtb0%253D&md5=0ea102a026666dc0cb9cf60a3de0e944</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-0453&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-0453%26sid%3Dliteratum%253Aachs%26aulast%3DCarey%26aufirst%3DK.%2BD.%26aulast%3DGarton%26aufirst%3DA.%2BJ.%26aulast%3DRomero%26aufirst%3DM.%2BS.%26aulast%3DKahler%26aufirst%3DJ.%26aulast%3DThomson%26aufirst%3DS.%26aulast%3DRoss%26aufirst%3DS.%26aulast%3DPark%26aufirst%3DF.%26aulast%3DHaley%26aufirst%3DJ.%2BD.%26aulast%3DGibson%26aufirst%3DN.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26atitle%3DKinetic%2520analysis%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520somatic%2520mutant%2520proteins%2520shows%2520increased%2520sensitivity%2520to%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitor%252C%2520erlotinib%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D8163%26epage%3D8171%26doi%3D10.1158%2F0008-5472.CAN-06-0453" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggon, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greulich, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span> <span> </span><span class="NLM_article-title">Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">217</span>â <span class="NLM_lpage">227</span>, <span class="refDoi">Â DOI: 10.1016/j.ccr.2006.12.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1016%2Fj.ccr.2006.12.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=17349580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVymtL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2007&pages=217-227&author=C.+H.+Yunauthor=T.+J.+Boggonauthor=Y.+Liauthor=M.+S.+Wooauthor=H.+Greulichauthor=M.+Meyersonauthor=M.+J.+Eck&title=Structures+of+lung+cancer-derived+EGFR+mutants+and+inhibitor+complexes%3A+mechanism+of+activation+and+insights+into+differential+inhibitor+sensitivity&doi=10.1016%2Fj.ccr.2006.12.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity</span></div><div class="casAuthors">Yun, Cai-Hong; Boggon, Titus J.; Li, Yiqun; Woo, Michele S.; Greulich, Heidi; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">217-227</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Mutations in the EGFR kinase are a cause of non-small-cell lung cancer.  To understand their mechanism of activation and effects on drug binding, we studied the kinetics of the L858R and G719S mutants and detd. their crystal structures with inhibitors including gefitinib, AEE788, and a staurosporine.  We find that the mutations activate the kinase by disrupting autoinhibitory interactions, and that they accelerate catalysis as much as 50-fold in vitro.  Structures of inhibitors in complex with both wild-type and mutant kinases reveal similar binding modes for gefitinib and AEE788, but a marked rotation of the staurosporine in the G719S mutant.  Strikingly, direct binding measurements show that gefitinib binds 20-fold more tightly to the L858R mutant than to the wild-type enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoogeLQ1CuEnLVg90H21EOLACvtfcHk0lhIFUPgx8OCKQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVymtL4%253D&md5=6bc3223df84d829d9cb2bb00fd88ca29</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2006.12.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2006.12.017%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DStructures%2520of%2520lung%2520cancer-derived%2520EGFR%2520mutants%2520and%2520inhibitor%2520complexes%253A%2520mechanism%2520of%2520activation%2520and%2520insights%2520into%2520differential%2520inhibitor%2520sensitivity%26jtitle%3DCancer%2520Cell%26date%3D2007%26volume%3D11%26spage%3D217%26epage%3D227%26doi%3D10.1016%2Fj.ccr.2006.12.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuzmic, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solowiej, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergqvist, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolanos, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almaden, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagata, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalvie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kath, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, B. W.</span></span> <span> </span><span class="NLM_article-title">Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">173</span>â <span class="NLM_lpage">178</span>, <span class="refDoi">Â DOI: 10.1073/pnas.1313733111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1073%2Fpnas.1313733111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=24347635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BC2cXps1eluw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=173-178&author=P.+A.+Schwartzauthor=P.+Kuzmicauthor=J.+Solowiejauthor=S.+Bergqvistauthor=B.+Bolanosauthor=C.+Almadenauthor=A.+Nagataauthor=K.+Ryanauthor=J.+Fengauthor=D.+Dalvieauthor=J.+C.+Kathauthor=M.+Xuauthor=R.+Waniauthor=B.+W.+Murray&title=Covalent+EGFR+inhibitor+analysis+reveals+importance+of+reversible+interactions+to+potency+and+mechanisms+of+drug+resistance&doi=10.1073%2Fpnas.1313733111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance</span></div><div class="casAuthors">Schwartz, Phillip A.; Kuzmic, Petr; Solowiej, James; Bergqvist, Simon; Bolanos, Ben; Almaden, Chau; Nagata, Asako; Ryan, Kevin; Feng, Junli; Dalvie, Deepak; Kath, John C.; Xu, Meirong; Wani, Revati; Murray, Brion William</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">173-178</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Covalent inhibition is a reemerging paradigm in kinase drug design, but the roles of inhibitor binding affinity and chem. reactivity in overall potency are not well-understood.  To characterize the underlying mol. processes at a microscopic level and det. the appropriate kinetic consts., specialized exptl. design and advanced numerical integration of differential equations are developed.  Previously uncharacterized investigational covalent drugs reported here are shown to be extremely effective epidermal growth factor receptor (EGFR) inhibitors (kinact/Ki in the range 105-107 M-1s-1), despite their low specific reactivity (kinact â¤ 2.1 Ã 10-3 s-1), which is compensated for by high binding affinities (Ki < 1 nM).  For inhibitors relying on reactivity to achieve potency, noncovalent enzyme-inhibitor complex partitioning between inhibitor dissocn. and bond formation is central.  Interestingly, reversible binding affinity of EGFR covalent inhibitors is highly correlated with antitumor cell potency.  Furthermore, cellular potency for a subset of covalent inhibitors can be accounted for solely through reversible interactions.  One reversible interaction is between EGFR-Cys797 nucleophile and the inhibitor's reactive group, which may also contribute to drug resistance.  Because covalent inhibitors target a cysteine residue, the effects of its oxidn. on enzyme catalysis and inhibitor pharmacol. are characterized.  Oxidn. of the EGFR cysteine nucleophile does not alter catalysis but has widely varied effects on inhibitor potency depending on the EGFR context (e.g., oncogenic mutations), type of oxidn. (sulfinylation or glutathiolation), and inhibitor architecture.  These methods, parameters, and insights provide a rational framework for assessing and designing effective covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTpPuRq8MwCLVg90H21EOLACvtfcHk0lhIFUPgx8OCKQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXps1eluw%253D%253D&md5=47197c5e7876a238eefb2e8e7de305ea</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1313733111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1313733111%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DP.%2BA.%26aulast%3DKuzmic%26aufirst%3DP.%26aulast%3DSolowiej%26aufirst%3DJ.%26aulast%3DBergqvist%26aufirst%3DS.%26aulast%3DBolanos%26aufirst%3DB.%26aulast%3DAlmaden%26aufirst%3DC.%26aulast%3DNagata%26aufirst%3DA.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DDalvie%26aufirst%3DD.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DWani%26aufirst%3DR.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26atitle%3DCovalent%2520EGFR%2520inhibitor%2520analysis%2520reveals%2520importance%2520of%2520reversible%2520interactions%2520to%2520potency%2520and%2520mechanisms%2520of%2520drug%2520resistance%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2014%26volume%3D111%26spage%3D173%26epage%3D178%26doi%3D10.1073%2Fpnas.1313733111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thress, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paweletz, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stetson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dougherty, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markovets, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vivancos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantarini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oxnard, G. R.</span></span> <span> </span><span class="NLM_article-title">Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">560</span>â <span class="NLM_lpage">562</span>, <span class="refDoi">Â DOI: 10.1038/nm.3854</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1038%2Fnm.3854" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=25939061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFemsbfJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=560-562&author=K.+S.+Thressauthor=C.+P.+Paweletzauthor=E.+Felipauthor=B.+C.+Choauthor=D.+Stetsonauthor=B.+Doughertyauthor=Z.+Laiauthor=A.+Markovetsauthor=A.+Vivancosauthor=Y.+Kuangauthor=D.+Ercanauthor=S.+E.+Matthewsauthor=M.+Cantariniauthor=J.+C.+Barrettauthor=P.+A.+Janneauthor=G.+R.+Oxnard&title=Acquired+EGFR+C797S+mutation+mediates+resistance+to+AZD9291+in+non-small+cell+lung+cancer+harboring+EGFR+T790M&doi=10.1038%2Fnm.3854"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M</span></div><div class="casAuthors">Thress, Kenneth S.; Paweletz, Cloud P.; Felip, Enriqueta; Cho, Byoung Chul; Stetson, Daniel; Dougherty, Brian; Lai, Zhongwu; Markovets, Aleksandra; Vivancos, Ana; Kuang, Yanan; Ercan, Dalia; Matthews, Sarah E.; Cantarini, Mireille; Barrett, J. Carl; Janne, Pasi A.; Oxnard, Geoffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">560-562</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Here we studied cell-free plasma DNA (cfDNA) collected from subjects with advanced lung cancer whose tumors had developed resistance to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) AZD9291.  We first performed next-generation sequencing of cfDNA from seven subjects and detected an acquired EGFR C797S mutation in one; expression of this mutant EGFR construct in a cell line rendered it resistant to AZD9291.  We then performed droplet digital PCR on serial cfDNA specimens collected from 15 AZD9291-treated subjects.  All were pos. for the T790M mutation before treatment, but upon developing AZD9291 resistance three mol. subtypes emerged: six cases acquired the C797S mutation, five cases maintained the T790M mutation but did not acquire the C797S mutation and four cases lost the T790M mutation despite the presence of the underlying EGFR activating mutation.  Our findings provide insight into the diversity of mechanisms through which tumors acquire resistance to AZD9291 and highlight the need for therapies that are able to overcome resistance mediated by the EGFR C797S mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTggAW5fpGrbVg90H21EOLACvtfcHk0li10bJXMnO-uw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFemsbfJ&md5=adac4cb6c7057855aff61fd62890d010</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnm.3854&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3854%26sid%3Dliteratum%253Aachs%26aulast%3DThress%26aufirst%3DK.%2BS.%26aulast%3DPaweletz%26aufirst%3DC.%2BP.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DStetson%26aufirst%3DD.%26aulast%3DDougherty%26aufirst%3DB.%26aulast%3DLai%26aufirst%3DZ.%26aulast%3DMarkovets%26aufirst%3DA.%26aulast%3DVivancos%26aufirst%3DA.%26aulast%3DKuang%26aufirst%3DY.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DMatthews%26aufirst%3DS.%2BE.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DBarrett%26aufirst%3DJ.%2BC.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DOxnard%26aufirst%3DG.%2BR.%26atitle%3DAcquired%2520EGFR%2520C797S%2520mutation%2520mediates%2520resistance%2520to%2520AZD9291%2520in%2520non-small%2520cell%2520lung%2520cancer%2520harboring%2520EGFR%2520T790M%26jtitle%3DNat.%2520Med.%26date%3D2015%26volume%3D21%26spage%3D560%26epage%3D562%26doi%3D10.1038%2Fnm.3854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capelletti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span> <span> </span><span class="NLM_article-title">EGFR mutations and resistance to Irreversible pyrimidine based EGFR inhibitors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">3913</span>â <span class="NLM_lpage">3923</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-14-2789</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1158%2F1078-0432.CCR-14-2789" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=25948633" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVCrsLfE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=3913-3923&author=D.+Ercanauthor=H.+G.+Choiauthor=C.+H.+Yunauthor=M.+Capellettiauthor=T.+Xieauthor=M.+J.+Eckauthor=N.+S.+Grayauthor=P.+A.+Janne&title=EGFR+mutations+and+resistance+to+Irreversible+pyrimidine+based+EGFR+inhibitors&doi=10.1158%2F1078-0432.CCR-14-2789"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors</span></div><div class="casAuthors">Ercan, Dalia; Choi, Hwan Geun; Yun, Cai-Hong; Capelletti, Marzia; Xie, Ting; Eck, Michael J.; Gray, Nathanael S.; Jaenne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">3913-3923</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Mutant selective irreversible pyrimidine-based EGFR kinase inhibitors, including WZ4002, CO-1686, and AZD9291, are effective in preclin. models and in lung cancer patients harboring the EGFR T790M gefitinib/erlotinib resistance mutation.  However, little is known about how cancers develop acquired resistance to this class of EGFR inhibitors.  We sought to identify and study EGFR mutations that confer resistance to this class of agents.  Exptl. Design: We performed an N-ethyl-N-nitrosourea (ENU) mutagenesis screen in EGFR-mutant (sensitizing alone or with concurrent EGFR T790M) Ba/F3 cells and selected drug-resistant clones.  We evaluated the sensitivity of EGFR inhibitors in models harboring drug-resistant EGFR mutations.  Results: We identified 3 major drug resistance mutations.  EGFR L718Q, L844V, and C797S cause resistance to both WZ4002 and CO-1686 while, in contrast, only EGFR C797S leads to AZD9291 resistance.  Cells contg. an EGFR-sensitizing mutation, Del 19 or L858R, in conjunction with L718Q, L844V, or C797S retain sensitivity to quinazoline-based EGFR inhibitors, gefitinib and afatinib.  The C797S mutation, in the presence of Del 19 or L858R and T790M, causes resistance to all current EGFR inhibitors, but L858R/T790M/C797S remains partially sensitive to cetuximab which leads to disruption of EGFR dimerization.  Conclusions: Our findings provide insights into resistance mechanisms to irreversible pyrimidine-based EGFR inhibitors and identify specific genomic contexts in which sensitivity is retained to existing clin. EGFR inhibitors.  These findings will guide the development of new strategies to inhibit EGFR.  Clin Cancer Res; 21(17); 3913-23. Â©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEcpT5h6UJorVg90H21EOLACvtfcHk0li10bJXMnO-uw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVCrsLfE&md5=9c2916156cb18726ff2f2d2881345548</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-2789&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-2789%26sid%3Dliteratum%253Aachs%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DChoi%26aufirst%3DH.%2BG.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DXie%26aufirst%3DT.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DEGFR%2520mutations%2520and%2520resistance%2520to%2520Irreversible%2520pyrimidine%2520based%2520EGFR%2520inhibitors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D3913%26epage%3D3923%26doi%3D10.1158%2F1078-0432.CCR-14-2789" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hornak, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strockbine, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roitberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmerling, C.</span></span> <span> </span><span class="NLM_article-title">Comparison of multiple Amber force fields and development of improved protein backbone parameters</span>. <i>Proteins</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">712</span>â <span class="NLM_lpage">725</span>, <span class="refDoi">Â DOI: 10.1002/prot.21123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1002%2Fprot.21123" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=16981200" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFWqt7fM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2006&pages=712-725&author=V.+Hornakauthor=R.+Abelauthor=A.+Okurauthor=B.+Strockbineauthor=A.+Roitbergauthor=C.+Simmerling&title=Comparison+of+multiple+Amber+force+fields+and+development+of+improved+protein+backbone+parameters&doi=10.1002%2Fprot.21123"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of multiple Amber force fields and development of improved protein backbone parameters</span></div><div class="casAuthors">Hornak, Viktor; Abel, Robert; Okur, Asim; Strockbine, Bentley; Roitberg, Adrian; Simmerling, Carlos</div><div class="citationInfo"><span class="NLM_cas:title">Proteins: Structure, Function, and Bioinformatics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">712-725</span>CODEN:
                <span class="NLM_cas:coden">PSFBAF</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The ff94 force field that is commonly assocd. with the Amber simulation package is one of the most widely used parameter sets for biomol. simulation.  After a decade of extensive use and testing, limitations in this force field, such as over-stabilization of Î±-helixes, were reported by the authors and other researchers.  This led to a no. of attempts to improve these parameters, resulting in a variety of "Amber" force fields and significant difficulty in detg. which should be used for a particular application.  The authors show that several of these continue to suffer from inadequate balance between different secondary structure elements.  In addn., the approach used in most of these studies neglected to account for the existence in Amber of two sets of backbone .vphi./Ï dihedral terms.  This led to parameter sets that provide unreasonable conformational preferences for glycine.  The authors report here an effort to improve the .vphi./Ï dihedral terms in the ff99 energy function.  Dihedral term parameters are based on fitting the energies of multiple conformations of glycine and alanine tetrapeptides from high level ab initio quantum mech. calcns.  The new parameters for backbone dihedrals replace those in the existing ff99 force field.  This parameter set, which the authors denote ff99SB, achieves a better balance of secondary structure elements as judged by improved distribution of backbone dihedrals for glycine and alanine with respect to PDB survey data.  It also accomplishes improved agreement with published exptl. data for conformational preferences of short alanine peptides and better accord with exptl. NMR relaxation data of test protein systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmoASzza-Gd7Vg90H21EOLACvtfcHk0lgcJnabQ1V5XA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFWqt7fM&md5=de683a26eca9e83ae524726e97ac22fa</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1002%2Fprot.21123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprot.21123%26sid%3Dliteratum%253Aachs%26aulast%3DHornak%26aufirst%3DV.%26aulast%3DAbel%26aufirst%3DR.%26aulast%3DOkur%26aufirst%3DA.%26aulast%3DStrockbine%26aufirst%3DB.%26aulast%3DRoitberg%26aufirst%3DA.%26aulast%3DSimmerling%26aufirst%3DC.%26atitle%3DComparison%2520of%2520multiple%2520Amber%2520force%2520fields%2520and%2520development%2520of%2520improved%2520protein%2520backbone%2520parameters%26jtitle%3DProteins%26date%3D2006%26volume%3D65%26spage%3D712%26epage%3D725%26doi%3D10.1002%2Fprot.21123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lindorff-Larsen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piana, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maragakis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klepeis, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dror, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, D. E.</span></span> <span> </span><span class="NLM_article-title">Improved side-chain torsion potentials for the Amber ff99SB protein force field</span>. <i>Proteins</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">1950</span>â <span class="NLM_lpage">1958</span>, <span class="refDoi">Â DOI: 10.1002/prot.22711</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1002%2Fprot.22711" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=20408171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvFegtLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2010&pages=1950-1958&author=K.+Lindorff-Larsenauthor=S.+Pianaauthor=K.+Palmoauthor=P.+Maragakisauthor=J.+L.+Klepeisauthor=R.+O.+Drorauthor=D.+E.+Shaw&title=Improved+side-chain+torsion+potentials+for+the+Amber+ff99SB+protein+force+field&doi=10.1002%2Fprot.22711"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Improved side-chain torsion potentials for the Amber ff99SB protein force field</span></div><div class="casAuthors">Lindorff-Larsen, Kresten; Piana, Stefano; Palmo, Kim; Maragakis, Paul; Klepeis, John L.; Dror, Ron O.; Shaw, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Proteins: Structure, Function, and Bioinformatics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1950-1958</span>CODEN:
                <span class="NLM_cas:coden">PSFBAF</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Recent advances in hardware and software have enabled increasingly long mol. dynamics (MD) simulations of biomols., exposing certain limitations in the accuracy of the force fields used for such simulations and spurring efforts to refine these force fields.  Recent modifications to the Amber and CHARMM protein force fields, for example, have improved the backbone torsion potentials, remedying deficiencies in earlier versions.  Here, the authors further advance simulation accuracy by improving the amino acid side-chain torsion potentials of the Amber ff99SB force field.  First, the authors used simulations of model alpha-helical systems to identify the four residue types whose rotamer distribution differed the most from expectations based on Protein Data Bank statistics.  Second, the authors optimized the side-chain torsion potentials of these residues to match new, high-level quantum-mech. calcns.  Finally, the authors used microsecond-timescale MD simulations in explicit solvent to validate the resulting force field against a large set of exptl. NMR measurements that directly probe side-chain conformations.  The new force field, which the authors have termed Amber ff99SB-ILDN, exhibits considerably better agreement with the NMR data.  Proteins 2010. Â© 2010 Wiley-Liss, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNFHrYs9024bVg90H21EOLACvtfcHk0lgcJnabQ1V5XA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvFegtLo%253D&md5=447a9004026e2b93f0f7beff165daa09</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2Fprot.22711&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprot.22711%26sid%3Dliteratum%253Aachs%26aulast%3DLindorff-Larsen%26aufirst%3DK.%26aulast%3DPiana%26aufirst%3DS.%26aulast%3DPalmo%26aufirst%3DK.%26aulast%3DMaragakis%26aufirst%3DP.%26aulast%3DKlepeis%26aufirst%3DJ.%2BL.%26aulast%3DDror%26aufirst%3DR.%2BO.%26aulast%3DShaw%26aufirst%3DD.%2BE.%26atitle%3DImproved%2520side-chain%2520torsion%2520potentials%2520for%2520the%2520Amber%2520ff99SB%2520protein%2520force%2520field%26jtitle%3DProteins%26date%3D2010%26volume%3D78%26spage%3D1950%26epage%3D1958%26doi%3D10.1002%2Fprot.22711" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Best, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hummer, G.</span></span> <span> </span><span class="NLM_article-title">Optimized molecular dynamics force fields applied to the helix-coil transition of polypeptides</span>. <i>J. Phys. Chem. B</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">9004</span>â <span class="NLM_lpage">9015</span>, <span class="refDoi">Â DOI: 10.1021/jp901540t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jp901540t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BD1MXntVGjsLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2009&pages=9004-9015&author=R.+B.+Bestauthor=G.+Hummer&title=Optimized+molecular+dynamics+force+fields+applied+to+the+helix-coil+transition+of+polypeptides&doi=10.1021%2Fjp901540t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Optimized molecular dynamics force fields applied to the helix-coil transition of polypeptides</span></div><div class="casAuthors">Best, Robert B.; Hummer, Gerhard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physical Chemistry B</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">9004-9015</span>CODEN:
                <span class="NLM_cas:coden">JPCBFK</span>;
        ISSN:<span class="NLM_cas:issn">1520-6106</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Obtaining the correct balance of secondary structure propensities is a central priority in protein force-field development.  Given that current force fields differ significantly in their Î±-helical propensities, a correction to match exptl. results would be highly desirable.  We have detd. simple backbone energy corrections for two force fields to reproduce the fraction of helix measured in short peptides at 300 K.  As validation, we show that the optimized force fields produce results in excellent agreement with NMR expts. for folded proteins and short peptides not used in the optimization.  However, despite the agreement at ambient conditions, the dependence of the helix content on temp. is too weak, a problem shared with other force fields.  A fit of the Lifson-Roig helix-coil theory shows that both the enthalpy and entropy of helix formation are too small: the helix extension parameter w agrees well with expt., but its entropic and enthalpic components are both only about half the resp. exptl. ests.  Our structural and thermodn. analyses point toward the phys. origins of these shortcomings in current force fields, and suggest ways to address them in future force-field development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6YKyHMhZcXLVg90H21EOLACvtfcHk0lgcJnabQ1V5XA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXntVGjsLs%253D&md5=0fead55a8bc1c9269f92184ba27fc443</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjp901540t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjp901540t%26sid%3Dliteratum%253Aachs%26aulast%3DBest%26aufirst%3DR.%2BB.%26aulast%3DHummer%26aufirst%3DG.%26atitle%3DOptimized%2520molecular%2520dynamics%2520force%2520fields%2520applied%2520to%2520the%2520helix-coil%2520transition%2520of%2520polypeptides%26jtitle%3DJ.%2520Phys.%2520Chem.%2520B%26date%3D2009%26volume%3D113%26spage%3D9004%26epage%3D9015%26doi%3D10.1021%2Fjp901540t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandrasekhar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madura, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Impey, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, M. L.</span></span> <span> </span><span class="NLM_article-title">Comparison of simple potential functions for simulating liquid water</span>. <i>J. Chem. Phys.</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">926</span>â <span class="NLM_lpage">935</span>, <span class="refDoi">Â DOI: 10.1063/1.445869</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1063%2F1.445869" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADyaL3sXksF2htL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=1983&pages=926-935&author=W.+L.+Jorgensenauthor=J.+Chandrasekharauthor=J.+D.+Maduraauthor=R.+W.+Impeyauthor=M.+L.+Klein&title=Comparison+of+simple+potential+functions+for+simulating+liquid+water&doi=10.1063%2F1.445869"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of simple potential functions for simulating liquid water</span></div><div class="casAuthors">Jorgensen, William L.; Chandrasekhar, Jayaraman; Madura, Jeffry D.; Impey, Roger W.; Klein, Michael L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Physics</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">926-35</span>CODEN:
                <span class="NLM_cas:coden">JCPSA6</span>;
        ISSN:<span class="NLM_cas:issn">0021-9606</span>.
    </div><div class="casAbstract">Classical Monte Carlo simulations were carried out for liq. H2O in the NPT ensemble at 25Â° and 1 atm using 6 of the simpler intermol. potential functions for the dimer.  Comparisons were made with exptl. thermodn. and structural data including the neutron diffraction results of Thiessen and Narten (1982).  The computed densities and potential energies agree with expt. except for the original Bernal-Fowler model, which yields an 18% overest. of the d. and poor structural results.  The discrepancy may be due to the correction terms needed in processing the neutron data or to an effect uniformly neglected in the computations.  Comparisons were made for the self-diffusion coeffs. obtained from mol. dynamics simulations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpK4QUFMvwYFrVg90H21EOLACvtfcHk0lg5SffuDiUc-g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXksF2htL4%253D&md5=a1161334e381746be8c9b15a5e56f704</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1063%2F1.445869&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1063%252F1.445869%26sid%3Dliteratum%253Aachs%26aulast%3DJorgensen%26aufirst%3DW.%2BL.%26aulast%3DChandrasekhar%26aufirst%3DJ.%26aulast%3DMadura%26aufirst%3DJ.%2BD.%26aulast%3DImpey%26aufirst%3DR.%2BW.%26aulast%3DKlein%26aufirst%3DM.%2BL.%26atitle%3DComparison%2520of%2520simple%2520potential%2520functions%2520for%2520simulating%2520liquid%2520water%26jtitle%3DJ.%2520Chem.%2520Phys.%26date%3D1983%26volume%3D79%26spage%3D926%26epage%3D935%26doi%3D10.1063%2F1.445869" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldwell, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kollman, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Case, D. A.</span></span> <span> </span><span class="NLM_article-title">Development and testing of a general amber force field</span>. <i>J. Comput. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1157</span>â <span class="NLM_lpage">1174</span>, <span class="refDoi">Â DOI: 10.1002/jcc.20035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1002%2Fjcc.20035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=15116359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksFakurc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2004&pages=1157-1174&author=J.+Wangauthor=R.+M.+Wolfauthor=J.+W.+Caldwellauthor=P.+A.+Kollmanauthor=D.+A.+Case&title=Development+and+testing+of+a+general+amber+force+field&doi=10.1002%2Fjcc.20035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Development and testing of a general Amber force field</span></div><div class="casAuthors">Wang, Junmei; Wolf, Romain M.; Caldwell, James W.; Kollman, Peter A.; Case, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1157-1174</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">We describe here a general Amber force field (GAFF) for org. mols.  GAFF is designed to be compatible with existing Amber force fields for proteins and nucleic acids, and has parameters for most org. and pharmaceutical mols. that are composed of H, C, N, O, S, P, and halogens.  It uses a simple functional form and a limited no. of atom types, but incorporates both empirical and heuristic models to est. force consts. and partial at. charges.  The performance of GAFF in test cases is encouraging.  In test I, 74 crystallog. structures were compared to GAFF minimized structures, with a root-mean-square displacement of 0.26 Ã, which is comparable to that of the Tripos 5.2 force field (0.25 Ã) and better than those of MMFF 94 and CHARMm (0.47 and 0.44 Ã, resp.).  In test II, gas phase minimizations were performed on 22 nucleic acid base pairs, and the minimized structures and intermol. energies were compared to MP2/6-31G* results.  The RMS of displacements and relative energies were 0.25 Ã and 1.2 kcal/mol, resp.  These data are comparable to results from Parm99/RESP (0.16 Ã and 1.18 kcal/mol, resp.), which were parameterized to these base pairs.  Test III looked at the relative energies of 71 conformational pairs that were used in development of the Parm99 force field.  The RMS error in relative energies (compared to expt.) is about 0.5 kcal/mol.  GAFF can be applied to wide range of mols. in an automatic fashion, making it suitable for rational drug design and database searching.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfW8Gsf8IiW7Vg90H21EOLACvtfcHk0lg5SffuDiUc-g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksFakurc%253D&md5=2992017a8cf51f89290ae2562403b115</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1002%2Fjcc.20035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.20035%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWolf%26aufirst%3DR.%2BM.%26aulast%3DCaldwell%26aufirst%3DJ.%2BW.%26aulast%3DKollman%26aufirst%3DP.%2BA.%26aulast%3DCase%26aufirst%3DD.%2BA.%26atitle%3DDevelopment%2520and%2520testing%2520of%2520a%2520general%2520amber%2520force%2520field%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D2004%26volume%3D25%26spage%3D1157%26epage%3D1174%26doi%3D10.1002%2Fjcc.20035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bergdorf, M.</span>; <span class="NLM_string-name">Baxter, S.</span>; <span class="NLM_string-name">Rendleman, C. A.</span>; <span class="NLM_string-name">Shaw, D. E.</span></span> <i>Desmond/GPU Performance as of October 2015</i>; D. E. Shaw Research Technical Report DESRES/TR--2015-01, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=M.+Bergdorf&author=S.+Baxter&author=C.+A.+Rendleman&author=D.+E.+Shaw&title=Desmond%2FGPU+Performance+as+of+October+2015"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26aulast%3DBergdorf%26aufirst%3DM.%26jtitle%3DDesmond%252FGPU%2520Performance%2520as%2520of%2520October%25202015%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, D. E.</span></span> In  <i>Anton 2: Raising the Bar for Performance and Programmability in a Special-Purpose Molecular Dynamics Supercomputer, SC14</i>. International Conference for High Performance Computing, Networking, Storage and Analysis, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=D.+E.+Shaw&title=Anton+2%3A+Raising+the+Bar+for+Performance+and+Programmability+in+a+Special-Purpose+Molecular+Dynamics+Supercomputer%2C+SC14"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DD.%2BE.%26jtitle%3DAnton%25202%253A%2520Raising%2520the%2520Bar%2520for%2520Performance%2520and%2520Programmability%2520in%2520a%2520Special-Purpose%2520Molecular%2520Dynamics%2520Supercomputer%252C%2520SC14%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lippert, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Predescu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ierardi, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackenzie, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eastwood, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dror, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, D. E.</span></span> <span> </span><span class="NLM_article-title">Accurate and efficient integration for molecular dynamics simulations at constant temperature and pressure</span>. <i>J. Chem. Phys.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>139</i></span>, <span class="NLM_elocation-id">164106</span> <span class="refDoi">Â DOI: 10.1063/1.4825247</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1063%2F1.4825247" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=24182003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1Kisb%252FL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2013&author=R.+A.+Lippertauthor=C.+Predescuauthor=D.+J.+Ierardiauthor=K.+M.+Mackenzieauthor=M.+P.+Eastwoodauthor=R.+O.+Drorauthor=D.+E.+Shaw&title=Accurate+and+efficient+integration+for+molecular+dynamics+simulations+at+constant+temperature+and+pressure&doi=10.1063%2F1.4825247"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Accurate and efficient integration for molecular dynamics simulations at constant temperature and pressure</span></div><div class="casAuthors">Lippert, Ross A.; Predescu, Cristian; Ierardi, Douglas J.; MacKenzie, Kenneth M.; Eastwood, Michael P.; Dror, Ron O.; Shaw, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Physics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">139</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">164106/1-164106/11</span>CODEN:
                <span class="NLM_cas:coden">JCPSA6</span>;
        ISSN:<span class="NLM_cas:issn">0021-9606</span>.
    
            (<span class="NLM_cas:orgname">American Institute of Physics</span>)
        </div><div class="casAbstract">In mol. dynamics simulations, control over temp. and pressure is typically achieved by augmenting the original system with addnl. dynamical variables to create a thermostat and a barostat, resp.  These variables generally evolve on timescales much longer than those of particle motion, but typical integrator implementations update the addnl. variables along with the particle positions and momenta at each time step.  We present a framework that replaces the traditional integration procedure with sep. barostat, thermostat, and Newtonian particle motion updates, allowing thermostat and barostat updates to be applied infrequently.  Such infrequent updates provide a particularly substantial performance advantage for simulations parallelized across many computer processors, because thermostat and barostat updates typically require communication among all processors.  Infrequent updates can also improve accuracy by alleviating certain sources of error assocd. with limited-precision arithmetic.  In addn., sepg. the barostat, thermostat, and particle motion update steps reduces certain truncation errors, bringing the time-av. pressure closer to its target value.  Finally, this framework, which we have implemented on both general-purpose and special-purpose hardware, reduces software complexity and improves software modularity.  (c) 2013 American Institute of Physics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoW51ZULlZFvrVg90H21EOLACvtfcHk0lga595qClzvVQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1Kisb%252FL&md5=0bd59b4b73b6999b9311306f4c32f3c1</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1063%2F1.4825247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1063%252F1.4825247%26sid%3Dliteratum%253Aachs%26aulast%3DLippert%26aufirst%3DR.%2BA.%26aulast%3DPredescu%26aufirst%3DC.%26aulast%3DIerardi%26aufirst%3DD.%2BJ.%26aulast%3DMackenzie%26aufirst%3DK.%2BM.%26aulast%3DEastwood%26aufirst%3DM.%2BP.%26aulast%3DDror%26aufirst%3DR.%2BO.%26aulast%3DShaw%26aufirst%3DD.%2BE.%26atitle%3DAccurate%2520and%2520efficient%2520integration%2520for%2520molecular%2520dynamics%2520simulations%2520at%2520constant%2520temperature%2520and%2520pressure%26jtitle%3DJ.%2520Chem.%2520Phys.%26date%3D2013%26volume%3D139%26doi%3D10.1063%2F1.4825247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoover, W. G.</span></span> <span> </span><span class="NLM_article-title">Canonical dynamics: Equilibrium phase-space distributions</span>. <i>Phys. Rev. A</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">1695</span>â <span class="NLM_lpage">1697</span>, <span class="refDoi">Â DOI: 10.1103/PhysRevA.31.1695</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1103%2FPhysRevA.31.1695" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=9895674" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A280%3ADC%252BC2sjotlWltA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1985&pages=1695-1697&author=W.+G.+Hoover&title=Canonical+dynamics%3A+Equilibrium+phase-space+distributions&doi=10.1103%2FPhysRevA.31.1695"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Canonical dynamics: Equilibrium phase-space distributions</span></div><div class="casAuthors">Hoover</div><div class="citationInfo"><span class="NLM_cas:title">Physical review. A, General physics</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1695-1697</span>
        ISSN:<span class="NLM_cas:issn">0556-2791</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSFX8fOxXRWv36CEoQgWY10fW6udTcc2ebEP4SaaEMW6bntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sjotlWltA%253D%253D&md5=99a2477835b37592226a5d18a760685c</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1103%2FPhysRevA.31.1695&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1103%252FPhysRevA.31.1695%26sid%3Dliteratum%253Aachs%26aulast%3DHoover%26aufirst%3DW.%2BG.%26atitle%3DCanonical%2520dynamics%253A%2520Equilibrium%2520phase-space%2520distributions%26jtitle%3DPhys.%2520Rev.%2520A%26date%3D1985%26volume%3D31%26spage%3D1695%26epage%3D1697%26doi%3D10.1103%2FPhysRevA.31.1695" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martyna, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tobias, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, M. L.</span></span> <span> </span><span class="NLM_article-title">Constant pressure molecular dynamics algorithms</span>. <i>J. Chem. Phys.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">4177</span>â <span class="NLM_lpage">4189</span>, <span class="refDoi">Â DOI: 10.1063/1.467468</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1063%2F1.467468" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADyaK2cXmtFeht7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=1994&pages=4177-4189&author=G.+J.+Martynaauthor=D.+J.+Tobiasauthor=M.+L.+Klein&title=Constant+pressure+molecular+dynamics+algorithms&doi=10.1063%2F1.467468"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Constant pressure molecular dynamics algorithms</span></div><div class="casAuthors">Martyna, Glenn J.; Tobias, Douglas J.; Klein, Michael L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Physics</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">4177-89</span>CODEN:
                <span class="NLM_cas:coden">JCPSA6</span>;
        ISSN:<span class="NLM_cas:issn">0021-9606</span>.
    </div><div class="casAbstract">Modularly invariant equations of motion are derived that generate the isothermal-isobaric ensemble as their phase space avs.  Isotropic vol. fluctuations and fully flexible simulation cells as well as a hybrid scheme that naturally combines the two motions are considered.  The resulting methods are tested on two problems, a particle in a one-dimensional periodic potential and a spherical model of C60 in the solid/fluid phase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3YN7wMRJpjrVg90H21EOLACvtfcHk0lga595qClzvVQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXmtFeht7o%253D&md5=c14bd79c6398b0b30541e3cbe92851b0</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1063%2F1.467468&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1063%252F1.467468%26sid%3Dliteratum%253Aachs%26aulast%3DMartyna%26aufirst%3DG.%2BJ.%26aulast%3DTobias%26aufirst%3DD.%2BJ.%26aulast%3DKlein%26aufirst%3DM.%2BL.%26atitle%3DConstant%2520pressure%2520molecular%2520dynamics%2520algorithms%26jtitle%3DJ.%2520Chem.%2520Phys.%26date%3D1994%26volume%3D101%26spage%3D4177%26epage%3D4189%26doi%3D10.1063%2F1.467468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Predescu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lerer, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippert, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Towles, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossman, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dirks, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, D. E.</span></span> <span> </span><span class="NLM_article-title">The u-series: A separable decomposition for electrostatics computation with improved accuracy</span>. <i>J. Chem. Phys.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>152</i></span>, <span class="NLM_elocation-id">084113</span> <span class="refDoi">Â DOI: 10.1063/1.5129393</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1063%2F1.5129393" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=32113352" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BB3cXktlaktrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=2020&author=C.+Predescuauthor=A.+K.+Lererauthor=R.+A.+Lippertauthor=B.+Towlesauthor=J.+P.+Grossmanauthor=R.+M.+Dirksauthor=D.+E.+Shaw&title=The+u-series%3A+A+separable+decomposition+for+electrostatics+computation+with+improved+accuracy&doi=10.1063%2F1.5129393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">The u-series: A separable decomposition for electrostatics computation with improved accuracy</span></div><div class="casAuthors">Predescu, Cristian; Lerer, Adam K.; Lippert, Ross A.; Towles, Brian; Grossman, J. P.; Dirks, Robert M.; Shaw, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Physics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">152</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">084113/1-084113/12</span>CODEN:
                <span class="NLM_cas:coden">JCPSA6</span>;
        ISSN:<span class="NLM_cas:issn">0021-9606</span>.
    
            (<span class="NLM_cas:orgname">American Institute of Physics</span>)
        </div><div class="casAbstract">The evaluation of electrostatic energy for a set of point charges in a periodic lattice is a computationally expensive part of mol. dynamics simulations (and other applications) because of the long-range nature of the Coulomb interaction.  A std. approach is to decomp. the Coulomb potential into a near part, typically evaluated by direct summation up to a cutoff radius, and a far part, typically evaluated in Fourier space.  In practice, all decompn. approaches involve approxns. - such as cutting off the near-part direct sum - but it may be possible to find new decompns. with improved trade-offs between accuracy and performance.  Here, we present the u-series, a new decompn. of the Coulomb potential that is more accurate than the std. (Ewald) decompn. for a given amt. of computational effort and achieves the same accuracy as the Ewald decompn. with approx. half the computational effort.  These improvements, which we demonstrate numerically using a lipid membrane system, arise because the u-series is smooth on the entire real axis and exact up to the cutoff radius.  Addnl. performance improvements over the Ewald decompn. may be possible in certain situations because the far part of the u-series is a sum of Gaussians and can thus be evaluated using algorithms that require a separable convolution kernel; we describe one such algorithm that reduces communication latency at the expense of communication bandwidth and computation, a trade-off that may be advantageous on modern massively parallel supercomputers.  (c) 2020 American Institute of Physics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpSUTM2JpQDbVg90H21EOLACvtfcHk0ljjziXN-tMLjA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXktlaktrg%253D&md5=5520109d55a7ceb66fbc2167da773d4c</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1063%2F1.5129393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1063%252F1.5129393%26sid%3Dliteratum%253Aachs%26aulast%3DPredescu%26aufirst%3DC.%26aulast%3DLerer%26aufirst%3DA.%2BK.%26aulast%3DLippert%26aufirst%3DR.%2BA.%26aulast%3DTowles%26aufirst%3DB.%26aulast%3DGrossman%26aufirst%3DJ.%2BP.%26aulast%3DDirks%26aufirst%3DR.%2BM.%26aulast%3DShaw%26aufirst%3DD.%2BE.%26atitle%3DThe%2520u-series%253A%2520A%2520separable%2520decomposition%2520for%2520electrostatics%2520computation%2520with%2520improved%2520accuracy%26jtitle%3DJ.%2520Chem.%2520Phys.%26date%3D2020%26volume%3D152%26doi%3D10.1063%2F1.5129393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neese, F.</span></span> <span> </span><span class="NLM_article-title">The ORCA program system</span>. <i>Wiley Interdiscip. Rev.: Comput. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">73</span>â <span class="NLM_lpage">78</span>, <span class="refDoi">Â DOI: 10.1002/wcms.81</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1002%2Fwcms.81" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvFGls7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=73-78&author=F.+Neese&title=The+ORCA+program+system&doi=10.1002%2Fwcms.81"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">The ORCA program system</span></div><div class="casAuthors">Neese, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Wiley Interdisciplinary Reviews: Computational Molecular Science</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">73-78</span>CODEN:
                <span class="NLM_cas:coden">WIRCAH</span>;
        ISSN:<span class="NLM_cas:issn">1759-0884</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  ORCA is a general-purpose quantum chem. program package that features virtually all modern electronic structure methods (d. functional theory, many-body perturbation and coupled cluster theories, and multireference and semiempirical methods).  It is designed with the aim of generality, extendibility, efficiency, and user friendliness.  Its main field of application is larger mols., transition metal complexes, and their spectroscopic properties.  ORCA uses std. Gaussian basis functions and is fully parallelized.  The article provides an overview of its current possibilities and documents its efficiency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq39ez8fWMbr7Vg90H21EOLACvtfcHk0ljjziXN-tMLjA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvFGls7s%253D&md5=a753e33a6f9a326553295596f5c754e5</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1002%2Fwcms.81&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fwcms.81%26sid%3Dliteratum%253Aachs%26aulast%3DNeese%26aufirst%3DF.%26atitle%3DThe%2520ORCA%2520program%2520system%26jtitle%3DWiley%2520Interdiscip.%2520Rev.%253A%2520Comput.%2520Mol.%2520Sci.%26date%3D2012%26volume%3D2%26spage%3D73%26epage%3D78%26doi%3D10.1002%2Fwcms.81" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parrish, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burns, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmonett, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DePrince, A. E.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohenstein, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bozkaya, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sokolov, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Remigio, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richard, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonthier, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAlexander, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saitow, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritchard, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaefer, H. F.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patkowski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valeev, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evangelista, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turney, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherrill, C. D.</span></span> <span> </span><span class="NLM_article-title">Psi4 1.1: An Open-Source Electronic Structure Program Emphasizing Automation, Advanced Libraries, and Interoperability</span>. <i>J. Chem. Theory Comput.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">3185</span>â <span class="NLM_lpage">3197</span>, <span class="refDoi">Â DOI: 10.1021/acs.jctc.7b00174</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jctc.7b00174" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnsV2ju7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=3185-3197&author=R.+M.+Parrishauthor=L.+A.+Burnsauthor=D.+G.+A.+Smithauthor=A.+C.+Simmonettauthor=A.+E.+DePrinceauthor=E.+G.+Hohensteinauthor=U.+Bozkayaauthor=A.+Y.+Sokolovauthor=R.+Di+Remigioauthor=R.+M.+Richardauthor=J.+F.+Gonthierauthor=A.+M.+Jamesauthor=H.+R.+McAlexanderauthor=A.+Kumarauthor=M.+Saitowauthor=X.+Wangauthor=B.+P.+Pritchardauthor=P.+Vermaauthor=H.+F.+Schaeferauthor=K.+Patkowskiauthor=R.+A.+Kingauthor=E.+F.+Valeevauthor=F.+A.+Evangelistaauthor=J.+M.+Turneyauthor=T.+D.+Crawfordauthor=C.+D.+Sherrill&title=Psi4+1.1%3A+An+Open-Source+Electronic+Structure+Program+Emphasizing+Automation%2C+Advanced+Libraries%2C+and+Interoperability&doi=10.1021%2Facs.jctc.7b00174"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">PSI4 1.1: An Open-Source Electronic Structure Program Emphasizing Automation, Advanced Libraries, and Interoperability</span></div><div class="casAuthors">Parrish, Robert M.; Burns, Lori A.; Smith, Daniel G. A.; Simmonett, Andrew C.; DePrince, A. Eugene; Hohenstein, Edward G.; Bozkaya, Ugur; Sokolov, Alexander Yu.; Di Remigio, Roberto; Richard, Ryan M.; Gonthier, Jerome F.; James, Andrew M.; McAlexander, Harley R.; Kumar, Ashutosh; Saitow, Masaaki; Wang, Xiao; Pritchard, Benjamin P.; Verma, Prakash; Schaefer, Henry F.; Patkowski, Konrad; King, Rollin A.; Valeev, Edward F.; Evangelista, Francesco A.; Turney, Justin M.; Crawford, T. Daniel; Sherrill, C. David</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Theory and Computation</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3185-3197</span>CODEN:
                <span class="NLM_cas:coden">JCTCCE</span>;
        ISSN:<span class="NLM_cas:issn">1549-9618</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Psi4 is an ab initio electronic structure program providing methods such as Hartree-Fock, d. functional theory, CI, and coupled-cluster theory.  The 1.1 release represents a major update meant to automate complex tasks, such as geometry optimization using complete-basis-set extrapolation or focal-point methods.  Conversion of the top-level code to a Python module means that Psi4 can now be used in complex workflows alongside other Python tools.  Several new features have been added with the aid of libraries providing easy access to techniques such as d. fitting, Cholesky decompn., and Laplace denominators.  The build system has been completely rewritten to simplify interoperability with independent, reusable software components for quantum chem.  Finally, a wide range of new theor. methods and analyses have been added to the code base, including functional-group and open-shell symmetry adapted perturbation theory (F-SAPT and O-SAPT), d.-fitted coupled cluster with frozen natural orbitals [DF-FNO-CCSD(T)], orbital-optimized perturbation and coupled-cluster methods (e.g., OO-MP2 and OO-CCSD), d.-fitted MC-SCF (DF-MCSCF), d. cumulant functional theory (DCT), algebraic-diagrammatic construction [ADC(2)] excited states, improvements to the geometry optimizer, and the "X2C" approach to relativistic corrections, among many other improvements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqX9YFhWdEVKbVg90H21EOLACvtfcHk0ljjziXN-tMLjA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnsV2ju7k%253D&md5=68be5ece3075b2184a4c804e50f4eca3</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Facs.jctc.7b00174&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jctc.7b00174%26sid%3Dliteratum%253Aachs%26aulast%3DParrish%26aufirst%3DR.%2BM.%26aulast%3DBurns%26aufirst%3DL.%2BA.%26aulast%3DSmith%26aufirst%3DD.%2BG.%2BA.%26aulast%3DSimmonett%26aufirst%3DA.%2BC.%26aulast%3DDePrince%26aufirst%3DA.%2BE.%26aulast%3DHohenstein%26aufirst%3DE.%2BG.%26aulast%3DBozkaya%26aufirst%3DU.%26aulast%3DSokolov%26aufirst%3DA.%2BY.%26aulast%3DDi%2BRemigio%26aufirst%3DR.%26aulast%3DRichard%26aufirst%3DR.%2BM.%26aulast%3DGonthier%26aufirst%3DJ.%2BF.%26aulast%3DJames%26aufirst%3DA.%2BM.%26aulast%3DMcAlexander%26aufirst%3DH.%2BR.%26aulast%3DKumar%26aufirst%3DA.%26aulast%3DSaitow%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DPritchard%26aufirst%3DB.%2BP.%26aulast%3DVerma%26aufirst%3DP.%26aulast%3DSchaefer%26aufirst%3DH.%2BF.%26aulast%3DPatkowski%26aufirst%3DK.%26aulast%3DKing%26aufirst%3DR.%2BA.%26aulast%3DValeev%26aufirst%3DE.%2BF.%26aulast%3DEvangelista%26aufirst%3DF.%2BA.%26aulast%3DTurney%26aufirst%3DJ.%2BM.%26aulast%3DCrawford%26aufirst%3DT.%2BD.%26aulast%3DSherrill%26aufirst%3DC.%2BD.%26atitle%3DPsi4%25201.1%253A%2520An%2520Open-Source%2520Electronic%2520Structure%2520Program%2520Emphasizing%2520Automation%252C%2520Advanced%2520Libraries%252C%2520and%2520Interoperability%26jtitle%3DJ.%2520Chem.%2520Theory%2520Comput.%26date%3D2017%26volume%3D13%26spage%3D3185%26epage%3D3197%26doi%3D10.1021%2Facs.jctc.7b00174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanan, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryan, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burdick, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dotson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heald, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lainchbury, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purkey, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaefer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seward, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sideris, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeap, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zilberleyb, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heffron, T. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of selective and noncovalent diaminopyrimidine-based inhibitors of epidermal growth factor receptor containing the T790M resistance mutation</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">10176</span>â <span class="NLM_lpage">10191</span>, <span class="refDoi">Â DOI: 10.1021/jm501578n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501578n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVyrur3O" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=10176-10191&author=E.+J.+Hananauthor=C.+Eigenbrotauthor=M.+C.+Bryanauthor=D.+J.+Burdickauthor=B.+K.+Chanauthor=Y.+Chenauthor=J.+Dotsonauthor=R.+A.+Healdauthor=P.+S.+Jacksonauthor=H.+Laauthor=M.+D.+Lainchburyauthor=S.+Malekauthor=H.+E.+Purkeyauthor=G.+Schaeferauthor=S.+Schmidtauthor=E.+M.+Sewardauthor=S.+Siderisauthor=C.+Tamauthor=S.+Wangauthor=S.+K.+Yeapauthor=I.+Yenauthor=J.+Yinauthor=C.+Yuauthor=I.+Zilberleybauthor=T.+P.+Heffron&title=Discovery+of+selective+and+noncovalent+diaminopyrimidine-based+inhibitors+of+epidermal+growth+factor+receptor+containing+the+T790M+resistance+mutation&doi=10.1021%2Fjm501578n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Selective and Noncovalent Diaminopyrimidine-Based Inhibitors of Epidermal Growth Factor Receptor Containing the T790M Resistance Mutation</span></div><div class="casAuthors">Hanan, Emily J.; Eigenbrot, Charles; Bryan, Marian C.; Burdick, Daniel J.; Chan, Bryan K.; Chen, Yuan; Dotson, Jennafer; Heald, Robert A.; Jackson, Philip S.; La, Hank; Lainchbury, Michael D.; Malek, Shiva; Purkey, Hans E.; Schaefer, Gabriele; Schmidt, Stephen; Seward, Eileen M.; Sideris, Steve; Tam, Christine; Wang, Shumei; Yeap, Siew Kuen; Yen, Ivana; Yin, Jianping; Yu, Christine; Zilberleyb, Inna; Heffron, Timothy P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10176-10191</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Activating mutations within the epidermal growth factor receptor (EGFR) kinase domain, commonly L858R or deletions within exon 19, increase EGFR-driven cell proliferation and survival and are correlated with impressive responses to the EGFR inhibitors erlotinib and gefitinib in nonsmall cell lung cancer patients.  Approx. 60% of acquired resistance to these agents is driven by a single secondary mutation within the EGFR kinase domain, specifically substitution of the gatekeeper residue threonine-790 with methionine (T790M).  Due to dose-limiting toxicities assocd. with inhibition of wild-type EGFR (wtEGFR), we sought inhibitors of T790M-contg. EGFR mutants with selectivity over wtEGFR.  We describe the evolution of HTS hits derived from Jak2/Tyk2 inhibitors into selective EGFR inhibitors.  X-ray crystal structures revealed two distinct binding modes and enabled the design of a selective series of novel diaminopyrimidine-based inhibitors with good potency against T790M-contg. mutants of EGFR, high selectivity over wtEGFR, broad kinase selectivity, and desirable physicochem. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHIAeWoyjC2LVg90H21EOLACvtfcHk0lgmwhdW0Pkt_Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVyrur3O&md5=b17adf4b49cebb2f2cea77015e1f6e4b</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm501578n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501578n%26sid%3Dliteratum%253Aachs%26aulast%3DHanan%26aufirst%3DE.%2BJ.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DBryan%26aufirst%3DM.%2BC.%26aulast%3DBurdick%26aufirst%3DD.%2BJ.%26aulast%3DChan%26aufirst%3DB.%2BK.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DHeald%26aufirst%3DR.%2BA.%26aulast%3DJackson%26aufirst%3DP.%2BS.%26aulast%3DLa%26aufirst%3DH.%26aulast%3DLainchbury%26aufirst%3DM.%2BD.%26aulast%3DMalek%26aufirst%3DS.%26aulast%3DPurkey%26aufirst%3DH.%2BE.%26aulast%3DSchaefer%26aufirst%3DG.%26aulast%3DSchmidt%26aufirst%3DS.%26aulast%3DSeward%26aufirst%3DE.%2BM.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DTam%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DYeap%26aufirst%3DS.%2BK.%26aulast%3DYen%26aufirst%3DI.%26aulast%3DYin%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DZilberleyb%26aufirst%3DI.%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26atitle%3DDiscovery%2520of%2520selective%2520and%2520noncovalent%2520diaminopyrimidine-based%2520inhibitors%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520containing%2520the%2520T790M%2520resistance%2520mutation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D10176%26epage%3D10191%26doi%3D10.1021%2Fjm501578n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Minor, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cymborowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otwinowski, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chruszcz, M.</span></span> <span> </span><span class="NLM_article-title">HKL-3000: the integration of data reduction and structure solution--from diffraction images to an initial model in minutes</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">859</span>â <span class="NLM_lpage">866</span>, <span class="refDoi">Â DOI: 10.1107/S0907444906019949</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1107%2FS0907444906019949" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=16855301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BD28XntVWksL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2006&pages=859-866&author=W.+Minorauthor=M.+Cymborowskiauthor=Z.+Otwinowskiauthor=M.+Chruszcz&title=HKL-3000%3A+the+integration+of+data+reduction+and+structure+solution%2D%2Dfrom+diffraction+images+to+an+initial+model+in+minutes&doi=10.1107%2FS0907444906019949"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">HKL-3000: the integration of data reduction and structure solution - from diffraction images to an initial model in minutes</span></div><div class="casAuthors">Minor, Wladek; Cymborowski, Marcin; Otwinowski, Zbyszek; Chruszcz, Maksymilian</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">D62</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">859-866</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A new approach that integrates data collection, data redn., phasing and model building significantly accelerates the process of structure detn. and on av. minimizes the no. of data sets and synchrotron time required for structure soln.  Initial testing of the HKL-3000 system (the beta version was named HKL-2000_ph) with more than 140 novel structure detns. has proven its high value for MAD/SAD expts.  The heuristics for choosing the best computational strategy at different data resoln. limits of phasing signal and crystal diffraction are being optimized.  The typical end result is an interpretable electron-d. map with a partially built structure and, in some cases, an almost complete refined model.  The current development is oriented towards very fast structure soln. in order to provide feedback during the diffraction expt.  Work is also proceeding towards improving the quality of phasing calcn. and model building.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0c0DYtjFP7rVg90H21EOLACvtfcHk0lgmwhdW0Pkt_Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XntVWksL8%253D&md5=2cd2fe288f954837abb4acae4c008a2f</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1107%2FS0907444906019949&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444906019949%26sid%3Dliteratum%253Aachs%26aulast%3DMinor%26aufirst%3DW.%26aulast%3DCymborowski%26aufirst%3DM.%26aulast%3DOtwinowski%26aufirst%3DZ.%26aulast%3DChruszcz%26aufirst%3DM.%26atitle%3DHKL-3000%253A%2520the%2520integration%2520of%2520data%2520reduction%2520and%2520structure%2520solution--from%2520diffraction%2520images%2520to%2520an%2520initial%2520model%2520in%2520minutes%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2006%26volume%3D62%26spage%3D859%26epage%3D866%26doi%3D10.1107%2FS0907444906019949" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosse-Kunstleve, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winn, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storoni, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, R. J.</span></span> <span> </span><span class="NLM_article-title">Phaser crystallographic software</span>. <i>J. Appl. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">658</span>â <span class="NLM_lpage">674</span>, <span class="refDoi">Â DOI: 10.1107/S0021889807021206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1107%2FS0021889807021206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=19461840" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnslWqsLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2007&pages=658-674&author=A.+J.+McCoyauthor=R.+W.+Grosse-Kunstleveauthor=P.+D.+Adamsauthor=M.+D.+Winnauthor=L.+C.+Storoniauthor=R.+J.+Read&title=Phaser+crystallographic+software&doi=10.1107%2FS0021889807021206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Phaser crystallographic software</span></div><div class="casAuthors">McCoy, Airlie J.; Grosse-Kunstleve, Ralf W.; Adams, Paul D.; Winn, Martyn D.; Storoni, Laurent C.; Read, Randy J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">658-674</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">0021-8898</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Phaser is a program for phasing macromol. crystal structures by both mol. replacement and exptl. phasing methods.  The novel phasing algorithms implemented in Phaser have been developed using max. likelihood and multivariate statistics.  For mol. replacement, the new algorithms have proved to be significantly better than traditional methods in discriminating correct solns. from noise, and for single-wavelength anomalous dispersion exptl. phasing, the new algorithms, which account for correlations between F+ and F-, give better phases (lower mean phase error with respect to the phases given by the refined structure) than those that use mean F and anomalous differences ÎF.  One of the design concepts of Phaser was that it be capable of a high degree of automation.  To this end, Phaser (written in C++) can be called directly from Python, although it can also be called using traditional CCP4 keyword-style input.  Phaser is a platform for future development of improved phasing methods and their release, including source code, to the crystallog. community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPeVyjN_FMGbVg90H21EOLACvtfcHk0li1ItT0a8T34Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnslWqsLk%253D&md5=c63b722ae97e0a74e6a5a079d388f09f</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1107%2FS0021889807021206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0021889807021206%26sid%3Dliteratum%253Aachs%26aulast%3DMcCoy%26aufirst%3DA.%2BJ.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DAdams%26aufirst%3DP.%2BD.%26aulast%3DWinn%26aufirst%3DM.%2BD.%26aulast%3DStoroni%26aufirst%3DL.%2BC.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26atitle%3DPhaser%2520crystallographic%2520software%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D2007%26volume%3D40%26spage%3D658%26epage%3D674%26doi%3D10.1107%2FS0021889807021206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">BrÃ¼nger, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clore, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeLano, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gros, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosse-Kunstleve, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuszewski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilges, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannu, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warren, G. L.</span></span> <span> </span><span class="NLM_article-title">Crystallography & NMR system: A new software suite for macromolecular structure determination</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">905</span>â <span class="NLM_lpage">921</span>, <span class="refDoi">Â DOI: 10.1107/S0907444998003254</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1107%2FS0907444998003254" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=9757107" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A280%3ADyaK1cvjslKhsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=1998&pages=905-921&author=A.+T.+Br%C3%BCngerauthor=P.+D.+Adamsauthor=G.+M.+Cloreauthor=W.+L.+DeLanoauthor=P.+Grosauthor=R.+W.+Grosse-Kunstleveauthor=J.+S.+Jiangauthor=J.+Kuszewskiauthor=M.+Nilgesauthor=N.+S.+Pannuauthor=R.+J.+Readauthor=L.+M.+Riceauthor=T.+Simonsonauthor=G.+L.+Warren&title=Crystallography+%26+NMR+system%3A+A+new+software+suite+for+macromolecular+structure+determination&doi=10.1107%2FS0907444998003254"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Crystallography & NMR system: A new software suite for macromolecular structure determination</span></div><div class="casAuthors">Brunger A T; Adams P D; Clore G M; DeLano W L; Gros P; Grosse-Kunstleve R W; Jiang J S; Kuszewski J; Nilges M; Pannu N S; Read R J; Rice L M; Simonson T; Warren G L</div><div class="citationInfo"><span class="NLM_cas:title">Acta crystallographica. Section D, Biological crystallography</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">Pt 5</span>),
    <span class="NLM_cas:pages">905-21</span>
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    </div><div class="casAbstract">A new software suite, called Crystallography & NMR System (CNS), has been developed for macromolecular structure determination by X-ray crystallography or solution nuclear magnetic resonance (NMR) spectroscopy.  In contrast to existing structure-determination programs, the architecture of CNS is highly flexible, allowing for extension to other structure-determination methods, such as electron microscopy and solid-state NMR spectroscopy.  CNS has a hierarchical structure: a high-level hypertext markup language (HTML) user interface, task-oriented user input files, module files, a symbolic structure-determination language (CNS language), and low-level source code.  Each layer is accessible to the user.  The novice user may just use the HTML interface, while the more advanced user may use any of the other layers.  The source code will be distributed, thus source-code modification is possible.  The CNS language is sufficiently powerful and flexible that many new algorithms can be easily implemented in the CNS language without changes to the source code.  The CNS language allows the user to perform operations on data structures, such as structure factors, electron-density maps, and atomic properties.  The power of the CNS language has been demonstrated by the implementation of a comprehensive set of crystallographic procedures for phasing, density modification and refinement.  User-friendly task-oriented input files are available for nearly all aspects of macromolecular structure determination by X-ray crystallography and solution NMR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRAeLCFcGBdlx0LsK7uFuY7fW6udTcc2ebMhq3E2TAif7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1cvjslKhsw%253D%253D&md5=37afee1b07ac44d3f3730a39061b4e79</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1107%2FS0907444998003254&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444998003254%26sid%3Dliteratum%253Aachs%26aulast%3DBr%25C3%25BCnger%26aufirst%3DA.%2BT.%26aulast%3DAdams%26aufirst%3DP.%2BD.%26aulast%3DClore%26aufirst%3DG.%2BM.%26aulast%3DDeLano%26aufirst%3DW.%2BL.%26aulast%3DGros%26aufirst%3DP.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DJiang%26aufirst%3DJ.%2BS.%26aulast%3DKuszewski%26aufirst%3DJ.%26aulast%3DNilges%26aufirst%3DM.%26aulast%3DPannu%26aufirst%3DN.%2BS.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26aulast%3DRice%26aufirst%3DL.%2BM.%26aulast%3DSimonson%26aufirst%3DT.%26aulast%3DWarren%26aufirst%3DG.%2BL.%26atitle%3DCrystallography%2520%2526%2520NMR%2520system%253A%2520A%2520new%2520software%2520suite%2520for%2520macromolecular%2520structure%2520determination%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D1998%26volume%3D54%26spage%3D905%26epage%3D921%26doi%3D10.1107%2FS0907444998003254" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Emsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohkamp, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowtan, K.</span></span> <span> </span><span class="NLM_article-title">Features and development of Coot</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">486</span>â <span class="NLM_lpage">501</span>, <span class="refDoi">Â DOI: 10.1107/S0907444910007493</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1107%2FS0907444910007493" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=20383002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=486-501&author=P.+Emsleyauthor=B.+Lohkampauthor=W.+G.+Scottauthor=K.+Cowtan&title=Features+and+development+of+Coot&doi=10.1107%2FS0907444910007493"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Features and development of Coot</span></div><div class="casAuthors">Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">486-501</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Coot is a mol.-graphics application for model building and validation of biol. macromols.  The program displays electron-d. maps and at. models and allows model manipulations such as idealization, real-space refinement, manual rotation/translation, rigid-body fitting, ligand search, solvation, mutations, rotamers and Ramachandran idealization.  Furthermore, tools are provided for model validation as well as interfaces to external programs for refinement, validation and graphics.  The software is designed to be easy to learn for novice users, which is achieved by ensuring that tools for common tasks are 'discoverable' through familiar user-interface elements (menus and toolbars) or by intuitive behavior (mouse controls).  Recent developments have focused on providing tools for expert users, with customisable key bindings, extensions and an extensive scripting interface.  The software is under rapid development, but has already achieved very widespread use within the crystallog. community.  The current state of the software is presented, with a description of the facilities available and of some of the underlying methods employed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAKBKszbqb_7Vg90H21EOLACvtfcHk0li1ItT0a8T34Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D&md5=67262cbfc60004de5ef962d5c043c910</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1107%2FS0907444910007493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444910007493%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DLohkamp%26aufirst%3DB.%26aulast%3DScott%26aufirst%3DW.%2BG.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DFeatures%2520and%2520development%2520of%2520Coot%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D486%26epage%3D501%26doi%3D10.1107%2FS0907444910007493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adams, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afonine, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunkoczi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Echols, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Headd, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapral, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosse-Kunstleve, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriarty, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oeffner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terwilliger, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zwart, P. H.</span></span> <span> </span><span class="NLM_article-title">PHENIX: a comprehensive Python-based system for macromolecular structure solution</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">213</span>â <span class="NLM_lpage">221</span>, <span class="refDoi">Â DOI: 10.1107/S0907444909052925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1107%2FS0907444909052925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=20124702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1Sisbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=213-221&author=P.+D.+Adamsauthor=P.+V.+Afonineauthor=G.+Bunkocziauthor=V.+B.+Chenauthor=I.+W.+Davisauthor=N.+Echolsauthor=J.+J.+Headdauthor=L.+W.+Hungauthor=G.+J.+Kapralauthor=R.+W.+Grosse-Kunstleveauthor=A.+J.+McCoyauthor=N.+W.+Moriartyauthor=R.+Oeffnerauthor=R.+J.+Readauthor=D.+C.+Richardsonauthor=J.+S.+Richardsonauthor=T.+C.+Terwilligerauthor=P.+H.+Zwart&title=PHENIX%3A+a+comprehensive+Python-based+system+for+macromolecular+structure+solution&doi=10.1107%2FS0907444909052925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">PHENIX: a comprehensive Python-based system for macromolecular structure solution</span></div><div class="casAuthors">Adams, Paul D.; Afonine, Pavel V.; Bunkoczi, Gabor; Chen, Vincent B.; Davis, Ian W.; Echols, Nathaniel; Headd, Jeffrey J.; Hung, Li Wei; Kapral, Gary J.; Grosse-Kunstleve, Ralf W.; McCoy, Airlie J.; Moriarty, Nigel W.; Oeffner, Robert; Read, Randy J.; Richardson, David C.; Richardson, Jane S.; Terwilliger, Thomas C.; Zwart, Peter H.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">213-221</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">A review.  Macromol. X-ray crystallog. is routinely applied to understand biol. processes at a mol. level.  However, significant time and effort are still required to solve and complete many of these structures because of the need for manual interpretation of complex numerical data using many software packages and the repeated use of interactive three-dimensional graphics.  PHENIX has been developed to provide a comprehensive system for macromol. crystallog. structure soln. with an emphasis on the automation of all procedures.  This has relied on the development of algorithms that minimize or eliminate subjective input, the development of algorithms that automate procedures that are traditionally performed by hand and, finally, the development of a framework that allows a tight integration between the algorithms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm_HgKRpa-ObVg90H21EOLACvtfcHk0lgsMDWcF5GR-Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1Sisbc%253D&md5=67b439ff4bd61c659cae37ca4209b7bc</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1107%2FS0907444909052925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909052925%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DP.%2BD.%26aulast%3DAfonine%26aufirst%3DP.%2BV.%26aulast%3DBunkoczi%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DV.%2BB.%26aulast%3DDavis%26aufirst%3DI.%2BW.%26aulast%3DEchols%26aufirst%3DN.%26aulast%3DHeadd%26aufirst%3DJ.%2BJ.%26aulast%3DHung%26aufirst%3DL.%2BW.%26aulast%3DKapral%26aufirst%3DG.%2BJ.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DMcCoy%26aufirst%3DA.%2BJ.%26aulast%3DMoriarty%26aufirst%3DN.%2BW.%26aulast%3DOeffner%26aufirst%3DR.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26aulast%3DRichardson%26aufirst%3DD.%2BC.%26aulast%3DRichardson%26aufirst%3DJ.%2BS.%26aulast%3DTerwilliger%26aufirst%3DT.%2BC.%26aulast%3DZwart%26aufirst%3DP.%2BH.%26atitle%3DPHENIX%253A%2520a%2520comprehensive%2520Python-based%2520system%2520for%2520macromolecular%2520structure%2520solution%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D213%26epage%3D221%26doi%3D10.1107%2FS0907444909052925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">SchÃ¼ttelkopf, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Aalten, D. M.</span></span> <span> </span><span class="NLM_article-title">PRODRG: a tool for high-throughput crystallography of protein-ligand complexes</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1355</span>â <span class="NLM_lpage">1363</span>, <span class="refDoi">Â DOI: 10.1107/S0907444904011679</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=10.1107%2FS0907444904011679" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=15272157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlvVegtbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2004&pages=1355-1363&author=A.+W.+Sch%C3%BCttelkopfauthor=D.+M.+van+Aalten&title=PRODRG%3A+a+tool+for+high-throughput+crystallography+of+protein-ligand+complexes&doi=10.1107%2FS0907444904011679"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">PRODRG: a tool for high-throughput crystallography of protein-ligand complexes</span></div><div class="casAuthors">Schuettelkopf, Alexander W.; van Aalten, Daan M. F.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">D60</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1355-1363</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">The small-mol. topol. generator PRODRG is described, which takes input from existing coordinates or various two-dimensional formats and automatically generates coordinates and mol. topologies suitable for x-ray refinement of protein-ligand complexes.  Test results are described for automatic generation of topologies followed by energy minimization for a subset of compds. from the Cambridge Structural Database, which shows that, within the limits of the empirical GROMOS87 force field used, structures with good geometries are generated.  X-ray refinement in X-PLOR/CNS, REFMAC and SHELX using PRODRG-generated topologies produces results comparable to refinement with topologies from the std. libraries.  However, tests with distorted starting coordinates show that PRODRG topologies perform better, both in terms of ligand geometry and of crystallog. R factors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbflrch0bs97Vg90H21EOLACvtfcHk0lgsMDWcF5GR-Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlvVegtbY%253D&md5=f9bfdb14be7b04ea5c0db67feb39f72a</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1107%2FS0907444904011679&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444904011679%26sid%3Dliteratum%253Aachs%26aulast%3DSch%25C3%25BCttelkopf%26aufirst%3DA.%2BW.%26aulast%3Dvan%2BAalten%26aufirst%3DD.%2BM.%26atitle%3DPRODRG%253A%2520a%2520tool%2520for%2520high-throughput%2520crystallography%2520of%2520protein-ligand%2520complexes%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2004%26volume%3D60%26spage%3D1355%26epage%3D1363%26doi%3D10.1107%2FS0907444904011679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZAU" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZAU','PDB','4ZAU'); return false;">PDB: 4ZAU</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIT" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIT','PDB','2JIT'); return false;">PDB: 2JIT</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2GS7" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2GS7','PDB','2GS7'); return false;">PDB: 2GS7</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2itv" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2itv','PDB','2itv'); return false;">PDB: 2itv</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2jit" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2jit','PDB','2jit'); return false;">PDB: 2jit</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i15"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00891">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_17134"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c00891?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00891</a>.<ul class="NLM_list-list_type-label"><li><p class="inline">Data collection and refinement statistics; plots of the Cys797 SGâAZD9291 warhead distances; Stereo views of 2Fo-Fc and Fo-Fc maps; Stereo views of omit maps; In vitro cross-linking assay; comparison of the quantum mechanics (QM) energy profile of AZD9291) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00891/suppl_file/jm0c00891_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00891/suppl_file/jm0c00891_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00891/suppl_file/jm0c00891_si_001.pdf">jm0c00891_si_001.pdf (2.19 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00891/suppl_file/jm0c00891_si_002.csv">jm0c00891_si_002.csv (1.53 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Coordinates and structural factors of T790M/skAZD9291, T790M/ccAZD9291, L858R/skAZD9291, and WT/ccAZD9291 have been deposited in the Protein Data Bank under the accession code 6JX4, 6JX0, 6JWL, and 6JXT, respectively.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c00891%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-15%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c00891" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677a5e3f1e7c32cd","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
